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Abstract
Congenital heart defects (CHDs) arise from perturbations in complex molecular and
cellular processes underlying normal embryonic heart development. CHDs are the most
common congenital malformation, occurring in 1 to 5% of live births, and are the leading
cause of pediatric mortality. Adverse genetic and environmental factors can impede normal
cardiogenesis, and increase the likelihood of CHDs. Pregestational maternal diabetes
increases the risk of CHDs in children by more than four-fold. As the prevalence of diabetes
rapidly rises among women of childbearing age, there is a need to investigate the
mechanisms and potential preventative strategies for these defects. The aim of this thesis was
to explore the pathogenesis of pregestational diabetes-induced CHDs and coronary artery
malformations

(CAMs),

while

testing

the

efficacy

of

two

clinically

relevant

pharmacotherapies. To this end, using a mouse model of pregestational diabetes, I examined
the impact of hyperglycemia-induced elevations in oxidative stress and miR-122 on heart
development, concurrently determining the preventative capabilities of sapropterin or
antimiR-122 treatment. I confirmed that pregestational diabetes results in spectrum of CHDs,
CAMs and cardiac function deficits, and that their incidence is significantly lowered with
either sapropterin or antimiR-122. Specifically, sapropterin treatment lowered the incidence
of CHDs and CAMs from 59% and 50% to 27% and 21%, respectively. Similarly, antimiR122 therapy reduced this incidence of CHDs from 57% to 23%. These morphological
malformations range in severity, and include septal and outflow defects (OFT), myocardium
deficiencies, and hypoplastic coronary arteries. Lineage tracing experiments revealed a
diminished commitment of second heart field progenitors to the OFT, endocardial cushions
and ventricular myocardium in embryonic hearts from diabetic dams. In addition, deficits in
i

cardiogenic gene expression, enzyme activity, cell proliferation, and epicardial EMT,
induced by pregestational diabetes, contribute to these defects, and were prevented by both
treatments. Specifically, sapropterin treatment reestablished the functional eNOS dimer and
restored its phosphorylation in embryonic hearts of diabetic dams, leading to normal
cardiovascular development. Conversely, antimiR-122 attenuated the targeting and inhibition
of key genes responsible for cardiogenesis by miR-122. These results suggest that
sapropterin and antimiR-122 may have therapeutic potential in preventing CHDs in children
of women with pregestational diabetes.

Key words:
Pregestational diabetes, congenital heart defects, embryonic heart development, sapropterin,
tetrahydrobiopterin, oxidative stress, coronary artery development, miR-122, antimiR-122
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Lay Summary
The most common birth defects are congenital malformations of the heart, accounting
for 1-5% of live births. Newborns with congenital heart defects have an increased risk of
mortality, as proper function of the heart is compromised when specific development is not
attained during gestation. Congenital heart defects can go unnoticed by doctors at birth,
however, as the child matures and is involved in increasing amounts of physical activity, the
congenital malformations can manifest themselves. Therefore, it is vital that research be
conducted into how and why these malformations develop, and more significantly, what
remedies during pregnancy can prevent their occurrence. In terms of how these defects arise,
it has been previously shown that pregestational diabetes in the mother increases the risk for
congenital heart defects in the child by over 50%. Studies in animal models have confirmed
diabetes as a risk factor for newborns with malformed hearts. This connection is alarming as
the incidence of diabetes in a younger demographic is seemingly increasing. This is also true
for the female population, specifically in North America. More and more women are being
diagnosed as diabetic at a younger age, and if these women have children, their offspring
may have a serious, life-threatening medical condition. Therefore, it is beneficial not only to
the lives of these children, but also to the health-care system to find a solution to this
problem. This research will attempt to do just that, as we will investigate whether
administration of sapropterin or antimiR-122 will decrease the presence of heart defects in
the offspring of diabetic mouse mothers.
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Chapter 1

1

Introduction

1.1 Pregestational Diabetes
Diabetes is a major health problem, currently affecting 451 million people
globally. The number of diabetic patients is estimated to reach 693 million by 2040.1 In
Canada, more than 11 million people are living with diabetes or prediabetes.2 Diabetes
has two subtypes. Type 1 diabetes (T1D) is also called juvenile or insulin-dependent
diabetes. In T1D, pancreatic beta cells produce little or no insulin, the hormone that
allows glucose to enter the cells, resulting in hyperglycemia. Type 2 diabetes (T2D) is
often associated with obesity and peripheral insulin resistance. In T2D, hyperglycemia is
present despite elevated blood levels of insulin or hyperinsulinemia. The prevalence of
T2D among the adolescent population in the US has increased 31% between 2001 and
2009, with pre-diabetes rising from 9 to 23%.3 It is well known that diabetes is an
important risk factor for cardiovascular disease, such as congenital heart disease, stroke,
peripheral artery disease and heart failure. In fact, about 80% of people with diabetes die
as a result of heart disease or stroke.4
Importantly, the incidence of T2D is rapidly increasing in women at their
childbearing age.1 It is estimated that 1 in 5 women are overweight/obese during
pregnancy.5 Diabetes not only affects adult health but also puts developing embryos at
risk in pregnant women as glucose can easily pass through the placenta and reach the
fetal circulation. When these women have diabetes, not only is their own health affected,
but their pregnancy is associated with a high risk of congenital malformations in the
fetus. In addition, emerging longitudinal data suggests that adult metabolic and
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cardiovascular disorders are in-part attributable to physiological insults in fetal life.6,
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Adverse uterine environments, including maternal obesity, diabetes, undernutrition and
stress, can compromise embryonic development, reprogramming the epigenetic
landscape.8
Pregestational diabetes (PGD) is the development of diabetes prior to conception
either by T1D or T2D. The risk of major congenital malformations in the offspring of
women with diabetes is 3 to 10-fold higher compared to the general population.9, 10 In a
recent population based study, similar rates of congenital malformations were reported
between T1D and T2D (4.8.% and 4.3%, respectively).11 Although circulating insulin levels
are elevated in T2D, maternal insulin does not cross the placenta. Thus, hyperglycaemia is
likely the main cause of the congenital malformations in the offspring of diabetic women.

1.2 Heart Development
The heart is the first fully functional organ to form during embryogenesis, and its
development is orchestrated by an interplay of conserved transcription factors that control
growth, morphogenesis, and contractility of this ancient pump.12 Cardiac development is
a complex and intricate process that in essence involves the harmonic combination of 3
pools of progenitor cells, that when present in a specific spatial and temporal orientation
together, form a self-excitable, four-chambered, vascular pump which only stops beating
at the time of death.13 Heart development commences at week 3 of human
embryogenesis, corresponding to embryonic day 7.5 (E7.5) in the mouse,14 with the
formation of a cardiac crescent and subsequent heart tube from cells of the anterior lateral
mesoderm. This first wave of cardiac progenitors has been termed the First Heart Field
(FHF), and includes myoblasts forming the tube and endothelial cells lining the entire
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structure.15 The primitive heart tube is elongated at its poles by the addition of
proliferative cells coming from the adjacent splanchnic pharyngeal mesoderm. This
consecutive wave of myoblasts has been termed the Second Heart Field (SHF), and
contributes to the rightward looping morphogenesis of the tube, whereby primitive
chambers of the heart can be distinguished.15 Chamber development by ballooning,
muscularization and fusion of endocardial cushions, ventricular myocardialization and
septation, outflow tract (OFT) and cardiac valve development are completed thereafter,
with the addition of cardiac neural crest cells (CNCs) migrating from the dorsal neural
tube.16 Cardiac development is therefore an extremely complex spatiotemporal process,
and a misstep in this orchestration could lead to a congenital heart defect (CHD). The
sections to follow will detail the nature of these cardiac heart fields, the numerous steps
involved in heart morphogenesis, as well as the transcriptional regulation that directs this
entire process.

1.2.1

The First Heart Field
In embryology, a heart field is defined as a source of cardiac progenitor cells at a

particular location that give rise to the heart.16 Clonal analysis has revealed that the FHF
segregates from the SHF early in gastrulation,17 and the basic helix–loop–helix
transcription factor MESP1 marks this nascent cardiac mesoderm.18 Following
gastrulation, cardiac precursors of both lineages migrate to either sides of the embryo
midline, below the head folds.19 Here, cardiogenesis begins, with the formation of a
cardiac crescent from cells of the anterior lateral mesoderm, at E7.5 in the mouse. These
cells are known as the FHF and contribute to the establishment of a linear heart tube,
which is formed by the joining of the edges of the cardiac crescent at the ventral
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midline.20 Here, the first evidence of a heart-beat is seen as calcium transients and
peristaltic contractions commence through the heart tube at E8.0 in the mouse.21 This
heart tube is composed of a concentric inner layer of endocardial cells and outer layer of
myocardial cells separated with extra-cellular matrix, also known as cardiac jelly.22 The
venous pole of this tube contains the cardiac inflow tract and the transient sinus venosus.
This is connected via the atrioventricular canal to the primitive ventricle, which will
develop into the left ventricle of the heart.15, 23 The FHF-derived heart tube specifically
contributes to parts of the atria and the left ventricle of the mature heart.

1.2.2

The Second Heart Field
The primitive heart tube is elongated with the addition of cells from a second

subpopulation of progenitors, originating from the pharyngeal mesoderm. This group of
cells was discovered after the FHF and has been termed the Second Heart Field (SHF),
and is originally situated medial to the cardiac crescent and then dorsal to the primitive
heart tube.24 A distinct gene expression profile is noted in these cells before gastrulation
in the early embryo. Lineage tracing experiments have revealed SHF-derived structures
and precursors marked with the Mef2C transcription factor driven by an anterior heart
field specific enhancer element. Activity of this enhancer is detectable as early as the late
primitive streak stage in a subset of cells, prior to gastrulation,16 suggesting that the
regional contributions to the heart are specified before the onset of cardiogenesis. These
cells elongate the heart tube by migrating to its arterial and venous poles, progressively
adding new myocardium and endocardium to the outflow and inflow tracts, respectively.
Accordingly, the cardiac outflow tract is derived from the anterior SHF whereas, the
cardiac inflow tract, which will become the atria of the heart, is posterior SHF-derived.15
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Posterior SHF progenitors can be further segmented into right and left regions, forming
the right and left atria, by early expression of Pitx2c confined to the left. 25 The
longitudinal growth of this tube brought about by the addition of the SHF is crucial for
proper looping of heart onto itself. The linear tube undergoes a rightward looping
morphogenesis, with the addition of the proliferative SHF progenitors between
embryonic days 8.25 and 10.5.24 Along with Mef2C marking the anterior SHF, the
expression of Fgf8 and Fgf10 is noted in these cells beginning at the crescent stage.26
These growth factors are a pro-proliferative signal for these progenitors, contributing to
proper cardiac looping leading to the formation of the primitive chambers of the heart.
While expression of these factors is restricted more anteriorly, Isl1 expression extends
into the posterior SHF, and is critical for both venous and arterial pole development. In
fact, Isl1-mutant mice have defects in the atria and great arteries of the heart.27
Additionally, ablation of Hand2 in the SHF using the Isl1-Cre transgenic mouse resulted
in high levels of apoptosis in the pharyngeal mesoderm, suggesting that Hand2 is
required for the survival of undifferentiated cardiac progenitors prior to their migration to
the heart tube.28 At the time of looping, another pro-proliferative signal for the SHF
comes from the pharyngeal endoderm via sonic hedgehog (Shh). Shh signaling promotes
SHF proliferation, survival and regulates migration of these progenitors into SHF-derived
structures such as the atrial septum and pulmonary trunk.29,

30

The canonical WNT

pathway as well as Notch signaling also promote proliferation of the SHF. The
progressive addition of the SHF to the looping heart tube contributes to the formation of
endocardial, myocardial and smooth muscle cells of the outflow tract (OFT), the
prospective right ventricle (RV), the atria and the interventricular septum.31
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1.2.3

Cardiac Looping and Endocardial Cushion Formation
Bilateral asymmetry in the early embryo is first established with the looping of

the primitive heart tube. Left-right patterning differences of gene expression and cell
polarity govern the asymmetric morphological formation of the heart.32, 33 Proper looping
in a rightward fashion, commencing at E8.25, is critical for correct orientations of the
atria and ventricles, establishing a circulatory system for the growing fetus.14 The dextral
looping results in an helical shape with an inner curvature between the outflow and
inflow tracts.34 Analysis of this morphogenesis using high-resolution episcopic
microscopy has rendered a 3D computer simulated model of this morphogenesis. Le
Garrec et al. show that the heart tube grows dorsally while remaining anchored at both
ends. The length of the tube increases by over 4-fold, while the distance between the
poles is fixed, resulting in a looped heart.32 The highly proliferative nature of the SHF,
discussed in the previous section, accounts for this elongation. Looping is followed by
formation of endocardial cushions within the OFT and atrioventricular canal (AVC)
eventually leading to a four chambered heart.35 These OFT cushions form in the
conotruncal region between the ventricle and aortic sac; and AVC cushions develop in
the transition zone between the primitive atria and ventricle, both arising from the
endocardium via epithelial-to-mesenchymal transition (EMT). The endocardial cushions
transform into cardiac valves and aid in the septation of the mature heart, but function to
shunt blood in the developing heart.36

1.2.4

Chamber Formation and Septation
The heart chambers grow outward from the heart tube in a process known as

ballooning beginning at E9.5. The cardiomyocytes on the outer curvature of the tube begin

7

to proliferate acquiring a distinct transcription profile that facilitates their growth22 as well as
differentiates them into the cardiac myocardium, with an increased conduction velocity.37
Cells along the inner curvature and AVC remain as undifferentiated myoblasts, which
express transcriptional repressors to prevent differentiation, and resemble nodal
myocardium.37 Concurrent with ballooning growth at proliferative zones along the ventricle
loop forming the right and left ventricle, trabeculae develop at proliferative zones on the
luminal myocardium by Notch, BMP10 and Neuregulin1 signals coming from the
endocardium.38, 39 The trabeculae function to increase surface area for oxygen uptake prior
to the establishment of the coronary vasculature. The atrial and ventricular septa are formed
between E9.5 and E14.5 in mice. Multiple primordia contribute to a central mesenchymal
mass, including the mesenchyme on the leading edge of the primary atrial septum, the
atrioventricular endocardial cushions, and the cap of mesenchyme on the spina vestibule.40
The membranous, primary atrial septum descends from the roof of the atrial segment of the
heart tube, reaching the AV cushion. This structure is completely SHF derived, driven by
the transcriptional activity of Gata4, initiating proliferative and cell cycle gene expression,
such as Cyclin D2 and Cyclin-dependent kinase 4.41 The primary atrial septum does not
fully fuse with the endocardial cushion, instead creating the foramen primum, which allows
for blood flow between the right and left atria until its closure at E12.5. At this point the
foramen secundum forms on the primary atrial septum through apoptosis.42 While this is
occurring, a muscular septum, known as the septum secundum, grows downward parallel to
the primary septum. An opening, termed the foramen ovale, exists between these two septa
and allows for shunting of blood between the atria during gestation as oxygenated blood is
not received from the fetal pulmonary circulation.43 Similar to the atrial septum, the
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ventricular septum has membranous and muscular components, however, they are fused
together as one structure. Formation of the intraventricular septum begins with the
invagination of muscular myocardium at the apical component of the heart tube during
chamber ballooning around E10.5.44 The muscular septum grows between the common
ventricular superiorly toward the AV cushions located at the base of the heart.44 The
majority of the muscular septum is derived from proliferation of cardiomyocytes as well as
compaction of the trabeculae; however, the epicardium also contributes to progenitors via
EMT to form this structure.45 The muscular septum fuses with the membranous component
of the intraventricular septum that originates from the AV cushion and grows downwards.
Lineage tracing with the anterior heart field specific Mef2c indicates that the interventricular
septum is almost entirely SHF-derived. Moreover, experiments knocking out Tbx5 and
Hand2 in the SHF result in atrial septal defects (ASDs) and ventricular septal defects
(VSDs), respectively.16, 24

1.2.5

Ventricular Myocardium Development
Maturation of the newly formed cardiac chambers occurs concurrently with

ventricular septation and continues into the later stages of embryonic development,
muscularizing the ventricles to meet the increased cardiac output demands of the embryo.
At the onset of heart development, at E8.0, the volume of the myocardium constituting
the linear heart tube is approximately 0.0014 mm3; by E17.5 the volume of the
myocardium reaches 2 mm3.22 This myocardial growth is achieved by hyperplysia of
cardiomyocytes, estimated to be 1 million cells at birth.22 About 30% of the cells forming
the mature ventricle wall are cardiomyocytes, the rest being endothelial cells, vascular
smooth

muscle

cells,

fibroblasts,

immune

and

epicardial

cells.46

Primitive
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cardiomyocytes are spherical and mononuclear and begin to mature at E13.5 when they
elongate and assume a rod shape.33 Many signaling pathways regulate cardiomyocyte
proliferation and maturation, including Hippo signaling.47 Proliferation and apoptosis
during normal cardiac development will be explored in a following section. Formation of
the mature myocardial architecture of the ventricle wall begins with trabeculation,
followed by compaction and growth. Prior to the development of the compact
myocardium, which is primarily governed by epicardial-derived signals, endocardialderived factors lead to the onset of trabecular development at E9.0.48 The interplay of
Notch and neuregulin/ErbB signals from the endocardium leads to rapid growth at the
proliferative centers along the ventricle wall, forming protrusions known as trabeculae.49,
50

Individual trabecular units are formed from endocardial projections into the lumen

resulting from Notch1-induced ECM degradation and neuregulin-induced ECM synthesis
and rearrangement by the myocardium.48 Since these trabeculations are established prior
to coronary circulation, the increased surface area to volume ratio they provide enables
sufficient oxygen uptake and nutrient exchange, facilitating growth of the myocardium.51
These sponge-like structures of cardiomyocytes are also important for ventricular
septation and papillary muscle development.52 As the embryo develops, the muscle layer
gradually thickens to compensate for the increased physiological load by cardiomyocyte
proliferation and trabecular compaction, driven by FGF signaling from the epicardium.
This process is concurrent with development of the coronary vasculature, and the spaces
formed between compacted trabeculae become capillaries. Abnormalities in the
formation of a multilayered myocardium, seen in cases of genetic perturbations of Notch
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signaling components, disrupts chamber development, resulting in a noncompacted
cardiomyopathy or ventricular hypoplasia.53, 54

1.2.6

Outflow Tract Development
Concurrent with chamber development and maturation, the arterial pole of the

heart tube undergoes several remodeling steps to form the aorta and pulmonary artery.
Prior to looping, the outflow tube of the heart is comprised of SHF-derived myocardial
cells with an inner lumen lined by endocardial cells. Collectively known as the outflow
tract, both arteries begin as a common arterial trunk connected to the right ventricle after
looping. The OFT endocardial cushions and myocardium are anterior SHF-derived,55 and
these proliferative progenitors connect the ventricle to the aortic sac. The OFT must
reorient and septate in order to establish proper connection of the aorta with the left
ventricle and the pulmonary artery with the right ventricle. This re-positioning and
counterclockwise rotation is accomplished by an asymmetric addition of SHF progenitors
to the future pulmonary artery and primitive right ventricle regions, in a process termed
the “pulmonary push.” This allows the pulmonary trunk and orifice to achieve a higher
and more anterior orientation compared to the aorta.56 Septation of the OFT is
accomplished by the contribution of the cardiac neural crest cells. These multi-potential
cells are a part of the cranial neural crest region of the dorsal neural tube from which
progenitors delaminate and migrate to various regions of the embryo at E9.0. In the heart,
the addition of these cells helps to separate the OFT, form the semilunar valves, and add
parasympathetic innervation.57, 58 Fusion of the OFT cushions with input from the CNC
result in the formation of the aorticopulmonary septum, which is complete by E14.0.59
Abnormalities in the convergence of SHF and CNCs cells, or the improper wedging of
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the OFT can cause major defects such as double outlet right ventricle (DORV) and
transposition of great arteries (TGA), which will be discussed in following sections.

1.2.7

Cardiac Valve Development
The interfaces between the heart chambers and OFT house specialized structures

that maintain unidirectional blood flow during a cardiac cycle. The semilunar valves exist at
the junction between the ventricles and the great arteries, whereas the AV valves connect the
atria to the ventricles. Both sets are comprised of a combination of connective tissue and
valvular interstitial cells.60 Valvulogenesis begins with the formation of endocardial
cushions in the OFT and AV canal, in response to BMP2 signals from the myocardium,
around E9.0.61 These localized swellings of cardiac jelly, containing endocardial-derived
mesenchyme and ECM components such as collagen and hyaluronic acid, initially act as
valves in the primitive heart tube as they control the flow of blood.62-64 TGF-beta, Notch and
the canonical Wnt signalling pathways control the proliferation and expansion of the
mesenchyme.65 Endocardial cells then undergo endocardial-to-mesenchymal transition
(EndMT), migrating and proliferating into the cushion causing its elongation. These
mesenchymal cells differentiate into valvular interstitial cells, which extensively remodel the
ECM and sculpt the valves.63 The valve leaflet becomes thin and elongated, with the ECM
becoming stratified, rich in elastin, fibrillar collagen and proteoglycans.66 The mitral and
tricuspid AV valves are derived from the endocardial cushion and epicardium, while the
aortic and pulmonary semilunar valves are formed from endocardial cushion and cardiac
neural crest cells.16, 35, 63 Genetic tracing experiments using the Wt1-Cre transgenic mouse
confirm that epicardial-derived cells differentiate into fibroblasts and contribute specifically
to the mural leaflets of the AV valves.67 Conversely, lineage tracing using the Cx43-lacZ,
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Wnt1-Cre and Krox20-Cre mouse lines show a CNC contribution to the interleaflet region
and insertion zone of the semilunar valves.68

1.2.8

Transcriptional Regulators of Heart Development
Recently, single cell RNA-sequencing to map the transcriptome of the developing

human heart revealed that cardiomyocytes can be partitioned into 4-chamber specific
clusters based on differential gene expression signatures as early as 5 weeks into
embryogenesis.69 A number of conserved transcription factors govern the complex
process of cardiac development. Transcription factors are DNA binding elements that
regulate the expression of downstream target genes. Through the use of genetic knockout
mice, several transcriptional factors have been identified to be critical in the development of
various cardiac structures. Mutations in GATA-4, Nkx2.5 and Tbx5 and MEF2 are
associated with CHDs in humans.70-73 Specific spatiotemporal interaction and crosstalk
between these factors are essential to control cardiogenic gene programs driving normal
heart development.74

1.2.8.1

Nkx2.5

Nkx2.5 (homeobox protein NKX2-5) is an early cardiomyocyte marker and
regulator of heart morphogenesis and function, conserved from Drosophila to humans.75
Its expression begins at the cardiac crescent stage in the FHF, SHF and adjacent
endoderm, controlling migration and differentiation of cardiac precursors.76,

77

In the

SHF, Nkx2.5 functions to maintain the proliferative progenitor cell pool.16 Loss of
Nkx2.5 results in impaired cardiac development, as decreased myocardial growth and
trabeculation are noted.78 Nkx2.5 null mice die between E9 and 10.5 due to an
underdeveloped heart.79 Specifically, mesodermal expression of Nkx2.5 is required for
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cardiogenesis, as its germ-layer specific deletion resulted in cardiac defects identical to
null embryos, whereas endodermal expression is dispensable for heart formation.80 Thus,
Nkx2.5 mutant mice have a spectrum of CHDs, including atrial septal defect (ASD),
ventricular septal defect (VSD), tetralogy of Fallot (TOF), transposition of the great
arteries (TGA) and double outlet right ventricle (DORV).81 Nkx2.5 is also implicated in
familial CHDs in the human population, where a similar variety of malformations
results.77 As Nkx2.5 is a dosage-sensitive regulator of cardiac development,
haploinsufficiency and inherited point mutations cause CHDs in humans.82,

83

Nkx2.5

directly associates with Gata4 early on in heart development to specify cardiac
mesoderm.73

1.2.8.2

Gata4

Three isoforms of the GATA family of zinc finger transcription factors are
cardiomyocyte specific. Specifically, Gata4 is a master regulator of cardiac progenitor
cell proliferation and differentiation, implicated in various facets of heart development
and function.84 Beginning its expression at E7.5, a number of cardiac transcriptional
targets have been identified for this factor. The expression of the cardiomyocyte
contractility protein α-MHC, the SHF specific Mef2c and the cell cycle regulator Cyclin
D2 are all controlled by Gata4.41, 85 In fact, a conserved enhancer element upstream of the
Mef2c gene has two consensus GATA sites bound by Gata4, thereby dictating early OFT
and right ventricle development in the anterior heart field.85 Gata4 also plays a pivotal,
dose-sensitive role in cardiac septation through its interactions with Hedgehog signaling
in the SHF.41 Loss of Gata4 is embryonically lethal in mice by E8.5 as a deregulation in
lateral-to-ventral and rostral-to-caudal folding prevents the cardiac crescent from fusing
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at the midline.86 In humans, defects in the atrial and ventricular septum at birth, and
dilated cardiomyopathy later in life, have been attributed to mutations in Gata4. This
gene is considered hyper-mutable as 110 different genetic mutations have been
identified.87,

72

Interestingly, in a case of familial CHDs due to a Gata4 missense

mutation, the physical interaction between Gata4 and Tbx5 was interrupted.72 It has since
been established that both these factors synergistically cooperate to activate cardiogenic
gene expression.88

1.2.8.3

Tbx5

Tbx5 (T-box 5) is another transcription factor expressed in early cardiogenesis,
beginning around E8.0.89 Although Tbx5 marks the left ventricular myocardium, its
expression is dynamic and even present in a subpopulation of the SHF.16,

90

As such,

Tbx5 is involved in the formation of the interventricular septum, but also plays a major
role in the development and maintenance of the cardiac electro-physiological conduction
system by regulating the expression of connexin 40.91 Tbx5 mutations affect cardiac
septation, inflow tract development and result in left ventricular hypoplasia; leading to an
arrest of cardiogenesis in null mice by E10.5.70, 90 Holt-Oram syndrome affects patients
with dominant mutations in Tbx5 and is characterized by septal and conduction defects in
the heart, along with impaired anterior forelimb development.90, 92 This factor not only
activates cardiogenic genes, but also functions to repress transcription of incompatible
gene programs by interacting with the nucleosome remodeling deacetytlase complex
(NuRD).93 Tbx5 also interacts physically with Mef2c early on in heart development,
leading to the activation of α-cardiac myosin heavy chain, critical for cardiomyocyte
differentiation.94
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1.2.8.4

Mef2C

Finally, Mef2C is a transcription factor expressed in the SHF precursors adjacent
to the cardiac crescent and continues to the OFT and right ventricle of the mature heart
from E7.5 to E11.5.95 It is specified to the anterior SHF through independent enhancer
elements, and controls myocyte differentiation.85 The monocyte enhancer factor 2
(MEF2) family regulates muscle-specific genes, and Mef2C is essential for sarcomere
contractile element expression, like α-actin.96 Absence of Mef2C results in a cardiac
looping impairment, lack of a right ventricle and is embryonic lethal between E9.5 and
E10.5.96, 97 This germline knockout phenotype is recapitulated by deletion of Mef2c in
early cardiac tissue using the Nkx2.5-cre transgenic mouse. However, deletion using the
endothelial-specific Etv2-cre line results in viable offspring with no CHDs, suggesting
that this factor is dispensable for endothelial progenitors, but is required for all
myocardial cells.98 Other SHF exclusive genes that distinguish this group of progenitors
from the FHF include the growth factors Fgf8 and Fgf10 as well as the transcription
factors Tbx1 and Isl1.24

1.2.9

Proliferation and Apoptosis in Cardiogenesis
Proliferation and apoptosis are key features of normal organ development. The

adult heart is generally considered to be post-mitotic, as mouse cardiomyocytes lose their
regenerative capacity after P7; unable to undergo cell division and instead increase in cell
volume. The embryonic heart, however, depends on high amounts of proliferation.
Multipotent cardiac progenitor cells of the FHF and SHF undergo proliferation followed
by differentiation into cardiomyocytes, which in turn undergo further clonal expansion.50
Specific regions of the heart tube undergo preferential proliferation resulting in chamber
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ballooning, forming the left ventricle at E8.5.99 The highest proliferation rates are
observed at the base of the ventricles at E11, after which the increase in cardiomyocyte
number declines.100 Notch signaling, at the base of the trabecules, lining the ventricle
wall, induces high rates of proliferation among less differentiated cardiomyocytes,
resulting in trabecular elongation.39, 53 Furthermore, mesodermal cells of the SHF are also
highly proliferative, elongating the primitive heart tube and resulting in its rightward
looping. These progenitors remain proliferative much after the FHF, and their capacity is
mediated by canonical Wnt signaling.100,

101

-catenin was found to be essential for

expansion of SHF cardiac progenitors through deletion of this Wnt pathway component
using the Ils1-cre mouse line.101 In addition, epicardial-derived growth factors induce
myocardial proliferation, contributing to the expansion of the compact myocardium.
These ligands include members of the Fgf, Igf and Wnt families (eg. Fgf-9, Igf-2 and
Wnt9B), as well as retinoic acid, promoting proliferation of the myocardium.102-104 The
hippo kinase cascade also dictates embryonic cardiomyocyte proliferation. In fact,
ablation of Yap1, the nuclear target of the hippo pathway, in vascular SMCs of the
embryonic heart suppressed their expansion and enhanced expression of cell cycle arrest
genes, leading to cardiac defects associated with decreased proliferation such as DORV
and ventricle wall hypoplasia.105 Deletion of Yap1 in fetal cardiomyocytes is embryonic
lethal by E16.5 due to decreased ventricle chamber size and cardiac hypoplasia, resulting
in pericardial effusion and heart failure.106 Conversely, overexpression of Yap1 in
cardiomyocytes increases heart size through elevated proliferation.106 Furthermore, Rac1,
a Rho GTPase and regulator of cellular structure, is required for anterior SHF progenitor
cell proliferation and organization of the splanchnic mesoderm. Loss of Rac1 signaling
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decreases the proliferation rate of SHF progenitors, subsequently resulting in OFT and
cardiac valve anomalies.107 Finally, nitric oxide is intimately linked to cardiomyocyte
proliferation. Postnatal eNOS knockout cardiomyocytes have lower levels of BrdU
incorporation and fewer cells in culture compared to WT.108 This decrease in
proliferation is mediated in part by an increased TIMP-3 expression, as treatment with an
anti-TIMP3 antibody increased proliferation of eNOS-/- cardiomyocytes.109 In the
embryonic heart eNOS deficiency decreased proliferation and growth of epicardial cells,
by decreasing activity of cGMP-dependent protein kinase G signaling, thereby
downregulating Gata4 and cardiac growth factor expression.110 Along with promoting
proliferation in the embryonic heart, nitric oxide promotes survival by protecting cardiac
progenitors against apoptosis.110
Apoptosis, or programmed cell death, is an intricately regulated process involving
cellular

disintegration

by

cell

shrinkage,

cytoskeletal

breakdown

and

DNA

fragmentation, and is a normal part of an organism’s development and life cycle. It is
initiated and executed by the caspase family of proteinases, which systematically cleave
proteins leading to blebbing and cell death.111 This process is an integral part of
embryonic development as it aids in the proper integration of cells into tissues, shaping
the structure of an organ.112 During cardiogenesis, apoptosis acts as a differentiation
mechanism by inducing changes to nearby cells, contributing to the development of the
OFT, cardiac valves, coronary vasculature and conduction system.113,

114

Significant

levels of apoptosis have been identified in the mesenchyme of the AV cushions, the
trabeculae and compact zones of the ventricles, and the OFT.115 Specifically, the
cardiomyocytes of the OFT undergo apoptosis to facilitate shortening and rotation of the
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myocardial conus, allowing for proper connection between the right ventricle and
pulmonary artery.116 In addition, high levels of programmed cell death have been
observed in the CNCs, which may be involved in the process of myocardialization of the
OFT.55 Changes to the microenvironment induced by apoptosis of CNCs in the OFT
cushion is thought to signal differentiation of the mesenchyme into myocardium.117
Whole embryo knockout of FADD, the Fas-associated death domain protein, involved in
the extrinsic pathway of programed cell death, is lethal by E11.5 with a dilated cardiac
phenotype. Similarly, mice with a deletion of the caspase-8 gene die in utero by E12.5
due to impaired cardiac muscle development leading to heart failure and edema.118
Consistent with the proliferation defects, eNOS-/- hearts displayed elevated levels of
cardiomyocyte apoptosis and myocardial cleaved caspase-3 at E12.5 and E15.5,
compared to controls. Atrial and ventricular septal defects were found at a higher
incidence in neonatal eNOS knockout hearts, in which increased apoptosis was
maintained.119 Interestingly, in neonatal cardiomyocytes, iNOS-derived nitric oxide
production mediates the apoptotic effects of TNF-α stimulation.120 Moreover, in cultured
H9C2 myocytes, transduction of microRNA-122 increased caspase-3 activity and cell
death.121

1.2.10

Fetal Cardiovascular Physiology

Circulation in the fetus shifts after birth as it becomes independent from the
maternal circulation. Normally, in the postpartum heart, deoxygenated blood enters the
right atrium from the venous inflow of the superior and inferior vena cavae. This blood
fills the right ventricle which subsequently contracts and pumps venous blood to the
pulmonary circulation through the pulmonary artery. Gas exchange occurs in the lungs,
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and oxygenated blood returns back to the heart via the pulmonary veins, entering the left
atrium. Once the left ventricle fills, oxygenated blood is pumped into the aorta and travels
through the systemic circulation, allowing arteries and arterioles to perfuse tissues of the
body.122 In contrast, since the lungs are not functional in the fetus, gas exchange occurs
via the placenta. Therefore, the fetal heart has structural adaptations, known as shunts, to
facilitate blood flow throughout development.122 The ductus arteriosus connects the
pulmonary artery to the aorta. Oxygenated blood from the placenta flows into the inferior
vena cava via the umbilical veins. This blood is pumped by the right ventricle, but, in this
case, is shunted by the ductus arteriosus into the dorsal aorta because of the high-pressure
resistance of the pulmonary artery. This shunt remains open throughout fetal
development due to the high oxygen tension and prostaglandin secretion from the
placenta.122 Another feature of the fetal heart is the foramen ovale, which shunts
oxygenated blood from the right to the left atria, following a pressure gradient. At birth,
as the newborn’s lungs inflate with air, the resistance in the pulmonary veins will
decrease allowing for blood flow through the pulmonary circulation. This is followed by
a closure of the foramen ovale by the septum secundum because of increased pressure in
the left atrium.122 Finally, hours to days after birth, the decline in prostaglandin levels in
the newborn will cause the ductus arteriosus to close, completing the separation of
pulmonary and systemic circulatory systems.123

1.3 Coronary Artery Development
The development of the coronary vasculature is distinct from the formation of the
myocardium these vessels feed (Figure 1.1). Angiogenesis in the primitive heart begins at
E9.5 in the proepicardial organ (PEO). The PEO is a transient structure adjacent to the
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developing heart tube, located at the pericardial surface of the septum transversum close to
the sinus venosus.124,

125

It contains a heterogenous population of mesothelial cells

expressing Wt1 and Tbx18, destined to migrate to the heart.126, 127 Cells originating in the
PEO migrate and proliferate to cover the surface of myocardium, forming an epicardium
(Figure 1.1).16 By E12.5 this epicardial layer is fully formed.124 A subset of these
epithelial cells undergo epithelial-to-mesenchymal transition (EMT) and become
epicardial-derived cells (EPDCs).125 These EPDCs migrate to the subepicardial space and
myocardium where they differentiate into vascular smooth muscle cells, adventitial
fibroblasts and endothelial cells (Figure 1.1).36 These mesenchymal cells migrate
throughout the developing myocardium and produce much of the coronary vasculature
through a vasculogenic process. This immature vascular plexus initially develops without
blood flow. The proximal ends of the coronary arteries connect to the ascending aorta
through coronary orifices at the level of the left and right sinuses of the semilunar valves,
initiating perfusion. This invasion occurs at the time of cardiac septation, following
separation of the aorticopulmonary trunk, and involves apoptosis.128 The establishment of
blood flow is needed for subsequent remodelling and maturation of the vessels. Coronary
veins connect to the right atrium via the coronary sinus.124, 125 Other sources of coronary
artery progenitors include the sinus venosus and the endocardium (Figure 1.1).36 Similar
to heart development, a complete coronary network is established by E15. Congenital
abnormalities of the coronary arteries can impact heart function and are associated with
coronary arteries diseases in adulthood. 125, 129
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Figure 1.1. Embryonic coronary artery development in the mouse.
Coronary vessels arise from progenitors originating from three distinct sources, the
proepicardial organ (PEO), sinus venosus and endocardium. Formation of these arteries
involved epithelial-to-mesenchymal transition (EMT) followed by differentiation and
growth. By E15 a fully formed vascular plexus supplies oxygen and nutrients to the heart.
E: Embryonic Day, EMT: Epithelial-to-Mesenchymal Transition, EndMT: Endocardialto-Mesenchymal Transition

22

1.3.1

Epithelial-to-Mesenchymal Transition
EMT is a transdifferentiation process of epithelial cells into motile mesenchymal

cells by way of transcriptional reprogramming.130 Cell polarity defines epithelial cells as
they have luminal and basilar domains, connected to one another by adherence junctions,
tight junctions, gap junctions and desmosomes. Delamination into a migratory cell type
involves loss of this polarity, a dismantling of cell-to-cell connections and cytoskeletal
rearrangement, all mediated via activating mesenchymal gene programs and repressing
epithelial signatures. This switch in phenotype is carried out by local upregulations of EMT
ligands and factors, as well as molecular signalling cascades initiated by receptor binding. In
the cardiovascular system, transforming growth factor beta (TGF-β) and bFGF signalling
induces the breakdown of the basement membrane, reorganizes actin filaments and allows
for cell movement.36 In addition, TGF-β binding results in the upregulation of the
transcription factors Snail and Slug, which further promote cell motility and repress
epithelial genes, such as Cdh1 (E-cadherin).131 A hallmark of EMT induction is cleavage
and endocytosis of E-cadherin, a transmembrane protein that forms cell junction in the
epithelium.132 This is followed by the expression of N-cadherin, a mesenchymal protein, and
together is known as the “cadherin switch.”130 Furthermore, cell motility is enabled by actin
reorganization and polymerization in the direction of migration, along with a degradation of
ECM.133 Following EMT and migration to the destination, the cells can re-differentiate into
other cell types.

1.3.2

Transcriptional Regulators of Coronary Artery Development
Many transcription factors including Gata-4, Fog2 Wt1, VCAM-1 and α-4 integrin

play critical roles in the development of coronary arteries.134, 135 The disruption of many
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mediators of EMT have been implicated the pathogenesis of coronary artery anomalies. For
instance, the master regulator of EMT in the embryonic heart, Wt1, is required for coronary
artery development and is indispensable for epicardial EMT.136 Wt1 is a DNA binding
protein, which directly regulates the expression of other mediators of EMT, such as Snail
and Cdh1 (E-cadherin).137 Mutation of Wt1 in the epicardium is embryonic lethal between
E16.5 and E18.5 due to cardiovascular defects.137 Additionally, Wt1 binds to the Raldh2
promoter in epicardial cells, thereby controlling retinoic acid signaling, essential for EPDC
formation.138 In fact, epicardium-specific mutation of the retinoic acid receptor reduced βcatenin and FGF2 expression, resulting in abnormal arterial branching in the embryonic
heart.138 In addition, genetic deletion of Gata-4 in mice impairs migration and EMT
resulting in the absence of coronary arteries.125, 139, 140 Coronary artery defects are also noted
in Tbx18 knockout (Tbx18-/-) mouse models, as Tbx18 is a transcription factor highly
expressed in the PEO, controlling early artery development. Moreover, coronary
arteriogenesis is also dependent on β-catenin signaling, as ablation of this factor in the
epicardium impaired epicardial expansion, invasion and differentiation; while specific
deletion in the PEO was embryonic lethal.141

1.4 microRNA Regulation of Cardiovascular Development
MicroRNAs (miRNAs) are a class of endogenous, short (20-26 nucleotide), noncoding RNA molecules that post-transcriptionally regulate gene expression by degrading
messenger RNA (mRNA) molecules or repressing their translation.142 A single miRNA
molecule does not require perfect sequence complementarity to bind the 3’ untranslated
region (UTR) of a target mRNA.142 This means that one microRNA can target and
modulate the expression of many mRNAs, and a particular mRNA molecule can be
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controlled by many different miRNAs. The human genome encodes over 2000 miRNAs
and it’s predicted that one-third of all protein-coding genes are regulated by at least one
miRNA.143 Specifically, the human heart expresses over 700 miRNAs, which, in turn,
fine tune the expression of 30% of the heart’s protein coding genes.8 In developmental
biology, miRNAs act as molecular coordinators of gene expression, switching on and off
transcription factors, activators and repressors, in complex regulatory circuits.144
Regulation through miRNA suppression of gene expression has been shown to be vital
for heart development.145

1.4.1

microRNA Biogenesis, Structure and Function
miRNAs are transcribed in the nucleus by RNA Polymerase II or III.146 They can

reside in coding and non-coding regions of the genome and can be the result of
alternative splicing. Expression of miRNAs is controlled in a cell-type specific manner
by transcription factors, thereby creating unique expression profiles for each organ.
Transcription results in a double-stranded RNA hairpin molecule with a 5’ polyadenyl
cap, known as a primary-miRNA (Figure 1.2).146 About 40% of human miRNAs are
transcribed together as clusters containing upwards of 8 distinct miRNA sequences.147
Micro-processing and cleavage of this primary-miRNA by the nuclear Drosha enzymecomplex (an RNaseIII-type nuclease) and , DiGeorge syndrome critical region 8 protein
(DGCR8) forms the ~70-nucleotide-long precursor-miRNA (pre-miRNA) molecule,
which is transported to the cytosol via the Ran-GTP-dependent nuclear transport receptor
Exportin5.148 In the cytosol, the ribonuclease Dicer and transactivator RNA-binding
proteins (TRBP) cleave the precursor-miRNA hairpin loop resulting in a short, ~22
nucleotide miRNA duplex of complementary strands.149 The thermodynamically less
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stable RNA strand is loaded into the RNA-induced silencing complex (RISC) and
functions as the guide strand to mediate miRNA-RISC interactions (Figure 1.2).142

150

The RISC loading complex is composed of Dicer, TRBPs, protein activator of PKR and
Argonaute-2 (Ago2), the latter of which is the RISC effector protein mediating mRNA
destabilization, decay or translational inhibition (Figure 1.2).151 Specifically, the seed
region of the mature miRNA, which usually spans from nucleotide 2 to 7 at the 5’ end of
the miRNA, participates in complementary base pairing at the 3’ UTR of target mRNAs
for mRNA repression.152 Consequently, miRNAs are highly conserved between species,
therefore having the same mRNA targets. Bioinformatic algorithms can predict the
mRNA targets of different miRNAs. 147
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Figure 1.2. microRNA biosynthesis and function.
microRNAs are transcribed in the nucleus as a long precursor transcript with a hairpin
loop, known as the primary microRNA (pri-miR). Processing steps occur in the nucleus
by the enzymes DROSHA and DGCR8 to produce a shorter precursor miRNA (pre-miR),
which is exported into the cytosol by Exportin 5. In the cytosol the precursor miRNA
associated with the DICER, TRBP and Ago2 enzyme complex. The mature miRNA is
loaded into the RNA-induced silencing complex (RISC) where it can execute its function
and inhibit target mRNA expression via complementary binding to 3’ UTRs. This leads
to target mRNA translational inhibition, cleavage or destabilization.
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1.4.2

microRNA in Cardiogenesis
In normal cardiogenesis, miRNAs control the expression of many critical genes

involved in proliferation and differentiation, and play roles in regulating the stages of
heart development.153 The importance of miRNAs in heart development is illustrated in
early cardiac progenitor-specific deletions of Dicer. Ablation of Dicer using Crerecombinase under the control of the endogenous Nkx2.5 promoter in mice, is embryonic
lethal due to cardiac failure by E12.5.154 Deletion of Dicer in the CNC using the Wnt1Cre transgenic mouse resulted in profound craniofacial defects and major CHDs,
including VSD and DORV, stemming from impaired migration and patterning of this
lineage.155 Similarly, using the Gata5-Cre to conditionally knockout Dicer in the PEO and
epicardium in mice led to complete mortality immediately after birth due to severe
coronary vessel malformations stemming from impairments in EMT.156 In addition,
vascular smooth muscle-specific Dicer knockout, with the SM22-Cre, resulted in
mutant mice having hypoplastic coronary arteries and diminished cardiac contractility,
with embryonic lethality around E16.5.157 These studies highlight the broad necessity of
miRNAs for proper cardiac development as Dicer is required for their processing and
function. Gain and loss-of-function experiments looking at specific miRNA families
delineate the pivotal roles of particular miRNAs in cardiogenesis. In organ development,
many miRNAs regulate the cell cycle and direct proliferation.158 For instance,
overexpression of miR-195 under control of the -myosin heavy chain promoter in the
embryonic heart results in VSD and ventricular hypoplasia in mice due to premature cell
cycle arrest.159 The same CHDs were seen when miR-133a is overexpressed by the myosin heavy chain promoter, along with reduced cardiac function and left ventricular
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dysfunction.160 Using the same promoter to overexpress miR-1-2 in mice, embryonic
lethality occurs at E13.5 due to heart failure from ventricular hypoplasia, which is
consistent with a significant decrease in proliferating cells and insufficient muscle
mass.154 Interestingly, deletion of miR-1-2 also results in an abnormal cardiac phenotype
and 50% embryonic lethality. miR-1-2-/- mice have decreased heart rate, prolonged
ventricular depolarization and VSDs.161 These mice have greater heart-weight to bodyweight ratios and larger ventricular cardiomyocytes. Combined deletion of the miR-133a1-2 complex results in VSDs and is embryonic lethal in half of all double mutants. miR1-2 modulates expression of genes involved in cell cycle progression and karyokinesis,
but also downregulates Hand2 by targeting its 3’UTR.161 Hand2 is a cardiogenic
transcription factor, needed for cardiomyocyte expansion and proliferation.162 Thus, the
close regulation of Hand2 expression by miR-1-2 is vital for normal heart development.
Taken together, the gain and loss-of-function studies on miR-1-2 exemplify the critical
role miRNAs play in fine-tuning gene expression in the embryonic heart. Notably, studies
on human congenital heart disease have revealed that some CHDs are associated with
altered miRNA expression. miRNA profiling of human fetal single ventricle
malformation identified 48 differentially expressed miRNAs in the heart, many of which
target genes involved in cardiac development.163 Moreover, in patients with Down
Syndrome (Trisomy 21) who also presented with CHDs, 5 miRNAs (miR-99a, let-7c,
miR-125b-2, miR-155 and miR-802) located on chromosome 21 were preferentially
overexpressed in the heart.164 Finally, case studies on infants with non-syndromic TOF
revealed 61 miRNAs significantly altered in expression in the myocardium compared to
normal subjects.165 These animal models and clinical studies display the fundamental role
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of miRNAs in fetal cardiovascular development, and the consequences of their
dysregulation.

1.4.3

microRNA-122 a novel player in CHD pathogenesis
MiRNA-122 is a conserved, 22 nucleotide miRNA molecule that plays a critical

role in liver development and homeostasis.166 MiRNA-122 is encoded on human and
mouse chromosome 18 and generates a ~4.5 kilobase primary-miR, which is processed to
a 66 nucleotide pre-miR-122. The gene expression of miR-122 is regulated by circadian
rhythms; however, miR-122 has a >24-hour half-life which maintains its constant
levels.167 The cytoplasmic poly(A) polymerase, GLD2, contributes to this stability by
adding an adenosine tail to the mature transcript.168 It is highly expressed in the adult
liver, where it serves as a key regulator of cholesterol and fatty-acid metabolism, as well
as blood alkaline phosphatase levels.166,

169

In fact, just prior to birth, miR-122 copy

numbers reach maximal levels (~50000 per cell) in the liver.170 Mir-122 is also an
important host factor for hepatitis C virus (HCV) replication as it binds to the 5’ UTR of
the viral genome, promoting HCV stability and accumulation, while protecting the RNA
genome from degradation.171, 172 In addition, miRNA-122 is regarded as a potent tumor
suppressor. Liver-specific knockout of miR-122 results in hepatobillary cysts leading to
hepatocellular carcinoma (HCC).173 MiR-122 is repressed in primary tumors in HCC
patients, and its decreased levels are associated with poor prognosis and acquisition of an
invasive, metastatic phenotype.174 Interestingly, it has been shown in vitro that miRNA122 inhibits the angiogenic potential of endothelial cells. Transfection of miRNA-122 to
human dermal microvascular endothelial cells reduced their proliferation, motility, and
ability to form interconnected tubes.175 Correspondingly, it has been reported that
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miRNA-122 is downregulated in many human cancers, which correlates with an increase
in metastasis and EMT.174,

176-182

In addition, miR-122 inhibition of the Wnt signaling

pathways was confirmed by a dual luciferase reporter assay, showing its targeting of catenin.183
The molecular processes involved in cancer and angiogenesis are also critical
components of cardiac development. Therefore, cardiac expression of miRNA-122
during embryogenesis could have deleterious effects by suppressing proliferation and
EMT. Recently, however, studies have shown the presence of miRNA-122 in the adult
heart following injury. In fact, miRNA-122 is regarded as a novel biomarker for
cardiomyopathies. Elevated plasma levels of miRNA-122 are present in patients
following myocardial infarction (MI),184 and in patients with coronary artery disease,185
with levels increasing linearly with the severity of atherosclerotic lesions.186 In fact,
plasma levels of miR-122 are also acutely increased in patients following cardiac
arrest.187 This elevation is noted in rat models of cardiac injury, as miRNA-122 is not
only increased post-infarction in heart tissue, but also directly contributes to the apoptosis
of cardiomyocytes.188 Thus, along with the established roles of miRNA-122 in the liver
and as a tumor suppressor, emerging evidence supports its involvement in cardiac
pathophysiology, as a biomarker and possible contributor, which provides support for
investigating this molecule in maladaptive cardiac development.

1.4.3.1

microRNA Silencing in vivo: antimiR-122

In addition to having clinical value as a diagnostic marker, miRNA-122 is
currently being tested as a therapeutic target in patients with chronic hepatitis C virus
(HCV) infection.166, 189, 190 MiRNA-122 specifically binds to two distinct sites in the 5’
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non-coding region of the HCV genome and upregulates viral RNA levels, thereby
facilitating viral replication.191, 192 Therefore, targeting miRNA-122 presents an avenue
for

anti-viral

intervention.

AntimiRNAs

are

chemically

modified

antisense

oligonucleotides that are designed to bind endogenous miRNAs with high affinity and
decrease their expression levels. Accordingly, to combat HCV infection, clinicians utilize
a locked nucleic acid (LNA) modulation of antimiRNA-122 (Miravirsen, SPC3649),
resistant to nuclease degradation in vivo.190, 193 Miravirsen has sequence complementarity
to human mature miRNA-122 allowing perfect hybridization, thereby blocking its
interaction with the viral RNA genome. Moreover, Miravirsen has sequence
complementarity with primary and precursor miRNA transcripts, and inhibits miRNA122 biogenesis.189 Currently in clinical trials, Miravirsen administration to patients with
chronic hepatitis C infections results in a dose-dependent and prolonged reduction in
plasma HCV RNA, without affecting the levels of other miRNAs.190

1.5 Congenital Heart Disease
CHDs arise from perturbations in complex cellular and molecular processes
underlying embryonic heart development. Thus, because of the intricate nature of cardiac
development, a misstep in the orchestration could lead to abnormalities. Alterations in
cardiogenic gene expression, cell migration or proliferation can have implications for
heart structure, and can result in CHDs. Congenital malformations of the heart are the
most common birth defect, accounting for 1-5% of live births.194,

195

Congenital heart

disease is the leading cause of pediatric deaths in developed nations.196,

197

Some

congenital defects can go unnoticed at birth; however, as the child matures and is
involved in increasing amounts of physical activity, the congenital malformations can

32

manifest themselves. A spectrum of congenital heart defects exist that span from minor
anomalies such as an atrial septal defect (ASD) to major malformations including
transposition of the great arteries (TGA).198 Septal defects are holes in the ventricular or
atrial septum, leading to a mixing of de-oxygenated and oxygenated blood. CHDs also
affect sites distant to the actual myocardium such as the descending aorta, which can be
narrowed resulting in coarctation. OFT defects such as persistent truncus arteriosus
(PTA), and malformations in the valves of the heart contribute to the spectrum of defects
of congenital heart disease and are a result of improper cardiogenesis. These defects
compromise the function of the cardiovascular system as the ability of the heart to
perfuse all tissues of the body with oxygenated blood is decreased. For instance, the
inability of the endocardial cushions to complete the process of septation could result in a
ventricular septal defect (VSD), which would allow for mixing of oxygenated and
deoxygenated blood from the systemic and pulmonary circulations resulting in a
decreased functional cardiac output. Congenital malformations can follow a pattern of
incidence where multiple CHDs are present in the same heart. Tetralogy of Fallot (TOF)
is an example of this phenomenon and is composed of a VSD, pulmonary stenosis, right
ventricular hypertrophy and an overriding aorta.199, 200 Genetic and environmental factors
are associated with CHDs. Mutations causing cardiac abnormalities can either be
sporadic or familial.77 Teratogen exposure during gestation, such as polychlorinated
biphenyls and pesticides, have been linked to CHDs, along with maternal alcohol
consumption, smoking, anti-seizure medications and rubella infection.77 Surgical
procedures to correct congenital malformations of the heart do not always have high
efficacy.201 Individuals with CHDs commonly require multiple operations and drug
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therapy, and are at an elevated risk for arrhythmias, bacterial endocarditis and heart
failure, placing a large burden on the health care system.202 Patients often have extracardiac co-morbidities, such as neurological deficits, which affect quality of life.203 The
prevalence of neurodevelopmental disabilities in the population of patients with CHDs
ranges from 10% to over 50% depending on the severity of the lesion and whether
pediatric surgery was required.204 The spectrum of these abnormalities includes
intellectual disability, autism spectrum disorder, and deficits in language, motor and
social skills.205 In fact, attention deficit hyperactivity disorder is 3 to 4 times more
prevalent in children with a CHD.206 Currently, an estimated 96,000 Canadian adults are
living with a CHD,207 making this disease a major cause of mortality and morbidity for
both adults and infants. Therefore, it is vital that research be conducted into how and why
these malformations develop, and more significantly, what remedies during pregnancy
can prevent their occurrence.

1.5.1

Types of Congenital Heart Defects
The International Classification of Diseases (ICD-10) classifies 25 distinct types

of anatomical or hemodynamic CHDs; however, due to varying nomenclature and the
wide variety of cardiac lesions, some variation may exist.3 CHDs can be categorized
based on severity of the morphological lesions and functional consequences.
Conventionally, CHDs are grouped into three categories: mild, moderate and severe. The
majority of CHD cases can be considered mild. The cardiac defects in these patients
would be largely asymptomatic, often undergoing spontaneous resolution.208 Moderate
CHDs are more complex and require expert care, but are less intensive than the severe
cases. Severe CHDs include univentricular hearts, heterotaxy, conotruncal defects, and
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atrioventricular canal defects, affecting one third of all patients with cardiac anomalies.209
Expert cardiologic care and intervention are required for these patients in the first year of
life. Accordingly, survival rate is dependent on the severity of the disease. This rate is
estimated to be 98% for patients with a mild CHD, whereas only 56% for patients with a
severe CHD.210 CHD-related hospitalizations in the US have steadily risen with a
financial burden of $6.1 billion per annum.211

1.5.1.1

Septal Defects

Septal defects are the most common cardiac malformations in humans.71 These
manifest as hemodynamically significant shunts between the left and right chambers of the
heart. ASDs involve a connection between the left and right atria, reducing heart function.
These defects are considered mild lesions and are not cyanotic as the high pressure in the
left atrium will cause oxygenated blood to partly shunt into the right atrium. There are three
major types of ASDs: defects of the ostium primum, secondum or a common atrium, where
the atrial septum is lacking completely.45 Ostium primum defects are less common but more
severe, and stem from incomplete growth of the primary atrial septum at the level of the
inferior margin due to partial development of the endocardial cushions.212 In comparison,
ostium secondum defects arise from a failure in the proper formation of the primary or
secondary atrial septum. The incidence of ASDs among patients with CHDs is
approximately 11%, whereas the incidence of VSDs is upwards of 30%.45, 77 VSDs are the
most common congenital anomaly in children and the second most prevalent abnormality in
adults.213 Two types of VSDs exist, which differ in anatomic location and histologic
variation, allow for shunting of blood between the left and right ventricle, and are
functionally more severe than ASDs. A membranous VSD occurs more frequently, and is
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usually a small shunt between the ventricles underneath the OFT, which is encircled by
fibrous tissue. In contrast, muscular VSDs involve a shunt enclosed by a muscular border.45
Accordingly, an open connection between all four chambers of the heart is considered an
AVSD. The incidence of AVSD can be as high as 15% in patients with Down Syndrome.214

1.5.1.2

Outflow Tract Defects

OFT defects manifest in the aorta and/or pulmonary artery and result in a
reduction of the functional cardiac output. Similar to septal defects, these malformations
also involve a mixing of the systemic and pulmonary circulatory systems. A persistent
truncus arteriosus, also referred to as a common arterial trunk (CAT), occurs as a result of
improper development of the aorticopulmonary septum, resulting in a shunt between both
arteries. This defect is always accompanied by a subarterial VSD.45 Mutations in the
Pax3 or Semaphorin3 gene in CNC progenitor cells can lead to CAT.215, 216 Next, as the
name suggests, a DORV involves both arteries drawing blood from the right ventricle. In
this case, the aorta is improperly connected to the right ventricle, thereby supplying the
body with partially deoxygenated blood. Again, this defect occurs along with a VSD,
compensating for the blood flow disruption.45 Finally, an overriding aorta represent an
alignment malformation instead of septation defect, and is linked to abnormal cardiac
looping. This defect is also accompanied by a VSD. Together, the incidence of OFT
defects is between 20 to 30% of total CHDs in humans at birth.3

1.5.1.3

Valvular Defects

Congenital valvular malformations can affect any of the four valves of the heart,
and occurs in approximately 2% of the general population. These defects commonly have
a genetic component as they tend to cluster in families.3 The aortic semilunar valve
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separates the aorta from the left ventricle, whereas the pulmonary semilunar valve
separates the pulmonary artery from the right ventricle. The mitral valve exists between
the left atrium and the left ventricle, and the tricuspid valve is between the right atria and
ventricle. Congenital valvular defects occur most frequently at the aortic valve. In fact, a
bicuspid aortic valve, in which only 2 out of 3 valve leaflets develop, is present in 1-2%
of the general population.217 Thickening of the aortic valve, also known as aortic valve
sclerosis, is a common OFT obstruction and can be a consequence of abnormal valve
remodeling in utero. The incidence of aortic valve sclerosis can be upwards of 25% in the
aged population; however, calcification of the valve and rheumatic aortic valve disease,
occurring later in life, can account for many cases.218 Therefore, this disease represents a
significant health problem, contributing to approximately 20,000 deaths annually.3

1.5.1.4

Hypoplastic Coronary Artery Disease

Congenital under-development of the coronary arteries can result in hypoplastic
coronary artery disease. This rare congenital abnormality is characterized by a marked
decrease in luminal diameter, length or number of the coronary arteries.219 This can occur
in one or more of the major branches of the coronary artery tree, where no other
compensatory collateral vessels exist. Hypoplastic coronary artery disease is usually
asymptomatic at birth, but can manifest later in life under conditions of stress or physical
exertion, possibly resulting in myocardial infarction or even sudden cardiac death.220 Due
to the asymptomatic nature of this disease, the incidence is estimated to be 1% in the
general population.221,

222

Post mortem analysis revealed hypoplastic coronary artery

disease in 2.2% of cases with coronary artery anomalies.223 Coronary angiography is the
current tool to diagnose these congenital anomalies.
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1.5.2

Epidemiology and Environmental Risk Factors of Congenital
Heart Disease
In the general population, CHDs are the most common structural birth defect.3, 198, 224

Congenital heart disease is the leading cause of pediatric deaths in developed nations.196
It is estimated that 257,000 Canadians and about 2 million Americans are living with a
CHD.207, 225 Approximately 40,000 infants are diagnosed with a CHD each year in the
US, and a quarter of these patients will need invasive treatment in the first year of life.3 In
the year 2000, the prevalence of CHDs in the province of Quebec was 14.75 per 1000
males and 17.22 per 1000 females.198 This remained consistent with the rest of the
country as 13.11 per 1000 children had a CHD in 2010.207 In terms of specific cardiac
malformations, the Centre for Disease Control reports that complex CHDs, such as TOF
and AVSD are as common as 1 in 2518 and 1 in 2122, respectively.226 Many
epidemiologists have noted a steady increase in occurrence of CHDs over time. One
study from metropolitan Atlanta states that from 1978 to 2005, malformations of the heart
increased from 50.3 per 10,000 to 86.4 per 10,000.227 This increase in proportion is
alarming and calls for increased research to be conducted in order to elucidate the
mechanisms behind potential insults to the developing heart. The variation in prevalence
rates can be attributed to age of the patient when the defect is detected. Severe CHDs are
usually cyanotic and can be diagnosed in utero or just after birth. Mild defects may not be
identified until later in life or adulthood, making population prevalence difficult to
estimate.3 Nevertheless, prevalence rates are expected to increase over time due to
improved screening techniques, such as fetal cardiac ultrasound by pulse oximetry.3
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Both intrinsic and extrinsic risk factors are associated with the development of
CHDs. Many of the intrinsic factors have been discussed in previous sections. These
include mutations in key transcription factors, such as NKX2.5, that govern heart
development, and chromosomal abnormalities, such as Trisomy 21.228,
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Extrinsic

factors are non-genetic, and represent environmental insults during pregnancy that
compromise developmental pathways in the embryo. These risk factors can include
maternal smoking, nicotine exposure, alcohol consumption, obesity, chlamydia or rubella
infections, preeclampsia and high altitude.230-238 For instance, there was an exposureresponse relationship between overweight, moderately obese and severely obese pregnant
women with CHD incidence in the offspring. In fact, offspring of severely obese women
were at a 1.94 times greater risk of having TOF.233 Pregestational maternal diabetes is an
established risk factor for offspring CHDs in both the clinic and experimental animal
models, which will be described in the following sections.

1.6 Pregestational Diabetes and Congenital Heart Defects
Congenital malformations in the offspring of women with PGD include defects of
the limb, neural tube and musculoskeletal systems. However, the predominant
malformations are CHDs, which represent about 40% of the total malformations.9, 10 PGD is
an established risk factor for congenital heart disease,239 and increases the risk of a CHD in
the child by more than four-fold.194, 240-242 This is a major concern as it is estimated that
451 million people are living with diabetes, and the incidence of this condition is
increasing at a rate of 10 million people per year. It is projected that by the year 2040,
approximately 693 million people will be affected.1 In terms of the developmental origins
of congenital heart defects, this increase in diabetes world-wide is alarming as
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approximately 3 to 9 females in every 1000 pregnancies surveyed in Europe and North
America are diabetic prior to conception of their child.243 As this number increases with
the increase in diabetes, more individuals will be born with congenital heart defects,
inevitably placing a large burden on the healthcare system.
We recently demonstrated that pregestational diabetes induced by streptozotocin
(STZ) in mice results in CHDs and coronary artery malformations (CAMs) in the offspring,
which simulates diabetes-induced congenital heart disease in humans.200, 244 In experimental
animal models, the incidence of congenital malformations induced by pregestational
diabetes has been successfully reduced by vitamin E, vitamin C, hydroxytoluene (BHT),
superoxide dismutase-1 (SOD1) and N-acetylcysteine (NAC) treatment.244-249 In the clinic,
new-borns of pregestational diabetic women have an altered heart rate variability, fetal
acidaemia and fetal glycaemia.250 During development, a higher fetal heart rate has been
reported by cardiotocographic analysis from the first to the third trimester in pregnancies
complicated with pregestational diabetes.251, 252 Accordingly, offspring of these women also
have an altered QRS complex.253 Although current prenatal care recommends tight glucose
control before and during pregnancy, CHD incidence in the offspring of diabetic women
remains unchanged, showing little improvement.240 Insulin or other anti-diabetic
medication, such as metformin for Type 2 diabetes, are currently prescribed for women with
diabetes during pregnancy. Although these drugs are not teratogenic, their long-term effect
on the offspring’s health is not known. Compliance and maintenance are also major factors
that can impact proper glycaemic control for diabetic women during pregnancy.254 In
addition, pregnancy can exacerbate and complicate diabetes management, usually requiring
higher dosing of medication. Finally, the prevalence of diabetes is rapidly rising among low-
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to-middle income populations, and access to proper prenatal care is often challenging.255
Thus, research must be conducted to find alternate interventions that support current
treatment practices, while being safe and accessible.

1.6.1

Potential Mechanisms of Diabetic Embryopathy
Maternal diet, nutrition and body composition have both short-term and long-term

consequences for the offspring.256 Uncontrolled maternal diabetes is not conducive to
proper gestation. Specifically, the hyperglycemic environment to which the embryo is
exposed is dangerous as increased serum glucose leads to oxidative stress in cells through
numerous pathways. High levels of glucose will increase glycolysis in cells and will
cause increased amounts of NADH and FADH2. These molecules act as electron sources
for the mitochondrial electron transport chain, and higher levels of electrons flowing
through this chain will lead to increased oxygen consumption and ATP formation.257
Superoxide generation will accompany this energy production, resulting in a rise in ROS.
Premature electron leak from the cytochrome chain occurs in pathological conditions,
resulting in ROS. At several points during the oxidative phosphorylation process,
electrons can react with oxygen, forming radicals.258 Mitochondrial ROS can stimulate
the production of cytosolic ROS through several mechanisms. Hydrogen peroxide can
lead to the activation of cellular Src kinase, which promotes NADPH oxidase activity,
producing superoxide.259 These reactive molecules can damage DNA and proteins critical
for organogenesis.260 The developing heart is sensitive to changes in glucose availability.
Early cardiac progenitors mainly rely on glycolysis for energy production; however, as
cardiomyocytes terminally differentiate they switch to mitochondrial oxidative
metabolism pathways.261 In fact, the expression of glucose transporter 1 (GLUT1) is
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upregulated in the embryonic heart in experimental models of maternal diabetes,
facilitating the glucose overload.8
Consequently, recent murine studies are attempting to examine whether miRNA
expression is altered in the embryonic heart under maternal pregestational diabetes. A
global miRNA profiling study reported a differential expression pattern of 149 miRNAs
in E12.5 hearts from diabetic dams compared to control.262 Of these, 3,960 miRNAmRNA complementary pairs were identified between 32 miRNAs and 2,111 mRNA
transcripts; 284 of which are transcriptional regulators involved in cardiac hypertrophy,
hypoplasia, and cardiomyocyte apoptosis.262 In addition, pregestational diabetes-induced
changes in miRNA expression in maternal exosomes can be relayed to the developing
fetal heart. RNA sequencing revealed 186 upregulated and 92 downregulated miRNAs in
maternal exosomes isolated from STZ-induced diabetic dams, compared to control.263 In
particular, levels of miRNA-122 are almost 3-fold higher in these diabetic exosomes.263
Taken together, these changes in miRNA expression, especially the increase in miRNA122, during fetal heart development in a diabetic environment warrant further
investigation as these findings could provide new insights into the pathogenesis of
diabetes-induced CHDs.

1.6.1.1

ROS

Molecules containing one or more unpaired elections in their valence orbital or
unstable bonds are reactive. ROS can exist as neutral molecules, ions or radicals, such as
hydrogen peroxide, the superoxide anion, or the hydroxyl radical, respectively.264 These
species oxidize other molecules by removing electrons in order to make themselves
stable. For instance, the superoxide anion can react with nitric oxide forming the highly
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reactive peroxynitrite.258 Superoxide cannot readily cross plasma membranes, therefore
having local, transient effects. This ion is spontaneously dismutated into hydrogen
peroxide, which has long-lasting effects and is freely diffusible across membranes. This
conversion can be catalyzed within cells by the enzyme superoxide dismutase.264
Elevated concentrations of ROS can react with proteins, lipids, carbohydrates and nucleic
acids causing non-specific damage and permanent functional changes. Along with
mitochondrial ROS production, intracellular sources of ROS include peroxisomes,
lysosomes, and the enzymes NADPH oxidase, xanthine oxidase and cytochrome p450.264
A major contributor of ROS in endothelial cells is NADPH oxidases, which transfer
electrons across membranes to an oxygen molecule.258

1.7 Endothelial Nitric Oxide Synthase
Nitric oxide (NO) is a lipophilic, small gaseous molecule that has numerous roles
in biological signaling processes, and, most notably, serves as a potent vasodilator.265
Nitric oxide production within the cell is accomplished by the enzyme nitric oxide
synthase (NOS), which catalyzes the conversion of L-arginine into nitric oxide through a
NADPH-dependent reaction. Three isoforms of this enzyme, neuronal (nNOS, NOS1),
cytokine-inducible (iNOS, NOS2), and endothelial (eNOS, NOS3) are distinctly
expressed in mammalian cells and produce NO in a tissue-specific manner.266 nNOS is
constitutively expressed in neurons of the central and peripheral nervous system, whereas
iNOS is expressed in cells of the immune system and produces high levels of nitric oxide
associated with inflammatory processes. eNOS is membrane bound and calciumsensitive, expressed in endothelial and myocardial cells, located on chromosome 7 in
humans.267 They are homodimeric, haem-containing globular proteins, with a N-terminal
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oxygenase domain and a C-terminal reductase domain, which are linked by a calmodulin
binding sequence. The dimer produces NO in the coupled state, and requires
Ca2+/calmodulin, flavin adenine dinucleotide (FAD), flavin mononucleotide (FMN), and
tetrahydrobiopterin (BH4) as cofactors.266 Calcium-activated calmodulin initiates the
election transfer to produce nitric oxide, which, when produced, acts on soluble guanylyl
cyclase to catalyze the formation of the second messenger, cyclic guanosine
monophosphate (cGMP). Downstream targets of cGMP include protein kinases (PKGs),
ion channels and cyclic nucleotide phosphodiesterases (PDEs).268 Activation or inhibition
of protein function via S-nitrosylation is also a downstream effect of nitric oxide.
Interestingly, eNOS can be itself S-nitrosylated, reducing its activity.269 Phosphorylation
of eNOS at serine-1177 by Akt (protein kinase B) activates the enzyme, which itself is
active when phosphorylated. Nitric oxide production via this PI3K/Akt/eNOS pathway
represents a highly regulated biological process involved in endothelial cell permeability,
vascular smooth muscle relaxation, calcium handling, immune regulation and
neurotransmission.270 The vital role of eNOS-derived NO in cardiovascular health and
development will be explored in following sections.

1.7.1

Tetrahydrobiopterin
The pteridine (6R) 5,6,7,8-tetrahydrobiopterin (BH4) is an antioxidant and

cofactor for many metabolic enzymes, involved in the production of neurotransmitters
and nitric oxide. As a cofactor, its heterocyclic ring structure functions to facilitate
complex chemical reactions in a wide variety of biological processes.271 Aromatic amino
acid hydroxylases utilize BH4 as a cofactor to produce monoamine neurotransmitters
such as serotonin, melatonin, dopamine, norepinephrine and epinephrine. As stated
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above, tetrahydrobiopterin is the principle co-factor for eNOS and can serve as an
endogenous antioxidant as well. BH4 is essential for NOS-mediated nitric oxide
synthesis, by all three isoforms, and serves both biochemical and structural functions.271
It is required for eNOS homo-dimer stabilization and is an allosteric modulator of Larginine binding to the active site.272 BH4 participates in the biochemical formation of
NO from O2 by donating an electron for the conversion of L-arginine to L-citrulline.273 It
“couples” the haem reduction to nitric oxide synthesis, and acts as a sequential oneelectron reductant and oxidant.266 However, BH4 is not consumed in this process as it
recaptures its electron from the iron-containing heme group, facilitating NO release.274
BH4 biosynthesis within the cell is carried out via a three-step enzymatic process with the
conversion of the nucleotide GTP into 7,8-dihydroneopterin triphosphate as the ratelimiting first step. The enzyme that catalyzes this conversion is GTP cyclohydrase 1
(GTPCH-1). It is encoded by the gene GHC1 on chromosome 14 in humans. The next
steps are catalyzed by 6-pyruvoyl tetrahydropterin synthase and sepiapterin reductase.271
GTPCH-1 expression and activity are tightly regulated at transcriptional, translational
and post-translational levels. For example, a negative feedback loop exists whereby BH4
allosterically downregulates activity of GTPCH-1 when it is bound, in a dose-dependent
manner, to the feedback regulatory protein, GFRP. Conversely, the interaction of GFRP
with L-phenylalanine can reverse this effect, and increase GTPCH-1 activity and BH4
production.275 Along with this de novo biosynthesis pathway, BH4 can also be recycled
within the cell through a salvage pathway. The enzyme dihydrofolate reductase (DHFR)
regenerates BH4 by reducing dihydrobiopterin (BH2), a byproduct of oxidation. DHFR is
ubiquitously expressed and needed by eukaryotes and prokaryotes for normal cellular
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metabolism. Apart from being involved in BH4 recycling, it also catalyzes the reduction
of folate to tetrahydrofolate, which is required for many biological processes, such as
amino acid biosynthesis.276 Therefore, the cellular bioavailability of BH4 is balanced
between its de novo synthesis, oxidation to BH2 and regeneration. Due to the critical role
of nitric oxide in the cardiovascular system, BH4 administration has been tested for its
clinical viability at improving endothelial function in many studies. Intravascular infusion
of BH4 to chain smokers improved their endothelium-dependent vasodilation.277
Similarly, in patients with hypercholesterolaemia, BH4 infusion improved coronary
microvascular circulation.278 In accordance, BH4 intra-arterial administration prevented
ischemia reperfusion injury in the human forearm. 279

1.7.1.1

Sapropterin Dihydrochloride

Sapropterin dihydrochloride is an FDA-approved synthetic formulation of BH4,
prescribed for the treatment of phenylketonuria.280 Orally active and stable, this drug is
marketed as Kuvan® and has been manufactured by Biomarin Pharmaceuticals since
2007.281 Patients with PKU are unable to metabolize the amino acid phenylalanine,
present in many food products, due to a mutation in the metabolizer phenylalanine
hydroxylase (PAH).282 This enzyme uses BH4 as a cofactor to oxidize phenylalanine to
tyrosine. When mutated its activity is reduced leading to hyperphenylalaninemia, the
toxic accumulation of phenylalanine in the blood. Complete phenylalanine restriction is
recommended for patients with PKU; however, long-term compliance can be difficult,
especially in youth and pregnant women. Treatment with sapropterin can activate the
residual PAH enzyme, allowing for the metabolism of phenylalanine, thereby decreasing
its levels in the blood. PKU patients administered sapropterin have increased
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phenylalanine tolerance, thereby allowing a relaxation in dietary restrictions.282 This drug
has an acceptable safety profile and is prescribed as 100 mg tablets at a starting dose of
10 mg/kg/day.281

1.7.2

BH4 Cycling and eNOS Coupling; a Positive Feedback Loop
BH4 production, either through de novo synthesis or regeneration, promotes

eNOS function, generating nitric oxide (Figure 1.3).283 In fact, diminished levels of BH4
or depletion of L-arginine can uncouple the eNOS dimer, rendering it incapable of
producing nitric oxide, instead generating oxygen derived free radicals.284 Similarly, in
states of oxidative stress, this process is insulted at many levels, sustaining the oxidative
environment and leading to cellular dysfunction. The production of ROS is often
amplified because of a positive-feedback loop; ROS generates more ROS. As mentioned
above, GTPCH-1 is an enzyme involved in antioxidant biosynthesis. Specifically, it
catalyzes the formation of BH4, an essential co-factor for eNOS.285 Recently, a study has
indicated that ROS causes the release of zinc from GTPCH-1, rendering it less functional
(Figure 1.3).286 Consequently, the intracellular levels of BH4 decline and eNOS is left
without a cofactor, triggering its uncoupling. When eNOS is uncoupled, it cannot form
nitric oxide, which has its own developmental implications, and instead generates ROS in
the form of superoxide. This superoxide anion participates in a rapid reaction with low
levels of NO in the cell and forms the peroxynitrite anion (ONOO-) (Figure 1.3).287 This
species is normally in equilibrium with peroxynitrous acid (ONOOH), which can decay
and form ONOOH•, another reactive radical. Proteins are especially vulnerable to
modification by the peroxynitrite system, as it incurs covalent changes to the amino acid
residues cysteine, methionine, tryptophan, and tyrosine.288 ONOO- specifically
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inactivates GTPCH-1, decreasing de novo BH4 synthesis, and the additional oxidative
stress furthers the oxidation of BH4 into BH2.286 BH2 is unable to couple eNOS, and
competes with BH4 for eNOS binding, exacerbating the superoxide production. Mice
lacking GTPCH-1 in the endothelium display significantly decreased BH4 levels, eNOS
uncoupling and increased ROS production, resulting in loss of vasodilation.
Another enzyme inactivated by O2- and ONOO- is dihydrofolate reductase
(DHFR), responsible for the recycling of BH2 back to BH4.273, 289 Experiments done in E.
coli demonstrate peroxynitrite-induced alterations to the catalytic site of DHFR, resulting
in functional compromise.276 Therefore, both the salvage and endogenous synthesis
pathways are crippled due to ROS, furthering the oxidative environment (Figure 1.3). In
states of oxidative stress, BH4 levels decline, and eNOS function is impaired.
Specifically, oxygen activation is functionally uncoupled to L-arginine oxygenation,
resulting in decreased NO production.290 Instead, activated O2, in the form of superoxide,
is released from the enzyme, perpetuating the oxidative environment of the cell. The
relationship between eNOS function and diabetes has been well established. Endothelial
dysfunction is a common consequence of diabetes and is mediated by oxidative stressinduced eNOS uncoupling.291-293 Previous studies indicate that dissolution of the eNOS
dimer also occurs in aging vessels and in cardiovascular disease states, such as
hypertension, ischemia-reperfusion injury and heart failure.294-296 Treatment with BH4
has been shown to recouple eNOS and improve vascular endothelial function in
diabetes.271, 297

48

Figure 1.3. eNOS uncoupling and inactivation in states of oxidative stress.
The functional eNOS dimer, producing nitric oxide, is seen on the left. eNOS
dysfunction, on the right, occurs in states of oxidative stress, where BH4 is oxidized, the
dimer is uncoupled and eNOS is inactive. In this state, nitric oxide is no longer produced
and instead superoxide radical is generated. The salvage and de novo BH4 biosynthesis
pathways are actively producing BH4 in normal conditions, but are impaired by oxidative
stress, specifically derived from eNOS uncoupling.
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1.7.3

The role of eNOS in Cardiovascular Development
eNOS is vital for heart development. Expression of the synthase starts at E9.5 in

the endothelium and cardiomyocyte precursors of the heart tube, and peaks at E13.5, after
which it begins to decline, but remains detectable at birth and into postnatal
development.270 The lung, liver, gastrointestinal tract, reproductive organs and brain all
express NOS3 during their organogenesis.298 In vitro incubation of NOS inhibitors to
embryonic stem cell-derived cardiomyocytes inhibited their maturation.298 Interestingly,
mouse embryonic stem cells exogenously treated with a NO donor or transfected with
NOS promoted their differentiation into cardiomyocytes, inducing the expression of
cardiac specific genes.299 Induced pluripotent stem cells and E14.5 ventricular tissue both
deficient in NOS3 show consistent transcriptome profiles, and particularly an upregulation of glucose metabolism genes.300 Gata4, a transcription factor needed for
cardiomyocyte specification and heart development, can modulate and increase the
expression of eNOS by binding to its promoter region.301 The importance of eNOS in
heart development has been showcased through the spectrum of cardiovascular anomalies
seen in eNOS-/- mice. Embryonic deletion of nNOS or iNOS display normal cardiac
phenotypes, however eNOS null mice have a high rate of CHDs, with a 75% incidence of
septal malformations in the offspring. These mice have increased postnatal mortality,
impaired heart function, and significant elevations in embryonic apoptosis in the heart.119
In addition, these mice have severe valvular malformations, including bicuspid aortic
valves (30 – 40% incidence), underdeveloped mitral and tricuspid valves, which have
significant regurgitation during systole (analyzed using pulse-wave Doppler), along with
aortic valve sclerosis and calcification.302-304 During embryonic development, eNOS null
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mice has less Snail+ mesenchymal cells in the endocardial cushions, suggesting impaired
EndMT. This was coupled with significantly lower mRNA levels of genes involved in
valve formation, such as Tgf- and Bmp2.303 Accordingly, patients with bicuspid aortic
valve disease had lower eNOS protein expression in aortic endothelial cells compared
with tricuspid aortic valves patient specimens.305 eNOS-derived NO regulates cell growth
and protects early cardiac progenitors against apoptosis.119 This is accomplished through
S-nitrosylation and inactivation of caspase-3.306 Shear stress-induced NO production and
up-regulation of superoxide dismutase also prevented endothelial cell death via inhibiting
caspase-3 activity.307 eNOS is also required for cardiomyocyte proliferation, as well as
VEGF expression to form the capillary network supplying the muscle.108 In fact, eNOS
intimately controls coronary artery development in mice, as loss of this enzyme results in
coronary artery hypoplasia and spontaneous postnatal myocardial infarction.110 Key
transcription factors that control EMT and vasculogenesis are downregulated in this
model, including Gata4, Wt1, Vegf, bFGF and EPO, all of which are rescued by eNOS
overexpression, restoring normal vasculature.110 The congenital coronary artery
anomalies and CHDs seen in eNOS knockout mice in utero and at birth impair heart
function in adult mice. Adult eNOS-/- mice display heart failure, characterized by a
molecular switch from - to -myosin heavy chain expression as well as an increase in
atrial naturetic peptide levels.308 Inhibition of eNOS function using L-NAME induces
comparable levels of fibrosis to eNOS null mice, following transverse aortic
constriction.309 eNOS restoration in the heart of eNOS-deficient mice attenuates LV
hypertrophy, cardiac dysfunction and protected against adverse myocardial remodeling
after aortic banding.310 Mechanistically, eNOS-derived NO signaling reduces cardiac
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calcium currents, decreasing the sympathetic β-adrenergic response and arrhythmia
incidence, protecting the heart. The same is true in the embryonic heart, as NO regulation
of L-type calcium channels also promotes mouse embryonic stem cell differentiation into
cardiomyocytes.311 Thus, the indispensable role of eNOS in the development of the heart
and coronary vascular means that any alterations to the NO balance could prove
deleterious.

1.8 Rationale and Hypothesis
CHDs are the most common birth defect and the leading cause of death in the first
year of infant life. Environmental, non-genetic factors are associated with the majority of
CHDs seen in the clinic, while inherited genetic mutations only account for 15% of
reported cases.195 Pregestational diabetes is an important risk factor of CHDs,
heightening the risk by 3 – 5 times.240 While good glycemic control in diabetic mothers
lowers the risk, the incident of CHDs in their children is still higher than in the general
population.241 The rapid increase of young adults with diabetes and pre-diabetes is
alarming, and warrants further research to broaden our understanding of the pathogenesis
of congenital cardiovascular malformations and their prevention. Due to of the critical
roles of eNOS and miRNAs in heart development, this thesis aims to study the effects
of sapropterin and antimiR-122 on CHDs and coronary artery malformations in a
mouse model of pregestational diabetes.
We hypothesized that:
(1) BH4 treatment during the full gestational term of pregnant female mice with
pregestational diabetes will decrease the incidence of CHDs and CAMs in
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fetal hearts, through changes in gene expression, cell migration and
proliferation, ROS handling and eNOS coupling, and
(2) microRNA-122 is involved in pregestational diabetes-induced CHDs and
CAMs, and antimiR-122 treatment will prevent these congenital cardiac
abnormalities.

1.8.1

Aim 1: Sapropterin on Diabetes-Induced CHDs
The first aim of this study was to determine if BH4 treatment during the full

gestational term of female mice with pregestational diabetes could decrease the incidence
of CHDs in fetal hearts by mitigating altered gene expression, cell proliferation, SHF
development, ROS levels, and eNOS coupling. Previous animal studies, as well human
clinical data, have suggested a strong association between diabetic pregnancy and CHD
incidence. In addition, eNOS has been demonstrated to play a vital role in embryonic
heart development.270 The activity of this enzyme is compromised in diabetes, leading to
endothelial dysfunction. Specifically, the eNOS dimer can be uncoupled, increasing the
already high levels of oxidative stress brought on by hyperglycemia.312 Sapropterin
dihydrochloride (Kuvan®) is an orally active synthetic form of BH4 and an FDA
approved drug for the treatment of phenylketonuria.281 We hypothesized that maternal
diabetes-induced oxidative stress would lead to eNOS uncoupling in the developing
myocardium, resulting in increased ROS, altered cardiogenic gene expression,
decreased proliferation and development of SHF structures, and subsequent CHDs
and damped cardiac function. We further hypothesized that exogenous sapropterin
treatment would re-instate oxidative balance and recouple eNOS in the embryonic
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heart, promote cell proliferation of cardiac progenitors and decrease the incidence
of CHDs.
Objectives:
1. Characterize the spectrum of CHDs induced by pregestational maternal diabetes,
and test if sapropterin therapy can rescue the disease phenotype.
2. Utilize lineage tracing to determine the impact of maternal diabetes on the
development of the SHF.
3. Determine if the eNOS dimer is uncoupled and if there is elevated ROS in the
embryonic myocardium from diabetic dams, and assess if sapropterin treatment
can recouple eNOS and reduce ROS.

1.8.2

Aim 2: Sapropterin on Diabetes-Induced CAMs
Congenital coronary artery malformations (CAMs) affect about 1% of the general

population.221-223 Hypoplastic coronary artery disease (HCAD) is a congenital
abnormality characterized by marked decrease in luminal diameter and length of
coronary vasculature.313 HCAD usually is asymptomatic at birth, and can go unnoticed
until the individual is older and/or subjected to increased physical exertion. Without
intervention, this could lead to myocardial infarction and even sudden cardiac death.220
As this disease is asymptomatic at birth and possibly for much of adulthood, it is pressing
that preventative precautions be taken during gestational coronary artery development.
The development of the coronary vasculature occurs in tandem with heart development,
but is distinct in its cellular origin and molecular drivers. It involves coordinated EMT
and differentiation, with eNOS again playing a major role. In fact, eNOS-/- mice display

54

hypoplastic coronary arteries and post-natal myocardial infarction.110 Additionally,
experiments in mice have indicated that hyperglycemia during pregnancy can induce
coronary artery anomalies.200 Therefore, we hypothesized that pregestational diabetes
would result in CAMs, akin to hypoplastic coronary artery disease, which would be
a result of impaired EMT during embryonic development. Further, we hypothesized
that sapropterin treatment would promote epicardial EMT and reduce the
incidence of CAMs in offspring of pregestational diabetes.
Objectives:
1. Analyze CAMs induced by pregestational diabetes, and determine if sapropterin
treatment can reduce their incidence.
2. Determine if epicardial EMT is impaired by diabetic pregnancy, and if sapropterin
can regulate the process under high glucose conditions.
3. Elucidate the impact of hyperglycemia during gestation on eNOS phosphorylation
and oxidative stress in the fetal heart.

1.8.3

Aim 3: Role of microRNA-122 in Heart Development
MicroRNAs play an important role in cardiogenesis, often acting as temporal

switches, turning on and off gene programs that govern developmental stages of the
heart. miRs are short, non-coding RNA molecules that post-transcriptionally regulate
gene expression by repressing mRNA.145 These small RNA molecules can freely cross
the placenta and enter fetal circulation. Patients with diabetes have a dysregulation in
miRNA expression.314 Diabetic pregnancy may illicit changes in the miRNA profile, in
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either the mother or the fetus, contributing to the pathogenesis of CHDs. Our preliminary
data confirms the finding of a differential miRNA transcriptome profile in embryonic
hearts from diabetic dams. In our laboratory, using global microarray analysis, we found
that miR-122 is upregulated 14-fold in E10.5 hearts from diabetic dams compared to
control. miR-122 is required for liver homeostasis and acts as tumor suppressor, by
inhibiting the expression of genes involved in proliferation and epithelial to mesenchymal
transition (EMT); two processes critical to cardiogenesis. Therefore, we hypothesized
that miR-122 would be upregulated in fetal hearts from diabetic dams and would
impair key developmental processes, such as cell proliferation, migration and
apoptosis, in the heart. We further hypothesized that antimiR-122 treatment to
diabetic dams would reduce the incidence of CHDs in the offspring.
Objectives:
1. Validate the expression of miR-122 in embryonic hearts from diabetic dams, and
determine if the expression of miR-122 targets is altered.
2. Determine the effects of miR-122 on cell proliferation, apoptosis and EMT in the
embryonic heart.
3. Determine if in vivo administration of antimiR-122 could reduce the incidence of
CHDs induced by pregestational diabetes.
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Chapter 2

2.1 Chapter Summary
Tetrahydrobiopterin (BH4) is a co-factor of endothelial nitric oxide synthase
(eNOS), which is critical to embryonic heart development. We aimed to study the effects
of sapropterin (Kuvan®), an orally active synthetic form of BH4 on eNOS uncoupling
and congenital heart defects (CHDs) induced by pregestational diabetes in mice. Adult
female mice were induced to pregestational diabetes by streptozotocin and bred with
normal males to produce offspring. Pregnant mice were treated with sapropterin or
vehicle during gestation. CHDs were identified by histological analysis. Cell
proliferation, eNOS dimerization and reactive oxygen species (ROS) production were
assessed in the fetal heart. Pregestational diabetes results in a spectrum of CHDs in their
offspring. Oral treatment with sapropterin in the diabetic dams significantly decreased the
incidence of CHDs from 59% to 27% and major abnormalities, such as atrioventricular
septal defect and double outlet right ventricle were absent in the sapropterin treated
group. Lineage tracing revealed that pregestational diabetes resulted in decreased
commitment of second heart field progenitors to the outflow tract, endocardial cushions,
and ventricular myocardium of the fetal heart. Notably, decreased cell proliferation and
cardiac transcription factor expression induced by maternal diabetes were normalized
with sapropterin treatment. Furthermore, sapropterin administration in the diabetic dams
increased eNOS dimerization and lowered ROS levels in the fetal heart. Sapropterin
treatment in the diabetic mothers improves eNOS coupling, increases cell proliferation
and prevents the development of CHDs in the offspring. Thus, sapropterin may have
therapeutic potential in preventing CHDs in pregestational diabetes.
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2.2 Introduction
Congenital heart defects (CHDs) are the most common structural birth defect,
occurring in 1-5% of live births, making them the leading cause of death in the first year
of infant life.1, 2 The prevalence of CHDs has been rapidly increasing,3 and it is estimated
that approximately 2.4 million Americans, including 1 million children, are living with a
congenital malformation of the heart.2 CHDs are formed when complex cellular and
molecular processes underlying embryonic heart development are disturbed. The heart is
developed from three pools of progenitor cells: the first heart field (FHF), the second
heart field (SHF) and cardiac neural crest (CNC).4 The FHF progenitors initially form the
primary heart tube. SHF cells are then added to the heart tube to form the right ventricle,
give rise to myocardial and endothelial cells of the outflow tract and semilunar valves, as
well as the vascular smooth muscle cells at the base of the aorta and pulmonary trunk.
The CNC cells contribute to septation of the outflow tract and remodeling of semilunar
valves, while the left ventricle is mainly formed from FHF progenitors. The SHF is
particularly significant to CHDs as many common cardiac abnormalities including atrial
and ventricular septal defects, cardiac valve malformation, double outlet right ventricle
and truncus arteriosus, are caused by defects in SHF progenitors.4
Pregestational diabetes (type 1 or 2) in the mother increases the risk of a CHD in
the child by more than four-fold.5,

6

While good glycemic control in diabetic mothers

lowers the risk, the incident of CHDs in their children is still higher than the general
population.7, 8 The prevalence of pregestational diabetes has nearly doubled from 0.58%
to 1.06% from 1996 to 2014 in Northern California,9 and has reached 4.3% in Saudi
Arabia.10 As the prevalence of pregestational diabetes further increases in women during
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their reproductive age, more individuals will be born with CHDs, inevitably placing a
large burden on the healthcare system.11, 12
Uncontrolled maternal diabetes is not conducive to proper gestation.
Hyperglycemia leads to cellular oxidative stress through numerous pathways,13 which
include increased electron transport chain flow resulting in mitochondrial dysfunction,
non-enzymatic protein glycosylation and glucose auto-oxidation all contributing to
reactive oxygen species (ROS) generation.14, 15 Increased oxidative stress can lead to the
inactivation of many molecules and proteins necessary for proper heart development.
Endothelial nitric oxide synthase (eNOS) is intimately regulated by redox balance within
the cell and is vital for cardiogenesis.16 eNOS expression in the embryonic heart regulates
cell growth and protects early cardiac progenitors against apoptosis.17 The importance of
eNOS in heart development has been demonstrated in eNOS-/- mice by a spectrum of
cardiovascular anomalies such as ventricular septal defects (VSDs), valvular
malformations and hypoplastic coronary arteries.17-19
Tetrahydrobiopterin (BH4) has antioxidant properties and is a critical co-factor for eNOS
function.20 It is required for eNOS dimer stabilization and is an allosteric modulator of
arginine binding to the active site.21 In states of oxidative stress, BH4 levels decline, and
eNOS is uncoupled, resulting in decreased NO synthesis and increased superoxide
production, perpetuating the oxidative environment of the cell.22 The production of ROS
is amplified by this feedback loop, further inducing eNOS uncoupling. Treatment with
BH4 has been shown to recouple eNOS and improve vascular endothelial function in
diabetes.23,

24

However, the potential of BH4 to reduce the severity and incidence of

CHDs is not known. Sapropterin dihydrochloride (Kuvan®) is an orally-active, synthetic
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form of BH4 and an FDA approved drug for the treatment of phenylketonuria.25 The
present study was aimed to examine the effects of sapropterin in mice with pregestational
diabetes. We hypothesized that sapropterin treatment during gestation re-couples eNOS,
improves cell proliferation in SHF derived cells, and reduces CHD incidence in the
offspring of mice with pregestational diabetes.

2.3 Methods
2.3.1

Animals
All procedures were performed in accordance with the Canadian Council on

Animal Care guidelines and approved by the Animal Care Committee at Western
University. C57BL/6 wild type and Rosa26mTmG mice were purchased from Jackson
Laboratory (Bar Harbor, Maine). Mef2ccre/+ embryos were obtained from Mutant Mouse
Regional Resource Center (Chapel Hill, NC) and rederived. All animals were housed in a
12-hour light/dark cycle and given ad libitum access to standard chow and water. A
breeding program was established to generate embryonic, fetal and post-natal mice.

2.3.2

Induction of Diabetes and Sapropterin Treatment
A study flow chart in Figure 2.1 illustrates timelines of saline or streptozotocin

(STZ) injection, breeding, sapropterin or insulin treatment and assessments of fetal hearts
in 5 groups of mice. Female C57BL/6 mice, 8 to 10 weeks old were made diabetic
through five consecutive daily injections of STZ (50 mg/kg body weight, IP, Sigma)
freshly dissolved in sterile saline. Mice were randomly assigned to STZ (n=37) or saline
treatment (n=19) groups. One week following the last STZ injection, non-fasting blood
glucose levels were measured with a tail snip procedure using a glucose meter (One
Touch Ultra2, LifeScan, Burnaby, BC). Mice were categorized as diabetic if blood
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glucose measurements exceeded 11 mmol/L, and were subsequently bred to 10 to 12
week old C57BL/6 male mice. In the morning when a vaginal plug was observed
indicating embryonic day 0.5 (E0.5), the female diabetic mouse was placed in a separate
cage with littermates. A cohort of diabetic and control female mice were treated with
sapropterin dihydrochloride (Kuvan®, BioMarin Pharmaceutical Inc.) at a dose of 10
mg/kg body weight per day during gestation. Sapropterin was dissolved in water and
mixed with a small amount peanut butter in a weigh boat, ensuring it was fully consumed
by the mouse. At the time of feeding, mice were separated and individually housed in
cages for about 15 min until the sapropterin or vehicle containing peanut butter mixture
was fully consumed under an investigator’s watch. All mice were fed in the morning,
once per day. Non-fasting blood glucose levels were monitored throughout pregnancy.
To prevent hyperglycemia, a long acting form of insulin (Lantus®, Sanofi Aventis) was
administered subcutaneously to a cohort diabetic dams (n=3) at a dose of 0.5 units/day.
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Figure 2.1. Experimental design to examine the effects of sapropterin (BH4) on
congenital heart defects induced by pregestational diabetes.
A study flow chart illustrates timelines of saline or STZ injection, breeding, sapropterin
or insulin treatment and assessments of fetal hearts in 5 groups of mice. IP indicates
intraperitoneal injection; PO, oral administration; STZ, streptozotocin. BG, blood
glucose; E, embryonic day; eNOS, endothelial NO synthase; OFT, outflow tract; ROS,
reactive oxygen species.

2.3.3

Histological and Immunohistochemical Analysis
Fetal samples were harvested at E10.5, E12.5 and E18.5 for histological and

immunohistochemical analysis. To diagnose CHDs in E18.5 hearts, fetuses were
decapitated and the isolated thorax was fixed overnight in 4% paraformaldehyde,
dehydrated in ethanol and paraffin embedded. Samples were sectioned in 5 μm slices and
hematoxylin/eosin (H&E) or toluidine blue stained to visualize morphology. Images were
taken and analyzed using a light microscope (Observer D1, Zeiss, Germany). Embryonic
samples at E10.5 and E12.5 were fixed in 4% paraformaldehyde for 1 and 2 hours,
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respectively, and processed as described above. Immunostaining to analyze cell
proliferation at E10.5 using anti-phosphohistone H3 (pHH3) antibody (1:1000, Abcam),
and sex determination at E18.5 using anti-sex-determining region Y protein antibody
(1:200, Santa Cruz) were performed after antigen retrieval in citrate buffer (10 mmol/L,
pH 6). This was followed by incubation with biotinylated goat anti-mouse IgG (1:300,
Vector Laboratories) secondary antibody. The signal was amplified by the ABC reagent
(Vector Laboratories) allowing for visualization through 3-3’di-aminobenzidine
tetrahydrochloride (DAB, Sigma) with hematoxylin as a counterstain. Blinded pHH3+
cell counts within the outflow tract (OFT) were taken from at least 3 heart sections per
heart and normalized to OFT length.

2.3.4

Lineage Tracing the Second Heart Field
Fate mapping of SHF progenitors was performed using the SHF specific

Mef2ccre/+ transgenic mouse and the global double fluorescent Cre reporter line
Rosa26mTmG that has LoxP sites on either side of a tomato-red fluorescence membrane
protein (mT) cassette, which is proceeded by a green fluorescence protein (GFP, mG)
cassette. In the Mef2cCre/+ transgenic line with C57BL/6 background, elements of the
Mef2c promoter drives Cre recombinase expression in all SHF derived cells. When
crossed with the Rosa26mTmG mice this results in a GFP signal that is detected in all SHF
derived cells.26, 27 In all other tissues, the absence of the Cre results in mT expression and
red fluorescence. Diabetes was induced in homozygous Rosa26mTmG females (8 to 10
weeks old) by STZ as described above. Hyperglycemic Rosa26mTmG female mice were
crossed

with

Mef2ccre/+;Rosa26mTmG

males

to

generate

E9.5

and

E12.5

Mef2ccre/+;Rosa26mTmG embryos, which were fixed, embedded and sectioned in the same
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manner as above. Immunostaining for membrane bound GFP was conducted using an
anti-GFP (1:500, Abcam) primary antibody, followed by biotinylated goat anti-rabbit IgG
(1:300, Vector Laboratories) secondary antibody using DAB for visualization. The SHF
derived cells, which are GFP+, were blindly quantified and compared between control
and diabetic groups.

2.3.5

Analysis of Superoxide Levels
Hearts collected from E12.5 fetuses from all four groups were cryo-sectioned

(CM1950, Leica, Germany) into 8 m thick slices and placed onto slides. A subset of
cryo-sectioned embryonic hearts from untreated and sapropterin-treated diabetic dams
were incubated with either 300 M L-NAME (Sigma), a nitric oxide synthase inhibitor,
or 100 units/mL superoxide dismutase (SOD, Sigma), recombinant antioxidant enzyme
for 30 minutes. Samples were then probed with 2 M dihydroethidium (DHE)
(Invitrogen Life Technologies, Burlington, Canada) for 30 minutes in a dark humidity
chamber at 37 C. After cover glass was mounted, DHE fluorescence signals were
visualized using a fluorescence microscope (Observer D1, Zeiss, Germany). Five – 8
images from each sample were captured at fixed exposure times for all groups and the
fluorescence intensity per myocardial area was blindly quantified using AxioVision
software.

2.3.6

Measurement of Cardiac Function
Pregnant dams were anesthetized and M-mode echocardiography images of E18.5

embryonic hearts were recorded using the Vevo 2100 ultrasound imaging system with a
MS 700 transducer (VisualSonics, Toronto, Canada) as previously described.18, 19 Briefly,
an incision was made to the abdominal wall of the pregnant dam to expose the uterine
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sacs containing the E18.5 fetuses. The transducer was aligned to the uterine sac to obtain
a short-axis view of the fetal heart. The end diastolic left ventricular internal diameter and
end systolic left ventricular internal diameter were measured from the short-axis M-mode
images to calculate LV ejection fraction and fractional shortening.

2.3.7

Western Blotting for eNOS Dimers and Monomers
Ventricular myocardial tissues from E12.5 hearts were dissected in PBS and used

for measurement of eNOS dimerization. In order to not disrupt the dimer, proteins were
isolated from three pooled hearts from each group via sonication using a non-reducing
lysis buffer, on ice.28 Protein lysates without boiling were run on an 8% SDS-PAGE at 4
C followed by transferring to a nitrocellulose membrane and immunoblotted with antieNOS polyclonal antibody (1:3000, Santa Cruz). This technique resulted in two distinct
bands at 260 and 130 kDa, representing the eNOS dimer and monomer, respectively.28
Proteins isolated from cultured coronary artery microvascular endothelial cells was boiled
and separated with the sample, acting as an eNOS monomer size control.

2.3.8

Real-Time RT-PCR
Total RNA was isolated from E12.5 hearts using TRIzol reagent (Invitrogen). 200

nanograms of RNA were synthesized into cDNA with Moloney murine leukemia virus
reverse transcriptase and random primers. Real-time PCR was conducted on cDNA using
Evagreen qPCR MasterMix (Applied Biological Systems, Vancouver, BC). Primers were
designed for Gata4, Gata5, Nkx2.5, Tbx5, Notch1, GCH1, DHFR using the Primer3
software v 4.1.0. The primer sequences are listed in Table 2.1. Eppendorf Realplex
(Eppendorf, Hamburg) was used to amplify samples for 35 cycles. Values were
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normalized to 28S ribosomal RNA, and mRNA levels were extrapolated through a
comparative CT method.19
Table 2.1. Specific primer sequences used in real-time PCR analysis.
Gene

Accession no.

Product Size

Gata4

NM_008092.3

134

Gata5

NM_008093.2

167

Nkx2.5

NM_008700.2

162

Tbx5

NM_011537.3

103

Notch1

NM_008714.3

142

Gch1

NM_008102.3

117

Dhfr

NM_010049.3

153

28S

NR_003279.1

178

Primer Sequence
F: GCCTGCGATGTCTGAGTGAC
R: CACTATGGGCACAGCAGCTC
F: ACCCCACAACCTACCCAGCA
R: GCCCTCACCAGGGAACTCCT
F: GACAGCGGCAGGACCAGACT
R: CGTTGTAGCCATAGGCATTG
F: AGGAGCACAGTGAGGCACAA
R: GGGCCAGAGACACCATTCTC
F: CAGCTTGCACAACCAGACAGA
R: TAACGGAGTACGGCCCATGT
F: TCAAGAGCGCCTCACCAAAC
R: TTCTGCACGCCTCGCATTAC
F: GAATCAACCAGGCCACCTCA
R: TTGATGCCTTTTTCCTCCTG
F: GGGCCACTTTTGGTAAGCAG
R: TTGATTCGGCAGGTGAGTTG

F: forward primer; R: reverse primer

2.3.9

Determination of Biopterin Levels
Tissue and plasma biopterin levels were determined using ultra-performance

liquid chromatography (UPLC) coupled to mass spectrometry. Briefly, dams were
anesthetized with an intraperitoneal injection of ketamine and xylazine cocktail at E12.5.
Whole embryos were harvested followed by blood collections from the dams for (UPLC)
analysis. About 1 mL of blood was collected via cardiac puncture using a 23-gauge
heparinized needle inserted into the beating left ventricle of the dam. Plasma samples
were then diluted 1:4 with 150 µl of acetonitrile containing internal standard (100 µM
aminopimilic acid and 2.5 µM chlorpromazine) before injection into the UPLC
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instrument. Total BH4 and BH2 levels were assessed using a Waters Acuity I Class
UPLC system coupled to a XEVO G2-S quadrupole time-of-flight mass spectrometer
(Waters Corporation: Milford, Massachusetts) as previously described.29

2.3.10

Statistical Analysis

Data are presented as the mean ± SEM. Statistical analysis was performed using
GraphPad Prism (Version 5, GraphPad Software, La Jolla, CA, USA). For comparisons
between two groups, unpaired Student’s t-test was used. Multiple group comparisons
between diabetic and control dams with and without sapropterin treatment, and their
interactions were conducted using two-way analysis of variance (ANOVA) followed by
the Bonferroni post-hoc test. Two-way repeated measures ANOVA followed by
Bonferroni post-hoc test was used to analyze blood glucose differences over time
between control and diabetic dams with or without sapropterin treatment. The incidence
of CHDs was assessed with Fisher’s exact test. Differences were deemed significant with
P<0.05.
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2.4 Results
2.4.1

Effects of sapropterin on blood glucose, fertility, litter size
and biopterin levels in pregestational diabetes
This study was conducted in the same pregestational diabetes model we recently

employed.30,

31

One week following the final administration of STZ, female mice with

random blood glucose levels >11 mmol/L were bred with normal adult males. During
gestation, blood glucose levels in the diabetic dams were progressively increased from
E0.5-18.5 compared to both sapropterin treated and untreated control mice (Fig. 2.2A).
Treatment with insulin but not sapropterin in the diabetic mice restored blood glucose to
normal levels. Diabetic dams had a significant lower fertility rate (38%) compared to
controls (82%, P<0.05), which was improved to 64% by sapropterin treatment (Fig.
2.2B).
Diabetic dams had a significantly smaller litter size (P<0.01), which was
improved by sapropterin treatment (Fig. 2.2C). Indeed, absorbed or dead fetuses were
more commonly seen in utero in diabetic dams. Fetal body weight was significantly
lower from diabetic dams than controls (P<0.001), and was restored to normal weight
with sapropterin (P<0.001, Fig. 2.2D). To assess biopterin levels following oral
sapropterin administration, maternal blood and embryos were collected at E12.5. Our
data show that sapropterin treatment significantly increased plasma BH2 levels in the
diabetic mothers (P<0.01, Fig. 2.2E). BH2 levels in E12.5 embryos from sapropterintreated dams were elevated by 91.3% (P=0.0537, Fig. 2.2F), and BH4 levels in E12.5
embryos of diabetic dams were significantly increased (P=0.0433, Fig. 2.2G).
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Figure 2.2. Blood glucose levels of pregnant mice, percent successful plugs, litter
size, fetal body weight and biopterin levels.
(A) Non-fasting blood glucose levels from before mating (basal) to E18.5 during
pregnancy in STZ-treated and control female mice with and without sapropterin (BH4)
administration (n = 4-8 mice per group). (B) The percent of successful pregnancy. The
numbers in the brackets indicate the number of successful pregnancy at the day of fetus
harvest to total plugs. (C) The offspring litter size measured at the day of fetus harvest (n
= 5-11 litters per group). (D) Fetal body weight at E18.5 (n = 5-8 fetuses per group). (EG) Levels of BH2 in maternal plasma, and fetal BH2 and BH4 levels at E12.5 with or
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without BH4 treatment in the diabetic dams (n = 3-9 mice per group). Two-way repeated
measures ANOVA (A) or two-way ANOVA (C-D) followed by Bonferroni post-hoc test
was used. B was analyzed by Fisher’s exact test. E-G were analyzed by unpaired
Student’s t test. *P<0.05, ***P<0.001 vs. corresponding controls, and ††P<0.001 vs.
untreated diabetes. Data are means ± SEM in A, C-G.

2.4.2

Sapropterin prevents CHDs induced by pregestational
diabetes
CHDs were observed in 59.4% of offspring from diabetic dams (Table 2.2 and

Fig. 2.3). Normal control heart sections are shown in Fig. 2.3A-C. Septal defects
constituted a large proportion of the anomalies with 47.4% atrial septal defects (ASD,
Fig. 2.3D) and 37.8% ventricular septal defects (VSD, Fig. 2.3E). The diagnosis of ASD
was based on a complete or partial absence of the septum secondum and/or primum in
multiple serial heart sections. Hypoplastic left heart was seen in 21.1% of offspring from
diabetic dams. In particular, 2 of these hearts displayed the characteristics of hypoplastic
left heart syndrome, with an underdeveloped left ventricle, a small ascending aorta, ASD
and abnormal mitral valve. Whereas, 6 hearts had an isolated hypoplastic left ventricle.
One fetus had an atrioventricular septal defect (AVSD). Outflow tract (OFT) defects
were also common in offspring from diabetic mothers. A double outlet right ventricle
(DORV) was present in one of the offspring (Fig. 2.3F) and truncus arteriosus was seen
in another fetus (Fig. 2.3G). Maternal diabetes also resulted in cardiac valve defects with
37.8% thickened aortic valves (Fig. 2.3H) and 29.7% thickened pulmonary valves (Fig.
2.3I). Finally, 24.3% of hearts from diabetic mothers displayed a narrowing aorta (Fig.
2.3H vs. B). Treatment with sapropterin to diabetic dams during pregnancy significantly
decreased the overall incidence of CHDs to 26.5% (Table 2.2). Specifically, offspring
from sapropterin-treated diabetic mothers show a significantly lower incidence of ASD
and thickened aortic valves, and did not display any VSD, AVSD, truncus arteriosus,
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DORV or hypoplastic left heart (Table 2.2, Fig. 2.3J-O). Cardiac anomalies were seen in
all litters from diabetic dams, and every dam in the sapropterin treatment group had at
least one offspring with a CHD. No CHDs were seen in diabetic dams who received a
daily dose of insulin to maintain normal blood glucose levels, indicating that CHDs seen
in the diabetic offspring were induced through hyperglycemia (Table 2.2, Fig. 2.3P-R).
The incidence of CHDs was significantly higher in males than females (65% vs. 47%,
P<0.05). Furthermore, sapropterin treatment was more effective in reducing the incidence
of CHDs to 16% in females compared to 35% in males (P<0.05, Fig. 2.3S). Cardiac
function of E18.5 fetuses was assessed through echocardiography. LV fractional
shortening and ejection fraction were significantly decreased in offspring of diabetic
dams, and were recovered by sapropterin treatment (P<0.001, Fig. 2.3T and U). In
addition, anterior wall thickness of the fetal heart during systole and diastole was reduced
in offspring of diabetic dams, which was restored following sapropterin treatment
(P<0.01, Fig. 2.3V and W). Pregestational diabetes also induced neural tube defects
(NTD) in our model. A case of exencephaly in the offspring of mother with
pregestational diabetes is shown in Fig. 2.3X.
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Table 2.2. The rate of congenital heart defects in the offspring of diabetic and
control mothers with and without sapropterin (BH4) treatment.
Control

Normal
Abnormal
ASD
VSD
Truncus
Arteriosus
AVSD
DORV
Pulmonary
Valve
Stenosis
Aortic Valve
Stenosis
RV
Hypertrophy
Hypoplastic
Left Heart
Narrowing
of the Aorta

STZ

BH4

STZ+BH4

STZ+Insulin

N

dams

N

dams

N

dams

N

dams

N

dams

14

3

38

9

23

4

34

5

20

3

n

%

n

%

n

%

n

%

n

%

14
0
0
0

100
0
0
0

16
22
18
14

40.6**
59.4**
47.4**
37.8*

23
0
0
0

100
0
0
0

25
9
9
0

73.5††
26.5††
26.5
0.0††

20
0
0
0

100
0
0
0

0

0

1

2.7

0

0

0

0.0

0

0

0
0

0
0

2
1

5.4
2.7

0
0

0
0

0
0

0.0
0.0

0
0

0
0

0

0

14

37.8*

0

0

0

0.0††

0

0

0

0

11

29.7*

0

0

1

2.9††

0

0

0

0

9

24.3

0

0

0

0.0††

0

0

0

0

8

21.1

0

0

0

0.0††

0

0

0

0

9

24.3

0

0

0

0.0††

0

0

Data was analyzed using Fisher’s exact test. *P <0.05, **P <0.001 vs. untreated control,
†P <0.05, ††P <0.001 vs. STZ. ASD: atrial septal defect, VSD: ventricular septal defect,
AVSD: atrioventricular septal defect, DORV: double outlet right ventricle. N indicates
total number of fetuses, dams are litter numbers.
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Figure 2.3. Effects of sapropterin (BH4) on congenital heart defects induced by
pregestational diabetes.
Representative histological sections of E18.5 hearts from offspring of diabetic mothers
with and without BH4 treatment. (A-C) show hearts sections from controls.
Pregestational diabetes resulted in atrial septal defect (D), ventricular septal defect (E),
double outlet right ventricle (F), truncus arteriosus (G), thickened aortic (H) and
pulmonary (I) valves. BH4 treatment in diabetic dams shows normal heart morphology
(J-O). Diabetic dams on insulin therapy to control blood glucose levels show normal fetal
heart morphology (P-R). Scale bars are 200 μm. (S) Incidence of CHDs as percent of
offspring separated by sex at E18.5 from diabetic dams with or without BH4 treatment.
*P<0.05 vs. STZ group of corresponding sex; †P<0.05 vs. corresponding males. (T-W)
LV fractional shortening and ejection fraction, anterior wall thickness during systole
(LVAWTs) and diastole (LVAWTd) assessed by echocardiography in E18.5 offspring (n
= 5-7 fetuses per group). *P<0.05, ***P<0.001 vs. corresponding controls, and
††P<0.001 vs. untreated diabetes. (X) An exencephaly was seen in the offspring of
mother with pregestational diabetes. A normal control fetus is shown on the right panel.
Fetuses are harvested at E13.5. S-W were analyzed by two-way ANOVA followed by
Bonferroni post-hoc test. Data are means ± SEM in T-W. Ao indicates aorta; LA, left
atrium; LV, left ventricle; PA, pulmonary artery; RA, right atrium, RV, right ventricle.
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2.4.3

Sapropterin prevents myocardial and valvular abnormalities
induced by pregestational diabetes
The free walls of the right and left ventricle at E18.5 were measured at the mid-

ventricular region (Fig. 2.4A). The RV and LV myocardium was thinner in the offspring
of diabetic mothers compared to those of control offspring, which was prevented by
sapropterin treatment (P<0.001, Fig. 2.4B and C). Additionally, since valve leaflets were
thickened (Fig. 2.3H and I), we assessed glycosaminoglycans, a component of
extracellular matrix in the cardiac valves using toluidine blue staining. Our data show that
glycosaminoglycans occupied a greater space in the leaflets of aortic and pulmonary
valves (light purple color) from E18.5 fetal hearts of diabetic mothers compared to
controls (Fig. 2.5A and B). Treatment with sapropterin decreased these extracellular
polysaccharides in both aortic and pulmonary valves (P<0.01, Fig. 2.5D and E). There
was no significant difference in glycosaminoglycan content in the mitral valve, however
the distal tip of mitral valve was thicker in the offspring of diabetic dams (P<0.01, Fig.
2.5F). Notably, the area of aortic orifice and diameter of pulmonary artery were
significantly smaller in hearts from diabetic mothers compared to controls (P<0.01, Fig.
2.5G and H).
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Figure 2.4. Effects of sapropterin (BH4) on fetal heart wall thickness of pregestational
diabetes at E18.5.
(A) Representative images of myocardial wall thickness in control and pregestational
diabetes with and without BH4 treatment. Arrows indicate compact myocardium
boundary from which measurements were obtained. (B-C) Quantification of right and left
ventricular myocardial thickness, respectively. n = 6 per group from 3 – 6 litters, ***P
<0.01 vs. untreated control, †P<0.01 vs. untreated diabetes. Data are means ± SEM in BC and analyzed using two-way ANOVA followed by Bonferroni post-hoc test. Scale bars
are 200 μm. LV indicates left ventricle; RV, right ventricle.
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Figure 2.5. Effects of sapropterin (BH4) on aortic, pulmonary and mitral valve
defects induced by pregestational diabetes at E18.5.
(A-C) Representative images of toluidine blue staining of glycosaminoglycans (GAG) in
aortic, pulmonary, and mitral valves in E18.5 hearts. (D) The ratio of GAG + area to total
valve leaflet area. (E) Pulmonary valve leaflet thickness. (F) Mitral valve leaflet
thickness. (G) Total aortic orifice area. (H) Pulmonary artery luminal diameter at the base
of the orifice. LCC, left coronary cusp; NCC, noncoronary cusp; RCC, right coronary
cusp; RC, right cusp; LC, left cusp; S, septal; L, lateral. Scale bars are 50, 20 and 20 μm
in A, B and C, respectively. *P<0.05, **P<0.01 vs. controls. †P<0.01, ††P< 0.01 vs.
untreated diabetes. n = 4-7 hearts per group from 3 – 4 litters. Data are means ± SEM in
B-C and analyzed using two-way ANOVA followed by Bonferroni post-hoc test.

2.4.4

Effects of sapropterin on outflow tract length and cell
proliferation in the fetal heart
Since offspring of diabetic mothers show OFT defects, we aimed to investigate

changes in cell proliferation at a critical stage in OFT formation. At E10.5 sagittal
sections of whole embryos reveal a shortened OFT in hearts from diabetic mothers
compared to control (P<0.001, Fig. 2.6A), which was restored with sapropterin treatment
(P<0.05, Fig. 2.6E). To further analyze this change, phosphorylated histone H3, a marker
for the mitotic phase of cell division, was used to compare the levels of proliferating cells
in the OFT at E10.5 using the same hearts (Fig. 2.6B-D). Embryos from mice with
pregestational diabetes had a significantly lower number of proliferating cells in the OFT
(P<0.01, Fig. 2.6F-G). Sapropterin treatment was able to prevent impaired cell
proliferation in the OFT in hearts from diabetic dams (P<0.001, Fig. 2.6F-G).
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Figure 2.6. Effects of sapropterin (BH4) on outflow tract development and cell proliferation
in E10.5 hearts of pregestational diabetes.
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(A) Length of the OFT was measured via sagittal sections according to the line. (B-D)
Immunostaining for phosphorylated histone H3 marking proliferating cells in the OFT
(B-C) and ventricular myocardium (D). Panel C is the magnification of boxed area in
panel B. (E) Quantification of OFT length. (F) Quantification of pHH3+ cells in the OFT.
(G) Quantification of pHH3+ cells in the ventricle. n = 3-6 hearts per group from 2 – 4
litters, **P<0.01 vs. untreated control, †P<0.05 vs. untreated control, ††P<0.01 vs.
untreated diabetes. Data are means ± SEM in E-G and analyzed using two-way ANOVA
followed by Bonferroni post-hoc test. Scale bars are 50 μm and 20 μm, respectively.
OFT indicates outflow tract; pHH3, phosphorylated histone H3.

2.4.5

Fate-mapping of SHF derived cells in the fetal heart of
diabetic mothers
In order to better understand the spectrum of malformations induced by maternal

diabetes seen at birth, embryonic lineage tracing of the SHF was carried out. Fate
mapping using Mef2c-Cre and the global double fluorescent Cre reporter line
Rosa26mTmG identified all SHF derived cells as GFP+. At E9.5, the number of GFP+ SHF
cells and total number of cells in the heart were significantly less than control (P<0.01,
Fig. 2.7A, D and E). Furthermore, significantly less GFP+ SHF cells were infiltrated into
the endocardial cushion at E12.5 in diabetic embryos compared to control (P=0.0476,
Fig. 2.7B and F). Additionally, E12.5 hearts from diabetic mothers had thinner
ventricular walls with significantly less myocardial cell layers than controls (P<0.01, Fig.
2.7C and G).
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Figure 2.7. Effects of pregestational diabetes on SHF progenitor contribution to
E9.5 and E12.5 hearts.
Fate mapping using the mT/mG reporter showing GFP+ cells expressing Cre recombinase
under the control of the anterior heart field specific Mef2c transcription factor.
Representative sections of OFT of E9.5 (A) and E12.5 (B) hearts from control and
diabetic mothers. (C) Representative sections showing the cell layers of the RV
myocardium from E12.5 hearts. Quantification of SHF GFP+ cells (D) and total number
of cells (E) in the OFT cushions at E9.5. Quantification of SHF GFP+ cells in the OFT
cushions (F) and number of cell layers in the RV myocardium (G) at E12.5. N = 3 per
group from 2 litters in D and E. N = 5 per group in F and G from 2 – 4 litters. *P<0.05,
**P<0.01, ***P<0.001 vs. control. Data are means ± SEM in D-G and analyzed using
unpaired Student’s t test. Scale bars are 50 μm. GFP indicates green fluorescent protein;
RV, right ventricle.
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2.4.6

Sapropterin prevents maternal diabetes-induced
downregulation of regulators of heart development
Pregestational diabetes induces changes in gene expression in the developing

heart.32 To determine if key transcriptional regulators of heart development were altered
under maternal diabetes and with sapropterin treatment, qPCR analysis was performed
from E12.5 hearts. Our data show that the mRNA levels of Gata4, Tbx5, Nkx2.5, Gata5,
Bmp10 and Notch1 were significantly lower compared to controls (P<0.05, Fig. 2.8A-F).
Treatment with sapropterin significantly improved mRNA levels of these transcription
factors (P<0.001, Fig. 2.8A-F). Additionally, gene expression of BH4 biosynthesis
enzymes including GTP cyclohydrolase 1 (Gch1) and dihydrofolate reductase (Dhfr) was
significantly decreased in embryonic hearts from diabetic mothers (P<0.05, Fig. 2.8G and
H). Of note, sapropterin treatment completely recovered the expression of Dhfr (P<0.001,
Fig. 2.8H).
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Figure 2.8. Effects of sapropterin (BH4) on molecular regulators of heart
development at E12.5.
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Real-time RT-PCR of cardiac transcription factors and regulators in E12.5 hearts of
offspring from control and diabetic mothers. (A-F) The expression of Gata4, Tbx5,
Nkx2.5, Gata5, Bmp10 and Notch1 were significantly decreased under maternal diabetes
and restored with BH4 treatment. (G-H) The expression of Gch1 and Dhfr was
significantly decreased with maternal diabetes. BH4 treatment rescues expression of
DHFR. n = 4 – 7 hearts per group. *P<0.05, **P<0.01 vs. untreated control, and †P<0.05,
††P<0.01 vs. untreated diabetes. Data are means ± SEM and analyzed using two-way
ANOVA followed by Bonferroni post-hoc test.

2.4.7

Sapropterin decreases oxidative stress and improves eNOS
dimerization in fetal hearts of pregestational diabetes
To examine the effects of sapropterin on ROS in the developing heart, DHE probe

was used to label the oxygen radical. Quantification of red fluorescence intensity
indicates that superoxide generation was significantly elevated in embryonic hearts from
mice with pregestational diabetes compared to control (P<0.05, Fig. 2.9A and 2.B).
Sapropterin treatment significantly reduced myocardial ROS levels to basal conditions
(P<0.05 Fig. 2.9B). Pre-treatment with L-NAME, a NOS inhibitor, and SOD, an
antioxidant enzyme, significantly decreased DHE fluorescence in embryonic hearts from
diabetic dams indicating eNOS uncoupling and superoxide generation, respectively
(P<0.05 Fig. 2.9B). Finally, eNOS uncoupling has been implicated as a mechanism for
endothelial dysfunction in diabetes.23 To assess the effects of sapropterin on eNOS
coupling, eNOS dimerization was analyzed using Western blotting in non-reducing
conditions, which yields two bands at 260 and 130 kDa, representing the intact dimer and
monomer of eNOS, respectively. Figure 2.9C shows a representative blot of the dimer
and monomer of eNOS. In control conditions, there was a higher level of eNOS dimers
than monomers, indicating a functional eNOS enzyme. However, embryonic hearts from
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diabetic dams show a significant decrease of dimer/monomer ratios compared to controls
(P<0.05, Fig. 2.9D), which was restored by sapropterin treatment (P<0.01, Fig. 2.9D).

Figure 2.9. Effects of sapropterin (BH4) on superoxide production and eNOS
dimer/monomer protein levels in E12.5 hearts.
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(A) Representative images of DHE staining in the ventricular myocardium of E12.5
hearts from control and diabetic dams with and without BH4 administration. A subset of
heart sections from diabetic dams were pre-treated with L-NAME (300 M) or SOD (100
units/mL) for 30 minutes prior to DHE probing. (B) Quantification of DHE fluorescence
signals. (C) Representative Western blotting showing eNOS dimer and monomer bands
of E12.5 hearts from control and diabetic dams with and without BH4 treatment.
Denatured endothelial cell lysate validates the size of the eNOS monomer band. (D)
Densitometric analysis of eNOS dimer/monomer ratios. n = 5 – 6 hearts per group from
2 – 4 litters. *P<0.05 vs. untreated control, ††P<0.01 vs. untreated diabetes, #P<0.05 vs.
untreated diabetes. Data are means SEM in B and D, and analyzed using two-way
ANOVA followed by Bonferroni post-hoc test. DHE indicates dihydroethidium; EC,
endothelial cell; L-NAME, Nω-Nitro-L-arginine methyl ester; SOD, superoxide
dismutase.

2.5 Discussion
The present study utilized a clinically relevant model of CHDs induced by
pregestational diabetes we recently established.30, 31 Consistent with our previous studies,
a spectrum of CHDs were observed in the offspring of diabetic mothers. The CHDs range
from ASD, VSD and valve thickening, to major malformations including AVSD, DORV,
truncus arteriosus and hypoplastic left heart, as clinically categorized by Hoffman et al.33
Sapropterin treatment was able to prevent all major defects and significantly reduce the
overall level of defects induced by pregestational diabetes. Other changes in the fetal
heart such as thinner ventricular myocardium, thickened valves, stenosis of the aorta and
pulmonary artery, impaired cardiac function along with decreased cell proliferation and
gene expression induced by maternal diabetes, were normalized with sapropterin
treatment. Furthermore, sapropterin administration in the diabetic dams increased eNOS
dimerization and decreased ROS levels in the fetal heart. Our study suggests that
sapropterin improves eNOS coupling and prevents CHDs in pregestational diabetes in
mice (Fig. 2.10).
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Figure 2.10. Schematic summary of sapropterin on diabetes-induced CHDs .
eNOS uncoupling and CHDs induced by pregestational diabetes and the inhibitory effects
by sapropterin treatment. Abnormalities of both second heart field (SHF) and non-SHF
derived structures are prevented by sapropterin treatment. LV indicates left ventricle;
OFT, outflow tract; ROS, reactive oxygen species; RV, right ventricle.

In this model, STZ was used to induce hyperglycemia in female mice at least 7
days before they were bred with normal healthy males. Since STZ has a short plasma
half-life of 10 minutes in rodents,34 it is unlikely that STZ would cause any teratogenic
effects in the fetus. To confirm that hyperglycemia is the cause of CHD in this model, a
group of mice were treated with insulin to lower glucose levels in diabetic dams. Our data
show that insulin treatment abrogated CHDs in pregestational diabetes, which is
consistent with clinical studies that good glycemic control in women with pregestational
diabetes lowers the incidence of CHDs.7 It should be noted that the incidence of CHDs
found in the diabetic groups with or without sapropterin treatment at E18.5 may be an
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underestimate as fetuses may have been absorbed in utero at around E12.5. To study the
effects of sapropterin on maternal diabetes, blood glucose levels were assessed during
pregnancy. Our data show that sapropterin treatment in the diabetic dams had no effect
on the hyperglycemic state of the animal, suggesting that the beneficial effects of
sapropterin on fertility (or percent successful pregnancy), litter size, and heart
development under pregestational diabetes are independent of blood glucose levels. In
humans, sex-related differences in the prevalence of CHDs have been reported. In a
recent large cohort study with 9,727 cases of CHDs, the male to female ratio was 55% to
45%, indicating a significant predisposition of CHDs in the male sex.35 In agreement with
clinical studies, our data show a male dominance of CHDs in the offspring of diabetic
mothers. Notably, sapropterin treatment appears to be more effective in preventing CHDs
in females than in males.
We have recently shown that defects in SHF signaling results in thin myocardium,
septal defects and OFT defects.26,

36

The defective SHF progenitor contribution may

explain the majority of heart malformations in the OFT, cardiac septum and cardiac
valves induced by pregestational diabetes. Since sapropterin treatment significantly
prevented these CHDs in the offspring of diabetic dams, it is likely that impairment in
SHF progenitors will be diminished by maternal sapropterin treatment, which still needs
to be confirmed in future studies. Considering the presence of hypoplastic left heart and
OFT septation defect (truncus arteriosus), it is possible that pregestational diabetes also
impairs FHF and CNC cells in our model. Notably, these defects were all prevented in
diabetic dams treated with sapropterin. These findings are consistent with previous
studies showing that oxidative stress during diabetic pregnancy disrupts CNC migration
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and causes OFT defects in rodents,37, 38 which are prevented by treatment with vitamin E,
an antioxidant.39 Our results suggest that sapropterin treatment improves the function of
both SHF and non-SHF (FHF and CNC) progenitors in pregestational diabetes (Fig.
2.10).
Cell proliferation is critical to cardiac morphogenesis and the growth of the fetal
heart.40 Decreased cell proliferation results in shortening of OFT length, thin myocardium
and CHDs.36,
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In the present study, E10.5 hearts show less cell proliferation and a

shorter OFT in embryos from diabetic dams. Furthermore, E18.5 hearts from diabetic
dams are notably smaller and their ventricular walls are significantly thinner than control
hearts. These abnormalities were all prevented by sapropterin treatment. Previous studies
have shown that BH4 increases DNA synthesis and cell proliferation in erythroid cells. 42
Additionally, BH4 mediates the proliferative effects of epidermal growth factor and nerve
growth factor in PC12 cells.43 We have previously shown that eNOS promotes
cardiomyocyte proliferation.17,
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Since BH4 increases eNOS coupling as shown by

higher dimer/monomer ratios in our study, it is possible that a normalized eNOS
signaling may contribute to the improved cell proliferation by sapropterin treatment.
Increases in cell apoptosis may also contribute to CHDs. However, we have previously
shown that the incidence of cell apoptosis in fetal hearts of diabetic offspring is low
(about 1%) and was not affected by anti-oxidant treatment, suggesting an insignificant
role of apoptosis in our model.31 We therefore did not assess cell apoptosis in the present
study.
Cardiac transcription factors including Gata4, Gata5, Nkx2.5 and Tbx5 are critical
to normal heart development, and genetic mutations of these transcription factors result in
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CHDs in humans.45 Interestingly, both eNOS and ROS can alter the expression of these
transcription factors.16, 31 For example, deficiency in eNOS decreases the expression of
cardiac transcription factors including Gata4 during embryonic heart development.19
Additionally, the expression of cardiac transcription factors was downregulated in the
fetal heart of offspring of diabetic mothers, which was restored by treatment with an
antioxidant, N-acetylcysteine.31 In agreement with our previous studies, we showed a
downregulation of Gata4, Gata5, Nkx2.5 and Tbx5 in fetal hearts of offspring from
diabetic mothers in the present study. Decreased expression was also seen in Bmp10,
essential in cardiac growth and chamber maturation.46 Importantly, sapropterin
administration to diabetic dams restored the expression profile of these factors to normal
levels. We also assessed the expression of Gch1 and Dhfr, which are enzymes
responsible for de novo BH4 biosynthesis and recycling of BH2 back to BH4,
respectively. Both GCH1 and DHFR are sensitive to oxidative stress and NO signaling. 21,
47

Of note, NO has been shown to stabilize DHFR protein from ubiquitination and

degradation by S-nitrosylation.48 During pregestational diabetes, GCH1 and DHFR
transcript levels in the fetal heart were downregulated, which was normalized by
sapropterin treatment. Our findings indicate a possible gene regulatory mechanism
governing DHFR expression. Recent studies show a strong interaction between eNOS
and Notch1 promoting semilunar valve and outflow tract development.49 Here we show
that Notch1 mRNA is decreased in embryonic hearts from diabetic dams, which is
rescued with sapropterin treatment. Our results indicate a perturbed NO-Notch1 signaling
pathway in the fetal hearts of diabetic dams. Together, these effects are consistent with
the ability of sapropterin treatment to recouple eNOS and restore ROS balance in the
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embryonic heart of diabetic dams. It should be noted that nNOS and iNOS are
dispensable for heart development since nNOS-/- and iNOS-/- mice do not exhibit any
developmental abnormalities of the heart.16
A major non-cardiac malformation induced by pregestational diabetes is NTD
such as anencephaly, exencephaly and spina bifida.50 It has been reported that 25-40%
offspring of diabetic dams have NTDs when the fetuses are examined at E10.5.51, 52 To
analyze cardiac malformation, we examined the fetuses at E18.5 and may have missed
most of the NTDs, which are likely absorbed beyond E10.5. This may be the reason that
we only observed one exencephaly in the present study and a low incidence of NTDs
(4.8%) in our previous study.31 Additionally, BH4 biosynthesis is important to neural
tube development. Inhibition of GCH1 activity, a rate limiting enzyme in the biosynthesis
of BH4, interrupts neural tube closure, which can be prevented by BH4 treatment in chick
embryos.53 Furthermore, GCH1 haplotypes are significantly associated with a higher risk
of NTD in infants.54 It is possible that sapropterin treatment may prevent NTD induced
by pregestational diabetes, a hypothesis that needs to be tested in future studies.
Surprisingly, the GCH1 knockout mice die at E13.5 due to bradycardia without any
structural anomalies.55 Apart from being a cofactor of eNOS, BH4 is also a substrate for
aromatic amino acid hydroxylases.56 BH4 treatment at postnatal day 14 elevated
dopamine levels in the brain and fully restored the loss of tyrosine hydroxylase protein
caused by the BH4 deficiency in infant mice,57 indicating an important role of BH4 in
dopaminergic function of the brain. The effects of pregestational diabetes and sapropterin
treatment on tyrosine hydroxylase expression and dopamine levels in the fetal brain are
beyond the scope of the present investigation.
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In summary, the present study demonstrates that treatment with sapropterin
(Kuvan®), an orally active synthetic form of BH4 during gestation improves eNOS
coupling, reduces ROS and increases cell proliferation in the embryonic heart of
offspring of diabetic mothers. Notably, sapropterin treatment prevents the development of
major CHDs induced by pregestational diabetes. Sapropterin is an FDA approved drug to
treat phenylketonuria (PKU), a genetic disorder due to mutations of phenylalanine
hydroxylase (PAH) gene leading to low levels of phenylalanine hydroxylase.25 Our study
suggests that sapropterin may also have therapeutic potential in preventing CHDs in
offspring of women with pregestational diabetes.
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Chapter 3

3.1 Chapter Summary
Endothelial nitric oxide synthase (eNOS) and oxidative stress are critical to
embryonic coronary artery development. Maternal diabetes increases oxidative stress and
reduces eNOS activity in the fetal heart. Sapropterin (Kuvan®) is an orally active,
synthetic form of tetrahydrobiopterin (BH4) and a co-factor for eNOS with antioxidant
properties. The aim of the present study was to examine the effects of sapropterin on
embryonic coronary artery development during pregestational diabetes in mice. Diabetes
was induced by streptozotocin to adult female C57BL/6 mice. Sapropterin (10
mg/kg/day) was orally administered to pregnant mice from E0.5 to E18.5. Fetal hearts
were collected at E18.5 for coronary artery morphological analysis. Sapropterin treatment
to diabetic dams reduced the incidence of coronary artery malformation in offspring from
50.0% to 20.6%. Decreases in coronary artery luminal diameter, volume and abundance
in hearts from diabetic mothers, were prevented by sapropterin treatment. Maternal
diabetes reduced epicardial epithelial-to-mesenchymal transition (EMT) and expression
of transcription and growth factors critical to coronary artery development including
hypoxia-inducible

factor

1a

(Hif1a),

Snail1,

Slug,

-catenin,

retinaldehyde

dehydrogenase 2 (Aldh1a2) and basic fibroblast growth factor (bFGF) in E12.5 hearts.
Additionally, eNOS phosphorylation was lower while oxidative stress was higher in
E12.5 hearts from maternal diabetes. Notably, these abnormalities were all restored to
normal levels after sapropterin treatment. In conclusion, sapropterin treatment increases
eNOS activity, reduces oxidative stress and prevents coronary artery malformation in
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offspring of pregestational diabetes. Sapropterin may have therapeutic potential in the
prevention of coronary artery malformation in pregestational diabetes.

3.2 Introduction
Diabetes is a global health concern. In 2013, approximately 21.4 million
pregnancies worldwide were affected by diabetes, of which 16% were pregestational
diabetes.1 Women with pregestational diabetes are at an increased risk of having a child
with a congenital heart defect (CHD).2 Hypoplastic coronary artery disease (HCAD) is a
congenital abnormality characterized by a marked decrease in luminal diameter and
length of one or more major branches of coronary arteries.3-6 HCAD can be
asymptomatic at birth but are often associated with myocardial infarction and sudden
cardiac death under physical exertion later in life.7, 8 In the clinic, newborns are screened
for many forms of CHDs, however, coronary artery branches are not reliably imaged
using non-invasive tools perinatally.9 HCAD is a rare form of congenital coronary artery
malformations (CAMs) including anomalous origins of the left and right coronary
arteries, single coronary artery, and coronary artery fistula, which collectively affect ~1%
of the general population.10, 11 While the clinical etiology of congenital coronary artery
anomalies is undefined, we have recently shown that pregestational diabetes results in
CAMs in the fetal heart of offspring in mice.12
The heart is the first functional organ to form during embryogenesis, and
vascularization in the primitive heart initiates at E9.5 in the proepicardial organ.13, 14 Cells
from this primitive structure migrate to cover the surface of myocardium, forming an
epicardium, which is fully formed by E12.5. These cells then undergo coordinated
epithelial-to-mesenchymal transition (EMT) and become epicardial-derived cells
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(EPDCs).14 EPDCs migrate to the subepicardial space and differentiate into vascular
smooth muscle cells, endothelial cells and adventitial fibroblasts, all which are needed to
form coronary vessels.14 The endocardium and sinus venosus also contribute to this
coronary plexus, and a complete coronary network is established by E15.15, 16 A misstep
in any of these processes including alterations in gene expression, cell proliferation and
epicardial EMT may result in coronary artery malformations.
Hyperglycemia-induced reactive oxygen species (ROS) is not conducive to heart
and coronary artery development as it oxidizes cardiogenic and angiogenic molecules.
Endothelial nitric oxide synthase (eNOS) is critical to embryonic heart development as
nitric oxide (NO) regulates transcription factor expression, progenitor cell growth and
EMT.17 In fact, eNOS-/- mice display hypoplastic coronary arteries and postnatal
myocardial infarction.18 Tetrahydrobiopterin (BH4) is a co-factor for eNOS, and an
antioxidant. It stabilizes the enzyme dimer and allows arginine binding.19 Under
oxidative stress, BH4 levels decline and eNOS is uncoupled and unable to form NO,
instead generates superoxide.20 BH4 improve eNOS coupling and vascular endothelial
function in diabetes.21 However, the ability of BH4 to regulate coronary artery
development in the fetal heart is not known. The FDA-approved drug, sapropterin
dihydrochloride (Kuvan®), is a stable, orally active, synthetic form of BH4. In the
present study, we aim to determine the effects of sapropterin on coronary artery
development under pregestational diabetes in mice. Our hypothesis was that sapropterin
treatment improves epicardial EMT and prevents CAMs during pregestational diabetes.
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3.3 Methods
3.3.1

Animals
C57BL/6 wild-type mice were purchased from Jackson Laboratory (Bar Harbour,

Maine), and a breeding program was implemented to generate postnatal and fetal mice.
All animals used in this study were handled according to the National Institute of Health
Guide for the Care and Use of Laboratory Animals (8th edition, 2011). All procedures
were approved by the Animal Care Committee at Western University, following the
Canadian Council on Animal Care guidelines.

3.3.2

Induction of Diabetes and Sapropterin Treatment
Diabetes was induced to six to eight-week old female C57BL/6 mice by

streptozotocin (STZ, 50 mg/kg body weight, I.P.) injections for five consecutive days, as
previously described.22,

23

STZ was dissolved in a sterile saline solution at the time of

administration, with sterile saline as vehicle controls. Non-fasting blood glucose levels
were measured one week following the last injection using a glucose meter (One Touch
Ultra2, LifeScan Canada, Burnaby, BC). Mice with blood glucose levels above 11.0
mmol/L were considered to be diabetic and subsequently bred with adult wild-type male
mice. A vaginal plug indicated embryonic day 0.5 (E0.5) and the pregnant female mice
were placed in a cage with littermates. A subset of the diabetic dams received a 10 mg/kg
per body weight oral dose of sapropterin dihydrochloride (Kuvan®, BioMarin
Pharmaceutical Inc., Novato, CA, USA) each day of gestation. Sapropterin
dihydrochloride was dissolved in water and combined with a small amount of peanut
butter. Blood glucose levels, food and water intake were monitored throughout
pregnancy.
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3.3.3

Histological and Immunohistochemical Analysis
To analyze coronary artery development and resulting vasculature, embryos were

harvested at E12.5 and E18.5 for morphological and immunohistochemical analyses.
Briefly, the thoraces of embryos were isolated and fixed in 4% paraformaldehyde
overnight. The samples were dehydrated, paraffin embedded and subsequently serial
sectioned into 5-m sections. Prior to immunostaining, antigen retrieval was conducted in
citric acid buffer (0.01 mol/L, pH 6.0) for 12 minutes at 94C using a microwave (BP111; Microwave Research & Applications, Inc., Carol Stream, IL).

The following

primary antibodies were applied and incubated overnight; anti--smooth muscle actin
(1:3,000, mus monoclonal, Sigma-Aldrich A2547, Lot 032M4822), biotinylated lectin-1
(1:250, Bandeiraea Simplicifolia, Sigma-Aldrich L2380, Lot 054M4086V), anti-sexdetermining region Y protein antibody (1:200, mus monoclonal, Santa Cruz SC-398567,
Lot J1316), anti-Wt1 (1:300, rb polyclonal, Santa Cruz SC-192, Lot F0513), anti-Ecadherin (1:200, goat polyclonal, Santa Cruz SC-31020, Lot D2413), and antiphosphohistone H3 (pHH3) (1:500, rb polyclonal, Abcam ab5176, Lot GR72823-1),
followed by either biotinylated goat anti-rabbit IgG (1:500) or biotinylated donkey antigoat IgG (1:500), for one hour. Signals were amplified through the ABC reagent (Vector
Laboratories), which enabled visualization by 3-3’ diaminobenzidine tetrahydrochloride
(DAB, Sigma). Counterstaining was performed with Mayer’s Hematoxylin (Thermo
Scientific, Waltham, MA), and images were captured with a light microscope (Observer
D1, Zeiss). To analyze coronary artery volume and branching, the AMIRA software (FEI
Visualization Sciences Group) was used to create three-dimensional reconstructions of smooth muscle actin stained sections 25-m apart. A ratio of coronary artery to
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myocardial volume was obtained using the AMIRA software. Counts of coronary
arteries, capillaries, and coronary progenitor cells were taken from a minimum of three
heart sections and normalized to the myocardium.

3.3.4

Analysis of 4-hydroxynonenal Levels
To analyze lipid peroxidation as an indication of oxidative stress in embryonic

hearts, E12.5 ventricles from all four groups were harvested and embedded in FSC22
frozen section media (Leica). Samples were cryosectioned (CM1950, Leica) into 8 m
thick sections, and immunostained with 4-hydroxynonemal (4-HNE) antibody (1:300,
goat polyclonal, ABM Y072093, Lot AP1217). This was followed by CY3-conjugated
anti-goat IgG secondary antibody (1:1000; Jackson Immunoresearch). Signals were
detected using fluorescence microscopy (Observer D1, Zeiss, Oberkochen, Germany).
Using a fixed exposure time, a minimum of 4 images were captured per heart, and
fluorescence intensity per area of myocardium were measured using AxioVision
Software (Zeiss, Oberkochen, Germany).

3.3.5

Assessment of Epicardial EMT using ex vivo Heart Explant
Culture

To assess epicardial EMT, ventricles of E12.5 embryonic hearts from non-diabetic dams
were harvested and cultured on a collagen gel matrix for 96 hours. To prepare the
collagen matrix, 1 mg/mL type I rat tail collagen (BD Bioscience) was added to 2x M199
media (M5017; Sigma) containing 5 mM D-glucose or 30mM D-glucose in a 24-well
plate. The casted collagen wells were hydrated with 500 L 1x M199 media plus 10%
FBS and insulin-transferrin-selenium, with or without 0.1 mM BH4 (Sigma), and 5 mM
or 30 mM D-glucose. E12.5 ventricles were isolated in sterile saline, placed centrally in a
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well containing the set collagen matrix and media, and incubated at 37°C for 4 days.
Images were captured with a phase contrast microscope (Zeiss, Oberkochen, Germany),
and spindle-shaped cell outgrowth distance was quantified.

3.3.6

Western Blotting for eNOS and Akt Phosphorylation
Ventricular myocardial tissue from E14.5 hearts, isolated in PBS, was used to

analyze eNOS and Akt activity. Briefly, 30 g of protein from isolated ventricular tissue
was separated via 10% SDS-PAGE and transferred to a nitrocellulose membrane. Blots
were probed with antibodies against p-NOS3 (Ser1177; 1:1000, rb polyclonal, Cell
Signaling 9571S, Lot 7), NOS3 (1:1000, rb polyclonal, Santa Cruz SC-654, Lot G2414),
p-Akt (Ser473; 1:5000, rb polyclonal, Cell Signaling 9271, Lot 19), Akt (1:5000, rb
polyclonal, Cell Signaling 9272, Lot 22), and -actinin (1:5000, mus monoclonal, SigmaAldrich A7811, Lot 029K4844). Washed blots were probed with horseradish peroxidase–
conjugated secondary antibodies (1:2500; Bio-Rad). The signal was detected using
enhanced chemiluminescence and quantified by densitometry.

3.3.7

Real-time RT-PCR Analysis
Total RNA was extracted from E12.5 hearts using TRIzol reagent (Invitrogen).

200 nanograms of RNA was reverse transcribed using the Maloney murine leukemia
virus reverse transcriptase and random primers. Evergreen qPCR MasterMix (Applied
Biological Systems, Vancouver, BC) was used to conduct Real-time PCR on cDNA.
Primers were designed for HIF-1, Aldh1a2, -catenin, bFGF, Slug, Snail1, and Tbx18
using the Primer3 software v 4.1.0 (Table 3.1). Samples were amplified for 35 cycles
using the Eppendorf Realplex (Hamburg, Germany). mRNA levels were extrapolated
using a comparative CT method by normalizing to 28S-Ribosomal RNA.
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Table 3.1. Specific primer sequences for real-time PCR analysis.
Gene

Accession no.

Product Size

Hif1-

NM_001313919

237

Snail1

NM_011427.3

133

Slug

NM_011415.2

161

Aldh1a2

NM_009022.4

219

-catenin

NM_001165902.1

178

bFgf

NM_008006.2

174

Tbx18

NM_023814.4

199

28S

NR_003279.1

178

Primer Sequence
F: CAGCCTCACCAGACAGAGCA
R: GTGCACAGTCACCTGGTTGC
F: CACACGCTGCCTTGTGTCT
R: GGTCAGCAAAAGCACGGTT
F: CAACGCCTCCAAGAAGCCCA
R: GAGCTGCCGACGATGTCCAT
F: GGCAGCAATCGCTTCTCACA
R: CAGCACTGGCCTTGGTTGAA
F: CTTGGCTGAACCATCACAGAT
R: AGCTTCCTTTTTGGAAAGCTG
F: CAAGGGAGTGTGTGCCAACC
R: TGCCCAGTTCGTTTCAGTGC
F: GAGCAGCAACCCGTCTGTGA
R: GGGACTGTGCAATCGGAAGG
F: GGGCCACTTTTGGTAAGCAG
R: TTGATTCGGCAGGTGAGTTG

F: forward primer; R: reverse primer

3.3.8

Statistical Analysis
Data are shown as mean  SEM. A two-way analysis of variance (ANOVA) was

used for multiple group comparisons between diabetic and control dams with and without
sapropterin treatment, and their interactions, followed by the Bonferroni post-hoc test
(Version 5, GraphPad Software, La Jolla, CA, USA). The incidence of coronary artery
malformations was assessed with Chi-square test. Differences were regarded significant
with P<0.05.
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3.4 Results
3.4.1

Sapropterin prevents coronary artery malformations in
offspring of diabetic mice without altering blood glucose
levels
The present study was conducted using the same model of pregestational diabetes

previously employed.12,

22, 23

A week following STZ administration, diabetes was

confirmed by measuring non-fasting blood glucose levels. Female mice with >11 mmol/L
blood glucose were considered diabetic and bred with normal males. The glycemic state
of the diabetic dam steadily increased from 15.9 ± 4.9 mmol/L at E0.5 to 25.1 ± 4.4
mmol/L by E18.5 (Table 3.2). The diabetic dams fed with sapropterin during gestation
displayed a similar increase in hyperglycemia, gradually reaching 26.9 ± 5.2 mmol/L at
the end of pregnancy. Of note, treatment with sapropterin did not affect blood glucose
levels in either the control or diabetic groups. A daily dose of insulin was administered to
a cohort of diabetic dams throughout gestation, which normalized their elevated blood
glucose levels (Table 3.2).
Half of all fetuses from untreated diabetic dams examined at E18.5 displayed
CAM. This ratio was significantly reduced to 20.6% with sapropterin treatment (Table
3.2). Furthermore, 36.8% of fetal hearts presented with both CHD and CAM. Sapropterin
effectively prevented the dual defect occurrence, as no hearts from the offspring of
sapropterin-treated diabetic dams had both CHD and CAM. No CAMs or CHDs were
found in either of the control groups or the insulin treatment groups, indicating that any
vascular abnormalities seen were induced by diabetes and not a teratogenic effect of STZ.
Finally, CAM incidence or the effectiveness of sapropterin treatment did not show any
bias towards the male or female sex (Table 3.2).
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Table 3.2. Effects of sapropterin (BH4) on nonfasting maternal blood glucose levels
and incidence of CAMs in E18.5 hearts during pregestational diabetes.
Control

Diabetes

BH4

Diabetes +
BH4

Diabetes
+ Insulin

3

9

4

5

3

Blood glucose at E0.5 (mmol/L)

7.5 ± 1.8

15.9 ± 4.9*

8.0 ± 0.6

16.8 ± 4.2†

6.2 ± 0.8

Blood glucose at E18.5 (mmol/L)

7.5 ± 0.6

25.1 ± 4.4**

9.1 ± 1.0

26.9 ± 5.2††

7.6 ± 0.7

CAM/total fetuses (n)

0/14

19/38*

0/23

7/34†

0/20

Males: CAM/total fetuses (n)

0/14

9/38*

0/23

3/34

0/20

Females: CAM/total fetuses (n)

0/14

10/38*

0/23

4/34

0/20

CAMs (%)

0.0

50.0

0.0

20.6

0.0

Litters (n)

3.4.2

Sapropterin prevents diabetes-induced fetal hypoplastic
coronary arteries and restores capillary density
Hearts with hypoplastic coronary arteries have marked decreases in vessel number

and luminal diameter.12 Immunostaining with -smooth muscle actin and biotinylated
lectin-1 was used to identify hypoplastic coronary arteries and capillaries, respectively in
E18.5 hearts. The left coronary artery originating from the aortic orifice in fetuses from
diabetic dams was significantly smaller in luminal diameter than control (P<0.01, Fig.
3.1A and E). Similarly, the diameter of the right ventricular coronary artery in offspring
from diabetic dams was also smaller than control (P<0.001, Fig. 3.1B and F). Sapropterin
treatment prevented this diabetes-induced reduction in luminal diameter of the left and
right coronary arteries (P<0.05, Fig. 3.1A, B, E and F). Sapropterin treatment also
rescued a maternal diabetes-induced decrease in coronary artery abundance within the
ventricular myocardium (P<0.01, Fig 3.1C and G). Interestingly, strong -smooth muscle
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actin staining was noted in hearts from diabetic dams throughout the myocardium at
E18.5, suggesting a delayed maturation of cardiomyocytes. Finally, immunostaining of
lectin-1 marking endothelial cells revealed a reduced capillary density in the ventricular
myocardium of E18.5 hearts from diabetic dams comparted to controls, which was
restored to normal with sapropterin treatment (P<0.05, Fig. 3.1D and H). Coronary
arteries were reconstructed in 3-dimensions to illustrate branching and extrapolate
volume measurements. Figure 2A shows a notable decrease of coronary artery
arborisation in E18.5 hearts from diabetic dams. The typical branching patterns were
restored in offspring from diabetic mothers treated with sapropterin, resulting in
normalization of the coronary artery volume to myocardial volume ratio (P<0.01, Fig.
3.2B).
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Figure 3.1. Effects of sapropterin (BH4) on coronary artery malformations induced
by pregestational diabetes.
Representative histological sections of E18.5 hearts from offspring of control and
diabetic dams with and without BH4 treatment. -smooth muscle actin staining of
vascular smooth muscle cells specifying the left (A) and right (B) coronary artery, with
arrows indicating diameter of the artery lumen measurements. (C) -smooth muscle actin
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staining for total number of coronary arteries throughout the ventricular and septal
myocardium. (D) Biotinylated lectin-1 immunostaining marking endothelial cells
forming myocardial capillaries in the right ventricle. (E-H) Analysis of left (E) and right
(F) coronary artery diameter, coronary artery abundance (G) and capillary density (H). n
= 7 – 9 per group, *P<0.05, **P<0.01 and ***P<0.001 vs. untreated control, †P<0.05
and ††P<0.01 vs. untreated diabetes. Scale bars represent 50, 20, 200 and 20 μm in A, B,
C and D, respectively.

Figure 3.2. Effects of sapropterin (BH4) on coronary artery volume at E18.5.
(A) Frontal views of 3D reconstructions of the coronary arteries with superimposed
myocardium. (B) Total coronary artery volume normalized to myocardial volume. n = 4
hearts per group. **P<0.01 vs. untreated control, ††P<0.01 vs. untreated diabetes.
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3.4.3

Sapropterin regulates coronary artery progenitor proliferation
and EMT
To determine if diabetes-induced perturbations in coronary artery formation could

give rise to the hypoplastic phenotype seen at E18.5, and whether sapropterin affected
coronary artery precursors, epicardial proliferation and EMT were examined at E12.5.
The epicardium is the source of coronary artery progenitors, which migrate from this
epithelial layer via EMT into the myocardium.24 Immunostaining for phosphorylated
histone H3 (pHH3), marking cells undergoing division, revealed less proliferation,
reduced cell density, a loosely attached epicardium in hearts from diabetic dams
compared to controls (P<0.01, Fig. 3.3A and D). Sapropterin treatment restored the
number of pHH3+ cells to almost control levels and rescued epicardial detachment (Fig.
3.3A). Concurrent with these changes in proliferation, a significantly greater number of
E-cadherin+ epicardial cells were found in embryonic hearts from diabetic dams, which
was abrogated by sapropterin treatment (P<0.01, Fig. 3.3B and E). To determine the
number of cells actively going through the process of EMT, immunostaining for the
transcription factor Wt1 was conducted and showed significantly fewer positive cells in
the epicardium and subepicardium in E12.5 hearts from diabetic dams compared to
controls (P<0.05, Fig. 3.3D). These abnormalities were also prevented by sapropterin
treatment (P<0.05, Fig. 3.3D, F-G).
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Figure 3.3. Effects of sapropterin (BH4) on epicardial cell proliferation and markers
of EMT in E12.5 hearts.
(A) Representative images of immunostaining for phosphorylated histone H3 marking
proliferating cells (red arrows), (B) E-cadherin (brown staining) representing cell-to-cell
adhesion, and (C) Wt1+ cells (brown staining) indicating EMT. Quantification of pHH3+
cells (D), E-cadherin+ cells (E) in the epicardium, and Wt1+ cells in the epicardium (F)
and subepicardium (G). n = 3 – 6 hearts per group, *P<0.05, **P<0.01 vs. untreated
control, †P<0.05, ††P<0.01 vs. untreated diabetes. Scale bars are 20 μm.
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3.4.4

Tetrahydrobiopterin normalizes high glucose-impaired
epicardial EMT ex vivo
To further investigate the ability of sapropterin to restore epicardial EMT and

thereby prevent diabetes-induced CAMs, effects of BH4 on EPDC migration was studied
ex vivo under high glucose conditions. The ventricular myocardium of E12.5 hearts from
control dams was isolated and cultured on collagen gel in both high glucose (30 mmol/L)
and normal glucose (5 mmol/L) conditions for 4 days (Fig. 3.4A). The outgrowth radius
of spindle shaped cells from the explanted heart tissue was measured. The data shows
that high glucose impaired EPDC migration through the collagen matrix with
significantly shorter outgrowth distance compared to normal glucose (P<0.01, Fig. 3.4A).
The addition of 0.1 mmol/L BH4 restored the distance travelled by the spindle-shaped
EPDCs to normal levels (P<0.05, Fig. 3.4A and B).

Figure 3.4. Effects of BH4 on epicardial EMT ex vivo.
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(A) Representative images of epicardial cell outgrowth and EMT from E12.5 heart
explants grown on a collagen matrix in normal (5 mM) and high (30 mM) glucose
conditions with and without BH4 (0.1 mM). Dashed line indicated the border of the
migrated cells. (B) Measurements of the average distance traveled by epicardial cells. (C)
Quantification of spindle shaped cells (epicardial-derived cells, EPDCs) that have
undergone EMT. *P<0.05, **P<0.01. n = 3-5 explants per group from five litters.

3.4.5

Sapropterin restores expression of coronary vessel
development and growth genes
Pregestational diabetes has been shown to alter gene expression in the developing

heart.12,

22, 25

To determine if the expression of key transcriptional regulators and

signaling molecules responsible for epicardial EMT, angiogenesis, differentiation and
growth were affected by maternal diabetes and sapropterin treatment, qPCR analysis was
performed on E12.5 hearts. The mRNA levels of Hif-1, Snail1, Slug, Aldh1a2, catenin, bFGF, and Tbx18 were significantly lower in hearts from diabetic dams
compared to controls (P<0.05, Fig. 3.5A-G). Treatment with sapropterin significantly
improved the expression levels of Hif-1, Snail1, Aldh1a2, -catenin and bFGF (P<0.05,
Fig. 3.5A-G).
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Figure 3.5. Effects of sapropterin (BH4) on gene expression of transcription and
growth factors critical to coronary artery development in E12.5 hearts of offspring
from diabetic and control dams.
mRNA levels were analyzed by qPCR. (A-G) The expression of Hif-1, Snail1, Slug,
Aldh1a2, -catenin, bFGF, and Tbx18 were significantly decreased under maternal
diabetes. All (A, B, D-F) were restored to control levels by BH4 treatment except Slug
and Tbx18 (C and G). (H) eNOS expression was not significantly changed. n = 4 – 7
hearts per group. *P<0.05, **P<0.01 vs. untreated control, and †P<0.05, ††P<0.01 vs.
untreated diabetes.

3.4.6

Sapropterin inhibits oxidative stress and restores activity of
the Akt/eNOS pathway
To assess levels of oxidative stress in the developing myocardium,

immunofluorescent staining of 4-hydroxynonenal (4-HNE), a product of lipid
peroxidation, was conducted on E12.5 hearts. Quantification of red fluorescence intensity
indicated higher levels of myocardial 4-HNE in offspring from diabetic dams compared
to controls (P<0.05, Fig. 3.6A and B). Sapropterin administration to diabetic dams
significantly reduced lipid peroxidation (P<0.05, Fig. 3.6B). Next, we assessed the
effects of pregestational diabetes on Akt and eNOS activity in E14.5 hearts. Western
blotting was used to analyze the phosphorylated and total amounts of Akt and eNOS (Fig.
3.6C). Fetal hearts from diabetic dams had significantly lower levels of p-Akt and peNOS compared to controls, without any major changes in total protein levels (P<0.001,
Fig. 3.6C-E). Phosphorylation of both enzymes was recovered to control levels with
sapropterin treatment (P<0.05, Fig. 3.6C-E).
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Figure 3.6. Effects of sapropterin (BH4) on oxidative stress and Akt/eNOS
phosphorylation in fetal hearts.
(A) Representative immunoflourescence images of 4-hydroxynonenal staining for lipid
peroxidation in the ventricular myocardium at E12.5. (B) Quantification of 4-HNE red
immunofluorescence signal. (C) Representative Western blots for phosphorylated and
total levels of Akt and eNOS with -actinin as a loading control in E14.5 hearts. (D and
E) Densitometric analysis of phosphorylated to total protein levels of Akt (D) and eNOS
(E). n = 4 hearts per group. ***P<0.001 vs. untreated control, †P<0.05 and ††P<0.01 vs.
untreated diabetes.
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3.5 Discussion
The current study displays the efficacy of the FDA-approved drug sapropterin
dihydrochloride (Kuvan®) in preventing congenital malformations of coronary arteries
induced by a clinically relevant model of pregestational diabetes (Figure 3.7). In
accordance with our previous studies,12 CAMs were observed in the offspring of diabetic
female mice. These CAMs manifest as hypoplastic coronary arteries, with marked
decreases in luminal diameter and abundance, which translates to an overall reduction in
the volume of coronary vasculature. We show that daily sapropterin administration to
diabetic dams prevents hypoplastic coronary arteries, restores myocardial coronary
arborisation and increases capillary density. Additionally, sapropterin decreases oxidative
stress, improves Akt/eNOS activity and epicardial EMT, leading to normal coronary
artery development.

Figure 3.7. Schematic summary of sapropterin on diabetes-induced CAMs.
Oral sapropterin (Kuvan®) treatment inhibits oxidative stress, improves Akt/eNOS
activity, and prevents coronary artery malformation (CAM) during pregestational
diabetes.
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Recently, we have shown the effectiveness of sapropterin in preventing CHDs in
the offspring of diabetic mice.23 Sapropterin treatment throughout gestation to diabetic
dams decreased the incidence of CHDs in their offspring from 59.4% to 26.5%, despite
dams having a comparable hyperglycemic status.23 No major CHDs were reported in the
treatment group, and insulin administration completely prevented the presence of
malformations.23 Correspondingly, our previous work show that N-acetylcysteine (NAC)
treatment in the same model of pregestational diabetes, significantly reduced the
incidence of CHDs and CAMs from 58.1% to 16.3% and from 46.6% to 6.0%,
respectively.12, 22 In fact, only 3% of fetal hearts from diabetic dams treated with NAC
showed dual congenital heart and coronary artery anomalies.12 In the present study,
sapropterin treatment completely prevented the presence of both a CHD and CAM within
the same heart, and significantly reduced CAM incidence from 50.0% to 20.6%. Whether
sapropterin and NAC have an additive or synergistic effect in preventing CHDs and
CAMs remains to be determined in future studies.
STZ is commonly used in animal models of diabetes to induce congenital
malformations.12, 22, 23, 25 Following STZ administration in our study, the glycemic levels
of female mice steadily rose throughout pregnancy. Daily insulin treatment, the clinical
gold-standard for controlling hyperglycemia in diabetes,26 to a cohort of these diabetic
mice normalized blood glucose levels. Interestingly, no CAMs were seen with insulin
treatment, indicating that STZ does not have teratogenic effects on coronary artery
development, and the defects seen in non-insulin treated STZ cohort are due to
hyperglycemia. Unlike insulin, sapropterin did not affect blood glucose levels of the
diabetic dam, suggesting that its beneficial effects are independent of maternal glucose
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levels. Clinically, a male predominance of coronary artery anomalies has been reported.27,
28

. In the present study, the incidence of pregestational diabetes-induced CAMs did not

show a sex bias and sapropterin treatment was equally effective in both females and
males. Of note, in dams with blood glucose exceeding 30 mmol/L, fetuses harvested at
E18.5 were 69% females, suggesting that more males with CAMs may have succumbed
to maternal diabetes, which may explain a lack of sex difference in the incidence of
CAMs in our study.
The epicardium is a major source of coronary arteries during embryonic heart
development. Between E11.5 and E12.5 many cells in the epicardium undergo EMT and
delaminate, forming EPDCs.14,

29

These EPDCs migrate into the myocardium and

differentiate into vascular smooth muscle cells, endothelial cells and perivascular
fibroblasts, and form coronary arteries.13 Wt1 is the master regulator of epicardial EMT,
and transcriptionally controls the expression of many mediators of EMT such as Snail1,
Aldh1a2 and E-cadherin.30, 31 In mice deficient of Wt1, epicardial cells fail to undergo
EMT, resulting in null coronary artery formation.32 In the present study, consistent with
our previous work,12 pregestational diabetes decreased epicardial and subepicardial
expression of Wt1, and inhibited epicardial cell proliferation and EMT in the developing
heart. We also showed lower mRNA levels of many drivers of EMT including, Snail1,
Slug, and Aldh1a2, and increased expression of E-cadherin. Notably these changes were
restored to control levels with sapropterin treatment. Interestingly, BH4 has been shown
to increase cell proliferation in retinal microvascular endothelial cells, mesangial (smooth
muscle) cells of the kidney, and human vascular endothelial cells (HUVECs), and
promote cell migration and tubulogenesis.33-35 Consistent with these studies, we showed a
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pro-angiogenic effect of sapropterin in the fetal heart of diabetic pregnancies in the
present study.
Akt and eNOS are critical for proper heart development. In fact, Akt1/3 double
knockout mice exhibit CHDs and early neonatal lethality.36 We have previously shown
that eNOS-deficient mice display major cardiac defects including ASD, VSD and
hypoplastic coronary arteries.18,

37, 38

Diabetes impairs eNOS function. For example,

eNOS Ser1177 phosphorylation is decreased in the heart of diabetic patients 39 and eNOS
is uncoupled in E12.5 hearts from diabetic dams.23 In the present study, maternal diabetes
induces a significant reduction in Akt and eNOS phosphorylation in E14.5 hearts, which
was restored by sapropterin treatment. eNOS-derived NO is a key signaling molecule
involved in proliferation, differentiation, EMT and ROS handling.17 High levels of 4hydroxynonenal, a marker of lipid peroxidation, reduces eNOS phosphorylation in bovine
aortic endothelial cells by decreasing cellular BH4 bioavailability.40 In our study,
sapropterin treatment in diabetic dams significantly reduced ROS and 4-hydroxynonenal
levels in fetal hearts. These findings suggest that sapropterin prevents hyperglycemiainduced oxidative stress and maintains redox balance and eNOS function in the
developing heart.
A notable observation from immunohistochemical analysis is α-SMA positive
staining in cardiomyocytes in addition to coronary arteries in E18.5 hearts of offspring
from diabetic mothers. During early cardiogenesis, immature cardiomyocytes express αSMA and as cardiac development progresses, α-SMA is eventually replaced by cardiac
actin isoforms.41,

42

The persistent α-SMA expression in cardiomyocytes and smaller

152

heart size at E18.5 in offspring of pregestational diabetes suggest that maternal diabetes
delays fetal heart maturation, which is also prevented by sapropterin treatment.
The present study is limited to simulate type 1 diabetes. In pregnant women, the
prevalence of pregestational type 2 diabetes is rapidly increasing in recent years.43 The
effects of type 2 diabetes on CAMs remain to be investigated in future studies.
Additionally, coronary arteries are formed from at least 3 sources of progenitors, the
epicardium, endothelial cells of sinus venosus and the endocardium.14-16 The present
study examined the changes of epicardial progenitors, which is considered a major
contributor to coronary arteries.14 Whether the other two sources of coronary progenitors
are affected by pregestational diabetes and/or sapropterin requires further investigation.
In conclusion, oral treatment with the FDA-approved drug sapropterin
dihydrochloride (Kuvan®), a stable, synthetic form of BH4, prevents the development of
CAMs induced by maternal diabetes in mice. Sapropterin increases Akt and eNOS
phosphorylation, decreases oxidative stress in the developing heart, and promotes cell
proliferation, EMT and growth of coronary artery progenitors. Sapropterin did not
negatively affect litter size, fetal weight or heart development in our studies,23 suggesting
an excellent safety profile in normal mouse pregnancies. Currently sapropterin is
prescribed as a phenylalanine hydroxylase activator for patients with phenylketonuria
(PKU), a genetic disorder. The potential of sapropterin as a treatment to prevent CHDs
and CAMs in the offspring of women with pregestational diabetes needs to be tested in
clinical trials.
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3.6 Footnotes
This study was funded in part by grants from the Canadian Institutes of Health
Research (CIHR) to Qingping Feng, and the Children’s Health Foundation in London,
Ontario, Canada to Kambiz Norozi, and Qingping Feng. Qingping Feng is a Richard and
Jean Ivy Chair in Molecular Toxicology at Western University.
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Chapter 4

4.1 Chapter Summary
Pregestational maternal diabetes increases the risk for congenital heart defects
(CHDs) in infants by over four times. Diabetes may alter maternal/fetal microRNA
(miRNA) profiles leading to the pathogenesis of CHDs. An elevation of miR-122 has
recently been reported in patients with impaired glucose tolerance, insulin resistance and
obesity. miR-122 is highly abundant in the liver and acts as tumor suppressor. The aim of
the present study was to determine if miR-122 is elevated in embryonic hearts from
diabetic female mice, and to examine the effects of antimiR-122 on pathogenesis of
CHDs during pregestational diabetes. Diabetes was induced by streptozotocin (50 mg/kg,
IP x5) to adult female C57BL/6 mice. Diabetic females were treated with a locked
nucleic acid (LNA) antimiR-122 or scramble LNA control (10 mg/kg, SC x2), and their
offspring’s hearts were examined at E18.5 for morphology and function. RT-qPCR
analysis showed that miR-122 was upregulated in E12.5 hearts of offspring from diabetic
dams. In cultured E12.5 hearts, treatment with miR-122 or high glucose inhibited cell
proliferation and epicardial EMT, and increased apoptosis. These effects of miR-122 and
high glucose were abrogated by antimiR-122 transfection. Downregulation of genes
critical to cell cycle progression, angiogenesis, and heart development, such as Cyclin
D1, Snail1, Gata4 and Hand2 under high glucose conditions, was also prevented by
anitmiR-122 transfection. Furthermore, in vivo antimiR-122 treatment to diabetic dams
decreased the incidence of CHDs and improved cardiac function of fetuses compared to
scramble LNA controls. The current study reveals for the first time a critical role of miR-
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122 in CHD pathogenesis, and may have therapeutic implications in preventing CHDs
during pregestational diabetes.

4.2 Introduction
Congenital heart defects (CHDs) are the most prevalent birth defect, accounting
for 1 to 5% of live births, and represent the leading, non-infectious cause of pediatric
mortality and morbidity worldwide.1-4 These defects result from perturbations in complex
molecular and cellular processes underlying normal embryonic heart development,
compromising cardiac structure and function at birth. Adverse genetic and environmental
factors impair cardiogenesis and increase the likelihood of CHDs. Pregestational
maternal diabetes increases the incidence of CHDs in children by more than four-fold.5-8
Importantly, the incidence of both type 1 (insulin-dependent) and type 2 (insulin
resistant) diabetes (T1D and T2D) is rapidly increasing in women of childbearing age and
youth aged 10 -19 years.9-11 In fact, between 2000 and 2010, there was a 37% rise in
pregnancies affected by pregestational diabetes in the U.S.12 Despite glycemic control,
congenital malformations occur at higher rates from pregnancies with pregestational
diabetes.13 With the rising number of women with pregestational diabetes, more children
are predicted to be born with CHDs, conferring a greater burden on the healthcare system
as this pediatric population enters into adulthood.14
The heart is the first functional organ to arise during mammalian embryogenesis,
and involves the combination of three pools of progenitor cells in a spatiotemporal
specific manner, reliant upon regulated cell proliferation, apoptosis and epithelial-tomesenchymal transition (EMT).15 First and second heart field-derived (FHF and SHF)
multipotent cardiac progenitors undergo proliferation followed by differentiation into
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cardiomyocytes, which further clonally expand resulting in chamber ballooning and
formation of the left and right ventricles.16,17 The canonical Wnt/-catenin signaling
pathway directs proliferation of the SHF allowing for cardiac looping and outflow tract
(OFT) development.18 Conversely, a basal level of apoptosis is necessary for proper heart
development, as it induces changes in both the endocardial cushions and myocardial
microenvironment, signaling differentiation and development of cardiac valves, OFT,
coronary vasculature and conduction system.19 Additionally, EMT is required for
coronary artery formation, causing a delamination and migration of epicardial cells into
the myocardium, whereby they differentiate into smooth muscle cells, fibroblasts and
endothelial cells, forming the vasculature. This trans-differentiation process is mediated
by upregulations of EMT factors, such as Wt1 and Snail1/2, which promote cell
motility.20,21 Thus, an insult to any of these coordinated cellular processes could result in
a misstep in heart development and lead to a CHD.
miRNAs are short, single-stranded RNA molecules that post-transcriptionally
modulate gene expression by targeting mRNA transcripts at the 3’ UTR and repressing
their expression.22 These endogenous, non-coding nucleic acids are key players in the
pathogenesis of diabetes and its cardiovascular comorbidities, and are recently being
recognized for their diagnostic potential, serving as biomarkers for disease progression,
and therapeutic targets.23 miRNAs are expressed in the embryonic heart and their levels
of expression are critical to heart development. For example, targeted deletion of miR-1-2
causes ventricular septal defects and 50% mortality at late gestation while overexpression
of miR-1 in the embryonic heart under the control of -myosin heavy chain results in
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lethality at E13.5.24 Maternal diabetes changes maternal and fetal miRNA profiles which
may contribute to the pathogenesis of CHDs.25-27
miR-122 is a conserved, 22 nucleotide molecule that plays a critical role in liver
development and homeostasis. It regulates lipid and cholesterol metabolism, and serves
as a tumor suppressor, protecting against hepatocellular carcinoma (HCC) by inhibiting
proliferation and angiogenesis.28-30 In patients with impaired glucose tolerance, insulin
resistance, obesity, metabolic syndrome or T2D, elevated levels of circulating miRNA122 (miR-122) have been reported.31-35 Upregulation of plasma miR-122 was
demonstrated in T2D rodent models on a high-fat, high-sucrose diet.32,36 However, the
role of miR-122 in pathogenesis of CHDs during pregestational maternal diabetes is
unknown. RNA sequencing of maternal exosomes from STZ-induced diabetic and
control dams noted significant alterations in plasma miRNAs, with a 3-fold increase in
miR-122.27 Using a global miRNA microarray we found a 14-fold upregulation in miR122 in E10.5 hearts from diabetic dams compared to control. The present study aimed to
assess miR-122 expression in embryonic hearts from maternal diabetes, and delineate its
role in CHD pathogenesis during pregestational diabetes using anti-miR-122 treatment in
mice. We hypothesized that miR-122 will be upregulated in embryonic hearts from mice
with pregestational diabetes, which will decrease cell proliferation and epicardial EMT,
and increase apoptosis in the developing heart, contributing to the pathogenesis of CHDs.
In addition, anti-miR-122 treatment will reduce the incidence of CHDs induced by
pregestational diabetes.
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4.3 Methods
4.3.1

Animals
All procedures on mice in this study were performed in accordance with the

Canadian Council on Animal Care guidelines and approved by the Animal Care
Committee at Western University. C57BL/6 wild-type mice were purchased from
Jackson Laboratory (Bar Harbor, Maine), and a breeding program was implemented to
harvest fetal mice. Animals were housed in a 12-hour light/dark cycle and given ad
libitum access to normal chow and water. All animals used in this study were handled
according to the National Institute of Health Guide for the Care and Use of Laboratory
Animals (8th edition, 2011).

4.3.2

Induction of Diabetes and AntimiR-122 Treatment
The in vivo and ex vivo experimental approach in Figure 4.1 illustrating timelines

for saline or streptozotocin injection, breeding, anti-miR-122 or scramble LNA
administration, organ culture conditions, and assessment of fetal hearts in 6 randomly
assigned groups of mice. Female C57BL/6 mice, 8 to 10 weeks old were made diabetic
through five consecutive, daily injections of streptozotocin (STZ, 50 mg/kg body weight,
IP, Sigma), as we previously described.37 STZ was dissolved in sterile saline (0.9%
NaCl) at time of administration; sterile saline served as vehicle control. One week
following the last STZ injection, non-fasting blood glucose levels were measured with a
tail snip procedure using a glucose meter (One Touch Ultra2, LifeScan Canada, Burnaby,
BC). Mice were categorized as diabetic if blood glucose measurements exceeded 11
mmol/L, and were subsequently injected with locked nucleic acid (LNA) oligos for antimiR-122 or scramble control at a dose of 10 mg/kg, dissolved in sterile saline,
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subcutaneously. A LNA oligo is a modified nucleic acid with a phosphothiate backbone
and methylene bridge connecting the 2’ oxygen and 4’ carbon, enhancing stability and
uptake in vivo (Exiqon, Qiagen). Mice were then bred with 10 to 12-week-old C57BL/6
male mice, and E0.5 was confirmed with presence of a vaginal plug after which pregnant
dams were places in a cage with littermates. At E7.5, the dams received another 10 mg/kg
dose of anti-miR-122 or scramble LNA control, subcutaneously. This dose was
determined based on the manufacturer’s in vivo guidelines (Exiqon, Qiagen). Food and
water intake, as well as non-fasting blood glucose levels were monitored throughout
pregnancy. Fetal samples were collected at E18.5 for morphological and gene expression
analysis, following in utero echocardiography. E12.5 embryonic hearts were isolated
from a cohort of LNA-untreated control and STZ-induced diabetic dams for gene
expression analysis. E10.5 and E12.5 hearts were collected under sterile conditions for
organ culture from non-diabetic dams.
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Figure 4.1. Ex vivo and in vivo approaches to examine the effects of miR-122 on
heart development, and antimiR-122 on pregestational diabetes-induced CHDs.
Flow charts illustrate timelines of saline or streptozocin injection, breeding, embryonic
heart harvest and culture, anti-miR-122 administration and assessment of fetal hearts for
gene expression at E12.5, and cardiac morphology and function at E18.5. To determine
miR-122 levels in the embryonic heart, E12.5 hearts from control and STZ-induced
diabetic dams were collected for RNA isolation and gene expression analysis. In order to
determine the effects of miR-122 on heart development, E10.5 and E12.5 hearts from
control dams were cultured ex vivo for 4 days in normal or high glucose media, with
miR-122 or antimiR-122 transfection for 24 hours. Two in vivo doses of anti-miR-122 or
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scramble LNA to control and diabetic dams were administered according to this timeline
to determine their effects on the fetal heart.

4.3.3

Histological Analysis
Fetal cardiac and liver samples were collected at E18.5 for histological analysis

from control and diabetic dams treated with anti-miR-122 or scramble LNA.
Morphological analysis of cardiac structures in order to diagnose CHDs was performed at
E18.5 by first decapitating the fetuses and isolating the thorax in PBS. After removing
skin and fascia, samples were fixed in 4% paraformaldehyde overnight at 4 C, after
which samples were dehydrated in ethanol and embedded in paraffin. The hearts were
serial sectioned into 5 m slices using a Leica RM2255 microtome, and mounted onto
positively charged albumin/glycerin-coated slides. Following dewaxing of the slides, they
were stained with hematoxylin/eosin (Thermo Scientific, Waltham, MA) to visualize
morphology under a light microscope (Observer D1; Zeiss, Germany). Fetal liver
samples were processed, sectioned and stained in the same manner.

4.3.4

Embryonic Heart Explant Culture
Figure 1 depicts the ex vivo organ culture system used to assess the effects of

miR-122 and its antagonist, anti-miR-122, on gene expression, proliferation, apoptosis
and EMT in heart development. E10.5 hearts from control, untreated dams were isolated
in sterile saline and placed individually in wells of a 24-well plate with 500 L of M199
cardiomyocyte media (with 10% FBS and 1% penicillin/streptomycin) containing either 5
or 30 mM D-glucose per well. JetPrime transfection reagent and buffer system (Polypus
Transfection, Illkirch, France) was used to transfect miR-122 to a cohort of explants in
normal (5 mM) D-glucose media, or anti-miR-122 to a subset of explants in high (30
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mM) D-glucose media for 24 hours, according to the manufacturer’s protocol. After 4
days of culture at 37°C in 5% CO2, the media was removed and the hearts were either
cryosectioned or used for gene expression analysis.

4.3.5

Ex vivo Assessment of Epicardial EMT
To investigate the effects of miR-122 on epicardial EMT during cardiogenesis,

E12.5 hearts from control, non-diabetic dams were harvested in sterile conditions,
dissected into small pieces in sterile saline, and placed on a collagen matrix. The collagen
matrix was prepared using 1 mg/mL type I rat tail collagen (BD Bioscience) diluted with
2x M199 cardiomyocyte media (M5017; Sigma) containing either 5 or 30 mM D-glucose
in a 24-well plate. The casted wells were then hydrated with 500 L 1x M199 media plus
10% FBS, 1% penicillin/streptomycin and insulin-transferrin-selenium, with either, 5 or
30 mM D-glucose, matching the collagen layer. The pieces of E12.5 ventricles were
placed centrally in the well on top of the matrix, and the JetPrime transfection reagent
and buffer system (Polypus Transfection, Illkirch, France) was used to deliver miR-122
to a cohort of explants in the 5 mM D-glucose condition, or anti-miR-122 to a subset of
explants in the 30 mM D-glucose group. The transfection was removed after 24 hours,
and explants were again incubated at 37°C in 5% CO2 for 72 hours. After culture, images
were captured by phase contrast microscopy (Observer D1; Zeiss, Germany), and
spindle-shaped EPDCs, which are epicardial cells that have undergone EMT, were
quantified and normalized to the area of the explant.

4.3.6

Immunofluorescence
To determine the effects of miR-122 on proliferation and apoptosis during cardiac

development, E10.5 heart explants from all 4 groups were aspirated and embedded in

168

FSC22 frozen section media (Leica) following 4 days of culture. Samples were
cryosectioned into 8 m thick sections using the CM1950 cryostat (Leica), and mounted
on glass slides. Immunostaining for proliferation and apoptosis markers was performed
using anti–phosphohistone H3 antibody (1:1000; Abcam) and anti-cleaved caspase 3
antibody (1:1000; Cell Signaling), respectively. After 2 hours of primary antibody
incubation, CY3-conjugated anti-goat IgG fluorescent secondary antibody (1:1000;
Jackson Immunoresearch) was aliquoted onto the slides for 1 hour, followed by Hoechst
33342 (Invitrogen). Fluorescence microscopy (Observer D1, Zeiss, Oberkochen,
Germany) was used to detect signals and capture images from which positive cells were
counted and normalized to myocardial area using the AxioVision Software (Zeiss).

4.3.7

Real-time RT-PCR analysis
Total RNA from individual E12.5 hearts, E10.5 heart explants and E18.5 livers

was isolated using miRNeasy Mini Kit (Qiagen, Burlington, Ontario, Canada). Stem-loop
pulsed reverse transcription was performed by using Moloney Murine Leukemia Virus
(MMLV) reverse transcriptase to synthesize cDNA from 800 nanograms of total RNA
with specific primers for miR-122, snord-47, as previously described.38 RT using random
primer was also conducted. Primers were specifically designed using the Primer3
software v 4.1.0 (Table 4.1) for miR-122, snord-47, 28S, GLD2, Gata4, Hand2, EPO,
Cyclin D1, Wnt1, Snail1, and Slug. Real-time PCR analysis was performed using
EvaGreen qPCR MasterMix (Applied Biological Material, Vancouver, British Columbia,
Canada). Sample amplification was set for 35 cycles via the usage of Eppendorf Realplex
(Eppendorf, Hamburg, Germany). Transcript levels were normalized with snord-47
miRNA or 28S, and extrapolated through the approach of comparative CT method.39
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Table 4.1. Primer sequences for PCR analysis.
Gene
Name

miR-122

Accession
Number

NR_029600.1

Product
Size

Primer Sequence (5’ → 3’)

56

RT: GTCGTATGCAGAGCAGGGTCCGAGG
TATTCGCACTGCATACGACCAAACA
Forward: AGGCTGGAGTGTGACAATG
Reverse: GAGCAGGGTCCGAGGT

Snord-47

NR_028543.1

70

RT: GTCGTATGCAGAGCAGGGTCCGAGG
TATTCGCACTGCATACGACAACCTC
Forward: ATCACTGTAAAACCGTTCCA
Reverse: GAGCAGGGTCCGAGGT

28S

NR_003279.1
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Forward: GGGCCACTTTTGGTAAGCAG
Reverse: TTGATTCGGCAGGTGAGTTG

GLD2

BC016629.1

236

Pri-miR122

NR_029600.1

141

Gata4

NM_008092.4

137

Forward: CACTATGGGCACAGCAGCTC
Reverse: GCCTGCGATGTCTGAGTGAC

Hand2

NM_010402.4.1

159

Forward: GCTACATCGCCTACCTCATGGAT
Reverse: TCTTGTCGTTGCTGCTCACTGT

Cyclin D1

NM_007631.2

155

Forward: CTGACACCAATCTCCTCAACG
Reverse: CTCACAGACCTCCAGCATCCA

Snail1

NM_011427.3

133

Forward: CACACGCTGCCTTGTGTCT
Reverse: GGTCAGCAAAAGCACGGT

Slug

NM_011415.2

161

Forward: CAACGCCTCCAAGAAGCCA
Reverse: GAGCTGCCGACGATGTCAT

Wt1

NM_144783.2

214

Forward: GATGTGCGGCGTGTATCTGG
Reverse: GCTGGTCTGAGCGAGAAAACCT

Wnt1

NM_021279

241

Forward: CTGGAACTGCCCCACTGCT
Reverse: GCCAAAGAGGCGACCAAAAT

EPO

NM_007942.2
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Forward: GGAATTGATGTCGCCTCCAG
Reverse: GCAGCAGCATGTCACCTGTC

RT: Reverse Transcription

Forward: CCGTTGTTTCACACGCACTAT
Reverse: AGTCTGCTTTGTGGGAAGAGC
Forward: AAAGCCTGAGCAAAACTGGA
Reverse: TGGCTTACCATAGCCACTCC
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4.3.8

Fetal Echocardiography
To assess the effects of anti-miR-122 treatment on cardiac function, in utero fetal

echocardiography using the Vevo 2100 ultrasound imaging system was conducted. Dams
were anesthetized and an incision was made to the abdomen to expose the uterine sacs
containing the E18.5 fetuses. A MS 700 transducer (VisualSonics, Toronto, ON, Canada)
was positioned to obtain a short-axis view of the fetal heart, and M-mode
echocardiography images of fetal hearts were recorded with, as previously described.39,40
LV ejection fraction and fractional shortening were calculated by measuring the enddiastolic LV internal diameter and end-systolic LV internal diameter from the short-axis
M-mode images.

4.3.9

Statistical Analysis
Statistical analysis was performed using GraphPad Prism, Version 5 (GraphPad

Software, La Jolla, CA) and data are presented as mean  SEM. An unpaired Student t
test was used for comparisons between 2 groups. For multiple group comparisons
between normal and high glucose conditions with miR-122 or anti-miR-122 treatment, a
one-way ANOVA, followed by the Tukey’s post hoc test was conducted. CHD incidence
was statistically assessed via a Chi-square test. Differences were deemed significant with
P<0.05.
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4.4 Results
4.4.1

miR-122 is upregulated in the fetal heart of pregestational
diabetes
Since miR-122 is highly expressed in the liver, we first assessed miR-122 levels

in the adult liver. RT-qPCR analysis shows that miR-122 was abundantly expressed in
the liver compared to the LV myocardium of the adult mice (P<0.001, Figure 4.2A).
Subsequent analysis revealed that significantly higher levels of miR-122 were present in
E12.5 hearts from diabetic dams compared to control (P<0.05, Figure 4.2B). To verify
that miR-122 is expressed in the fetal heart, the levels of primary-miR-122, a longer
precursor transcript, existing only in the nucleus was analyzed. Pri-miR-122 was
significantly increased in E12.5 hearts from diabetic dams compared to control (P<0.05,
Figure 4.2C). Once in the cytoplasm, mature miRNA transcripts are processed by
cytoplasmic poly(A) polymerases, which confer stability to the RNA molecules. miR-122
is stabilized by GLD2,41 and we found it to be significantly elevated in E12.5 hearts from
diabetic dams compared to control (P<0.001, Figure 4.2D). Taken together, these results
show, for the first time, that a significantly higher level of miR-122 is expressed in hearts
from diabetic dams.
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Figure 4.2. Expression analysis of miR-122, Pri-miR-122 and GLD2.
(A) Real-time qPCR of miR-122 in the liver and left ventricle of adult mice. Gene
expression analysis of E12.5 hearts from control or diabetic dams for miR-122 (B), primiR-122 (C) and GLD2 (D). (E) miR-122 expression analysis from E10.5 explanted
hearts following four days of culture in normal (5 mM) or high (30 mM) D-glucose
conditions transfected with either miR-122 or anti-miR-122. n = 3 to 6 hearts per group.
Data are mean ± SEM. *P<0.05, ** P<0.01 and ***P<0.001 vs. respective controls.

4.4.2

Gene targets of miR-122 in the embryonic heart
To identify 3’ UTR mRNA targets of genes critical to embryonic heart

development that are affected by miR-122, the miRbase and TargetScan online databases
were used. Over 200 genes were predicted to be the targets of miR-122, however direct
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targets that have an active role in embryonic heart development include, Gata4, Hand2,
EPO, Cyclin D1, Wnt1, Snail1, and Slug (Figure 4.3B-H), which are critical to cell cycle
progression, angiogenesis and cardiogenesis. An ex vivo embryonic heart culture was
used to further assess the effects of miR-122 and antimiR-122 on the expression of these
genes in E10.5 hearts under normal or high glucose conditions. Transfection of miR-122
significantly elevated its levels in the cultured hearts, compared to control, whereas miR122 was not detectable in antimiR-122 transfected hearts (P<0.001, Figure 4.2D). Hearts
exposed to high glucose media showed a slight elevation in miR-122 levels, however this
change was not statistically significant. Hyperglycemia is known to alter gene expression
in the embryonic heart.37,42,43 In agreement with this notion, mRNA levels of Gata4,
Hand2, Cyclin D1, Wnt1 and EPO were significantly reduced in the high glucose (30
mM) compared to the normal glucose (5 mM) conditions (P<0.05, Figure 4.3A-D, G).
Strikingly, in normal glucose conditions miR-122 transfection significantly lowered the
expression of these genes in the cultured hearts compared to control (P<0.05, Figure
4.3A-C, E-F). Treatment with antimiR-122 in the high glucose conditions was effective
in restoring expression back to normal levels for all 6 genes (P<0.05, Figure 4.3A -F). In
addition, antimiR-122 treatment significantly elevated Gata4, Hand2, Cyclin D1, and
Snail1 levels back to normal when compared to miR-122 administration (P<0.05, Figure
4.3A-C, E). Taken together, these results demonstrate that miR-122 and high glucose
independently inhibit the expression of genes required for heart development, and the
changes can be reversed by antimiR-122.
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Figure 4.3. Analysis of target gene expression of miR-122.
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mRNA isolated from E10.5 hearts and analyzed by RT-qPCR. Values are normalized to
reference gene 28S. (A) Gata4, (B) Hand2, (C) Cyclin D1, (D) Wnt1, (E) Snail1, (F)
Slug, (G) EPO. miR-122 to 3’ UTR sequence complementarity prediction was performed
using online databases (miRbase, TargetScan). n=4-5 per group from three litters. Data
are mean ± SEM. *P<0.05, **P<0.01, ***P<0.001.

4.4.3

Role of miR-122 in Cell Proliferation and Apoptosis in the
Embryonic Heart
MiR-122 is a tumor suppressor and many studies have shown its ability to inhibit

cell proliferation and increase apoptosis.44-46 These two processes are integral to
embryonic heart development.47,48 E10.5 explanted hearts were cultured for four days in
normal or high glucose conditions. A subset of hearts cultured in normal glucose were
transfected with miR-122, and a cohort of hearts grown in high glucose were transfected
with antimiR-122. Cell proliferation was analyzed using immunostaining for
phosphorylated histone H3 (pHH3). Results show that high glucose or miR-122
transfection significantly lowered pHH3+ cells in E10.5 hearts compared to normal
glucose control (P<0.001, Figure 4A and C). Transfection with antimiR-122 under high
glucose conditions restored cell proliferation to normal control levels (P<0.05, Figure
4.4A and C). Conversely, cell apoptosis as assessed by immunostaining of cleaved
caspase 3 revealed a significant higher level of cell death under high glucose conditions
as well as miR-122 transfection (P<0.05, Figure 4.4B and D). Notably, antimiR-122
transfection in explants grown under high glucose conditions significantly lowered the
number of cleaved caspase 3 positive cells to basal levels (P<0.05, Figure 4.4D).
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Figure 4.4. Effects of miR-122 and high glucose on cell proliferation and apoptosis
in the embryonic heart.
Representative images of immunohistological staining of pHH3 (A) and cleaved caspase
3 (B). E10.5 hearts isolated from normal dams were used for ex vivo heart explant
cultures. Explants cultured in 5 mM D-glucose were transfected with miR-122; whereas
those exposed to 30 mM D-glucose received antimiR-122 for 24 hours. Heart sections
were incubated with rhodamine phalloidin and DAPI to stain for pHH3+ or cleaved
caspase 3+ cells and nuclei, respectively. Quantification of pHH3+ (C) and cleaved
caspase 3+ cells (D). n = 5-6 hearts per group. Data are mean ± SEM. *P<0.05,
**P<0.01, ***P<0.001; Scale bar is 20 μm.

4.4.4

Role of miR-122 in epicardial EMT
In addition to inhibiting cell proliferation, miR-122 has been shown to impede

EMT in tumorgenesis.45,49,50 High glucose has been previously shown to impair epicardial
EMT ex vivo.42 To study the role of miR-122 on epicardial EMT in the developing heart,
an ex vivo EMT assay was performed by culturing E12.5 hearts on a collagen matrix for 4
days. The number of spindle like cells, which are epicardial-derived cells (EPDCs) that
underwent EMT and migrated into the collagen matrix was counted and their migration
distance was measured (Figure 4.5A). The data indicates that, after 4 days of culture, the
number of EPDCs was significantly lowered by miR-122 transfection and by high
glucose compared to normal glucose control (P<0.01, Figure 4.5C). However, treatment
with antimiR-122 to the high glucose cultures restored the number of EPDCs back to
control levels (P<0.001, Figure 4.5C). During EMT, mesenchymal cells migrate away
from the explant to form the outgrowth area. The outgrowth distance, which is the
distance from the edge of the explant to the edge of the outgrowth area, was quantified
(Figure 4.5A-B). The data demonstrates that outgrowth distance was significantly
reduced in the presence of miR-122 and under high glucose conditions compared to the
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normal glucose control (P<0.001, Figure 4.5B). Finally, antimiR-122 transfection under
high glucose conditions restored the outgrowth distance to normal glucose levels
(P<0.001, Figure 5B).

Figure 4.5. Ex vivo assessment of epicardial EMT.
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(A) Representative images of E12.5 heart explant cultures grown on collagen matrix.
Dashed lines outline the edge of the EPDC outgrowth area. (B) Quantification of the
number of spindle shaped EPDCs normalized to the total explant area. (C) Quantification
of outgrowth distance from the cultured heart explants. Values are measured from the
edge of the explant to the edge of EPDC outgrowth area. n =5 - 8 explants per group from
four litters. Data are mean ± SEM. *P<0.05, **P<0.01, ***P<0.001. Scale bar is 50 μm.

4.4.5

Effects of antimiR-122 on blood glucose, litter size, cardiac
function and fetal liver
To study the role of miR-122 in heart development in vivo, a stable, a locked

nucleic acid (LNA) version of antimiR-122 was formulated. STZ-induced diabetic female
mice received two subcutaneous 10 mg/kg doses of either antimiR-122 or scramble LNA
control, one prior to pregnancy and one during pregnancy. Figure 4.6A shows the blood
glucose profile of female mice before pregnancy to fetal harvest with progressive
increases throughout gestation, which were not affected by antimiR-122 or scramble
LNA control. While CHDs were present in an equal number of male and female offspring
from diabetic dams administered scramble LNA, anti-miR-122 treatment was more
effective in preventing CHDs in males compared to females (P<0.05, Figure 4.6B). No
significant changes in offspring litter size was noted between the two groups (Figure
4.6C). Next, cardiac function of E18.5 fetuses was measured using M-Mode
echocardiography. Left ventricle ejection fraction (Figure 4.6D) and fractional shortening
(Figure 4.6E) were significantly higher in offspring of diabetic dams treated with
antimiR-122 compared to scramble LNA (P<0.001). Finally, fetal livers were analyzed at
E18.5 to determine whether the antimiR-122 treatment had any adverse consequences on
normal development in vivo. As antimiR-122 treatment is expected to decrease the
abundance of miR-122, the levels of miR-122 in the fetal liver were analyzed.51 Indeed,
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qPCR results indicate that antimiR-122 treatment significantly reduced miR-122 levels in
the fetal liver in offspring of control and diabetic dams compared to scramble LNA
administration (P<0.01, Figure 4.6F). This result indicates that antimiR-122 treatment
decreases miR-122 levels in mice. To determine whether antimiR-122 treatment had any
effect on the fetal liver, hepatic histology was examined. No significant differences were
seen in the average number of nuclei per liver section, or the ratio of sinusoid area to total
hepatic area between anti-miR-122 and scramble LNA treated groups (Figure 4.6G-I).
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Figure 4.6. Outcomes of in vivo administration of antimiR-122 during diabetic
pregnancy.
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(A) Blood glucose profile of diabetic dams administered with antimiR-122 (n=4) or
scramble LNA control (n=5-6). (B) Sex differences in CHDs incidence in the offspring of
diabetic dams administered with antimiR-122 or scramble LNA. (C) The offspring litter
size measured at the day of fetus harvest (n=6-7 per group). (D) Ejection fraction and (E)
fractional shortening measured through fetal echocardiography (n=4 per group). (F)
E18.5 fetal liver miR-122 levels in offspring of control and diabetic dams treated with
scramble LNA or anti-miR-122 (n=4 per group). (G) Effects of antimiR-122 on fetal liver
morphology at E18.5. Representative histological sections of E18.5 liver samples from
dams administered with scramble LNA or antimir-122. Scale bar is 100 μm. (H) Average
number of nuclei per fetal liver section and (I) ratio of sinusoid area to total fetal hepatic
area (n=4 per group). Data are mean ± SEM except B. *P<0.05, **P<0.01, ***P<0.001
vs. respective controls.

4.4.6

Anti-miR-122 administration reduces the incidence of
diabetes-induced CHDs
CHDs were observed in 55.6% of offspring from diabetic dams treated with

scramble LNA. This ratio was significantly reduced to 23.0% with antimiR-122 treatment
(Table 4.2). Congenital malformations of the heart were present in all litters from
scramble LNA-treated diabetic dams, and every dam in the antimiR-122 treatment group
had at least one offspring with a CHD. Septal defects were commonly found in both
groups. Atrial septal defects (ASD, Figure 4.7A) were observed in similar proportions.
Diabetic dams treated with scramble LNA had 22.2% of offspring with a ventricular
septal defect (VSD, Figure 4.7B), which was reduced to 4.2% with antimiR-122
treatment (Figure 4.7E). Two fetal hearts with double outlet right ventricles (DORV)
were present in the scramble LNA group (Figure 4.7C), whereas normal aortic
connections were maintained with antimiR-122 treatment (Figure 4.7F). Other severe
CHDs of the outflow tract, such as truncus arteriosus and a vascular ring constricting the
esophagus and trachea were only present in fetuses from diabetic dams treated with
scramble LNA. Valvular defects were also prevalent in offspring of diabetic dams given
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scramble LNA. Thicker pulmonary (13.9%, Figure 4.7G) and aortic (19.4%, Figure 4.7H)
valves were more common in hearts from scramble-treated diabetic dams compared to
antimiR-122-treated diabetic dams (2.6% and 7.4%, Figure 4.7J-K, respectively). Finally,
non-compaction of the ventricular myocardium was more prevalent in the right ventricle
of offspring from scramble-treated diabetic dams (8.3%, Figure 4.7I). No such defect was
seen in offspring of diabetic dams administered with antimiR-122 (Figure 4.7L).
Table 4.2. The rate of congenital heart defects in the offspring of diabetic dams
treated with anti-miR-122 or scramble LNA.

Normal
Abnormal
ASD
VSD
AVSD
DORV
TGA
Truncus
Arteriosus
OA
Vascular Ring
PA Stenosis
Thick PV
Thick AV
NCVM

STZ +
Scramble LNA
N
dams
36
7
n
%
16
44.4**
20
55.6**
7
19.4*
8
22.2*
2
5.6
2
5.6
1
2.8

STZ +
antimiR-122
N
dams
39
5
n
%
30
76.9††
9
23.0††
6
18.5
2
4.2†
0
0.0
0
0.0
0
0.0

Control
Scramble LNA
N
dams
24
2
n
%
24
100.0
0
0.0
0
0.0
0
0.0
0
0.0
0
0.0
0
0.0

Control
antimiR-122
N
dams
17
2
n
%
17
100.0
0
0.0
0
0.0
0
0.0
0
0.0
0
0.0
0
0.0

1

2.8

0

0.0

0

0.0

0

0.0

1
1
1
5
7
3

2.8
2.8
2.8
13.9
19.4*
8.3

0
0
0
1
4
0

0.0
0.0
0.0
2.6
7.4
0.0

0
0
0
0
0
0

0.0
0.0
0.0
0.0
0.0
0.0

0
0
0
0
0
0

0.0
0.0
0.0
0.0
0.0
0.0

Morphological analysis was performed on E18.5 hearts. Data was analyzed using the
Chi-square test. *P<0.05, **P<0.001 vs. scramble control, †P<0.05, ††P<0.001 vs.
scramble diabetes. ASD: atrial septal defect, VSD: ventricular septal defect, AVSD:
atrioventricular septal defect, DORV: double outlet right ventricle, PA: pulmonary artery,
OA: overriding aorta, PV: pulmonary valve, AV: aortic valve, NCVM: Non-compaction
of the ventricular myocardium. N indicates total number of fetuses, dams are litter
numbers.
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Figure 4.7. Effects of antimiR-122 on congenital heart defects induced by
pregestational diabetes.
Representative histological sections of E18.5 hearts from offspring of diabetic mothers
either administered with antimiR-122 or scramble LNA during gestation. Scramble LNA
administered to diabetic dams resulted in offspring with atrial septal defect (A),
ventricular septal defect (B), double outlet right ventricle (C), thickened pulmonary (G)
and aortic (H) valves, and noncompaction of the myocardium (I). AntimiR-122 treatment

185

reduced or fully prevented the incidence of these defects: intact atrial septum (D), intact
ventricular septum (E), normal aortic connections (F), normal pulmonary (J) and aortic
valves (K), and normal compact myocardium (L). Scale bars are 200 μm.

4.5 Discussion
Pregestational diabetes is an established risk factor for CHDs, and increases the
risk in infants by 3 to 5 times.5,7 The molecular mechanisms behind the pathogenesis of
diabetes-induced cardiac malformations require further understanding, and effective
preventative measures need to be elucidated. Here, we employ an ex vivo and in vivo
approach to delineate the effects of miR-122 upregulation in embryonic heart
development, and test the efficacy of antimiR-122 treatment in a clinically relevant
model of diabetes-induced CHDs in mice. The results of this study demonstrate that
pregestational diabetes results in a high incidence of offspring CHDs and impaired
cardiac function, which are rescued by maternal antimiR-122 treatment. This study also
shows an upregulation of miR-122 in embryonic hearts from diabetic dams, and
experimentally verified its target genes critical to heart development. miR-122 decreases
the proliferative capacity of the developing heart, increases apoptosis, and inhibits
epicardial EMT, leading to CHDs during pregestational diabetes (Figure 4.8).
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Figure 4.8. Schematic summary showing the effect of miR-122 on embryonic heart
development.
Our findings suggest that pregestational diabetes induces cardiac expression of miR-122
in the early heart tube, which negatively affects heart development. miR-122 alters the
expression of key genes involved in cell proliferation, apoptosis and epicardial EMT,
processes crucial to proper cardiogenesis. AntimiR-122 administration to diabetic dams
during gestation reduces the incidence of congenital heart defects in their offspring.

We recently demonstrated, using the same model of pregestational diabetes, the
efficacy of the drug sapropterin dihydrochloride (Kuvan) at reducing the incidence of
CHDs from 59.4 to 26.5% in E18.5 fetal mice.37 Accordingly, our previous work testing
N-acetylcysteine treatment in this model prevented these cardiac malformations in a
comparable fashion from 58.1 to 16.3%.43 In a similar manner, maternal exercise also
abrogated the effects of diabetes on the fetal heart by reducing the rate of CHDs from
56.8 to 25.0%.52 These studies, as well as others, all focus on mitigating the damaging
consequences of hyperglycemia-induced oxidative stress on the embryonic heart.53-55
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However, in the present study we show that antimiR-122 treatment to diabetic dams
significantly reduces offspring CHD incidence from 55.6 to 23.0%, specifically
decreasing the VSD rate from 22.2 to 4.2%, via a potential epigenetic mechanism. By
controlling aberrant miR-122 upregulation during diabetic pregnancy, the incidence of
offspring cardiac malformations is reduced, and normal cardiac function is restored.
Since antimiR-122 or antioxidant treatment alone does not completely prevent diabetesinduced CHDs, further studies are required to investigate whether the combination of
antimiR-122 and N-acetylcysteine has a synergistic effect in preventing these
malformations.
miRNAs play an indispensable role in cardiogenesis, acting as molecular
switches, turning on and off gene programs controlling different stages of heart
development.56 In fact, cardiac progenitor-specific deletion of Dicer, a cytosolic RNase
essential for miRNA maturation, results in major CHDs, such as VSD and DORV, and
can be embryonic lethal depending on progenitor lineage.57-59 Here we show a 3-fold
increase in both miR-122 and pri-miR-122 in E12.5 hearts from diabetic dams. During
embryonic development, miR-122 expression is normally limited to the developing liver,
where it maintains hepatic transcriptome signatures, and has been shown to direct
differentiation of mouse embryonic stem cells into hepatocytes.60,61 miR-122 is also
regarded as a tumor suppressor, and miR-122 null mice spontaneously develop
hepatocellular carcinoma.30 In the present study, we noted high miR-122 abundance in
the fetal liver. Our novel finding is that miR-122 expression was elevated in embryonic
hearts from diabetic dams. Expression of primary and precursor miR-122 transcripts
follows circadian rhythm regulation, with expression fluctuating diurnally.62 However,
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the mature miRNA is sustained at constant levels in the cytosol due to the cytoplasmic
poly(A) polymerase, GLD2, which confers stability and prolongs the half-life of miR-122
by adding a 3’ adenosine cap.41 In the present study, mRNA levels of GLD2 were
significantly elevated in embryonic hearts from diabetic dams, suggesting miR-122
stabilization is a possible cause of its higher levels in our model. To identify miR-122
target genes critical to embryonic heart development, E10.5 and E12.5 heart explant
culture was employed. Downregulations of Gata4 and Hand2 were seen with miR-122
transfection. Gata4 is involved in SHF progenitor proliferation and differentiation,
necessary for atrioventricular septation and OFT formation.63 Similarly, deletion of
Hand2 in the cardiac neural crest results in VSD and DORVs, and in the SHF, Hand2
protects the pharyngeal mesoderm against apoptosis.64,65 Accordingly, in the present
study, miR-122 transfection to E10.5 hearts induced high levels of apoptosis. This data
agrees with previous findings that transduction of miR-122 promoted cell apoptosis in
H9C2 cultured cardiomyocytes, and that its knockdown enhanced cell survival.44 The
increase in apoptosis could be due to miR-122 targeting the X-linked inhibitor of
apoptosis (XIAP), relieving the inhibition of caspase-mediated programmed cell death
pathways.66 miR-122-induced apoptosis was similar to levels seen in the high glucose
conditions, which is consistent with our previous in vivo findings of increased cell death
in the endocardial cushion of E12.5 hearts from diabetic dams.43 Targeting of the
cardiogenic factors, Gata4 and Hand2, as well as induction of apoptosis by miR-122 may
contribute to the diabetes-induced outflow tract defects, such as TGA, truncus arteriosus
and DORV in E18.5 fetuses.
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Regulated cell proliferation is vital for cardiac morphogenesis and growth of the
fetal heart. Proliferation deficiencies can result in thin, non-compact myocardium,
shortening of the outflow tract and its incomplete septation, leading to the spectrum of
CHDs.67,68 In the present study, miR-122 targeted and inhibited the expression of Cyclin
D1, thereby halting cell cycle progression, which may translate into a reduced number of
pHH3-postive cells in these heart explants. AntimiR-122 in high glucose conditions
restored both Cyclin D1 levels and cell proliferation to normal. In addition to inhibiting
cell cycle progression, miR-122 targets the growth factor receptors, TGFR2, IFG1R and
FGFR1 in the liver.69,70 Ligands for these receptors, TGF-, FGF-10 and IGF-2, originate
from the epicardium and promote proliferation and expansion of the adjacent
myocardium.71-73 Furthermore, in the present study, E12.5 heart explants grown on
collagen exhibited stunted outgrowth and epicardial EMT with miR-122 transfection.
Their migratory capacity and outgrowth mirrored the hearts in high glucose conditions,
which is in agreement with our previous findings.42 In fact, in a similar model of diabetes
we have demonstrated an in vivo increase in E-cadherin expression, decreased Wt1postive cells in the epicardium, as well as a downregulation of transcriptional drivers of
epicardial EMT.42 Here, we demonstrate that miR-122 targets and significantly reduces
the transcript abundance of Snail, Slug and EPO by 2-fold. This is consistent with its role
as a tumor suppressor, inhibiting EMT.74 Recently, studies have explored the association
of miR-122 with TGF-1/Smad signaling or the Wnt/-catenin signaling pathway in the
development of liver fibrosis or cancer, particularly focusing on EMT and
tumorigenesis.45,75 They indicate that miR-122 reverses the ‘cadherin switch’ necessary
for EMT, by increasing E-cadherin expression and decreasing N-cadherin levels via its
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inhibition of Smad4.75 Likewise, addition of miR-122 mimic to HCCs significantly
diminished Wnt1 and -catenin protein expression, decreasing tumor size.45 Finally,
miR-122 targets the transcription factor RUNX2, which functions independent of
Snail1/2 in mediating EMT

76,77

and should be investigated in the developing heart in

future studies.
The presented study is constrained by only examining a T1D model, and currently
the prevalence of pregestational T2D is on the rise.78 This is of particular interest as
recent studies have revealed elevated levels of miR-122 in patients with obesity, insulin
resistance and diabetic retinopathy, along with its already established roles as a
biomarker for myocardial infarction and coronary artery disease.31,32,34,79-82 The reason
for this upregulation remains to be determined, however there is an inverse association
between miR-122 and leptin, which is deregulated in diabetic patients.83,84
In conclusion, the present study is the first to reveal the role of miR-122 in
embryonic heart development, and provide novel insights into the mechanisms
underlying pregestational diabetes-induced CHDs. We show that embryonic hearts from
diabetic dams have elevated levels of primary and mature miR-122, and that this nucleic
acid could be stabilized in the cytosol by increased expression of GLD2. miR-122 targets
the 3’ UTR of many genes responsible for cardiogenesis, including Gata4, Hand2, Wnt1
and Snail1/2, and specifically inhibits their expression ex vivo.

This epigenetic

modulation impairs key developmental processes of cell proliferation, apoptosis, and
epicardial EMT, mirroring the negative effects of high glucose. In addition, we utilized a
LNA form of the experimental drug antimiR-122 to effectively reduce the incidence of
pregestational diabetes-induced CHDs and restore cardiac function. AntimiR-122
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treatment had no adverse effects on litter size, fetal liver histology, or heart development,
and can be considered safe for studies on fetal mice. Currently, undergoing phase II
clinical trials for the treatment of chronic hepatitis C infection, our study suggests that
antimiR-122 may have therapeutic potential in the prevention of CHDs in pregestational
diabetes.
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5

Chapter 5

5.1 Summary of Major Findings
The overall aim of this thesis was to explore the pathogenesis of pregestational
diabetes-induced congenital heart defects (CHDs) and coronary artery malformations
(CAMs), and investigate the efficacy and mechanisms behind two preventative strategies.
Specifically, I studied the impact of elevated levels of eNOS uncoupling/oxidative stress
and miR-122 during gestation on embryonic heart development in a model of
streptozotocin-induced (STZ) pregestational diabetes in mice. Concurrently, we tested the
efficacy of sapropterin and antimiR-122 pharmacotherapy on preventing a range of
defects induced by pregestational diabetes. Altered gene expression, impaired protein
activity and function, and deregulated cellular processes in embryos of diabetic dams
resulted in morphological and functional congenital heart abnormalities at birth, which
were reduced in incidence by both treatments. The experimental approaches used to carry
out these experiments included histological analysis of heart structure, using a serial
sectioning technique to accurately diagnose heart malformations. Next, we employed in
vivo lineage tracing using transgenic mice to specifically map a group of cardiac
progenitors. In addition, we performed ex vivo heart explant cultures to examine certain
cellular processes under normal and high glucose conditions. Finally, we conducted
immunostaining to identify certain cells, and molecular analysis of embryonic hearts via
Western blotting or qPCR analysis.
Pregestational diabetes in the mother increases the risk of a CHD in the child by
over 4-fold.1 In Chapter 2, I investigated the effects of maternal sapropterin treatment on

201

CHDs induced by pregestational diabetes in mice. To carry out this aim, C57BL/6 adult
female mice were made diabetic via STZ administration, a model of pregestational
diabetes previously employed in our lab. Mice were categorized as diabetic if non-fasting
blood glucose measurements were above 11 mM. Pregnant diabetic dams steadily
increased in hyperglycemia throughout gestation. The offspring of these mice were born
in smaller litters, had a lower body weight, impaired cardiac function, and a spectrum of
morphological anomalies, including both cardiac and neural tube defects. Daily
sapropterin treatment throughout gestation did not impact the hyperglycemic state of the
pregnant dams; however, it prevented a decrease in fetal weight, and improved the
functional and morphological defects in the hearts of the offspring. Importantly, oral
sapropterin treatment to diabetic dams significantly decreased the incidence of CHDs
from 59.4% to 26.5%, and all major malformations, such as AVSD and DORV, were
absent in the treatment group. A higher proportion of male offspring had CHDs, and
sapropterin treatment was effective in lowering the incidence of CHDs in both sexes.
Fetal hearts from diabetic dams had thinner ventricular free walls, and thicker aortic,
pulmonary and mitral valves, indicating defects in myocardialization and valve
remodeling, respectively. Sapropterin treatment recovered the thickness of ventricular
compact myocardium, and improved cardiac valve remodeling. In addition, treatment
with insulin to diabetic dams restored normal blood glucose levels and resulted in no any
CHDs, indicating that malformations in the offspring of diabetic dams were due to
hyperglycemia. To determine the mechanism of hyperglycemia-induced CHDs,
cardiogenesis was examined at different time-points during embryonic development.
Lineage tracing of cardiac progenitors using the SHF-specific Mef2ccre/+ transgenic
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mouse and the global double fluorescent Cre reporter line Rosa26mTmG was conducted at
E9.5 and E12.5. Analysis revealed a lower commitment of SHF progenitors to the OFT,
endocardial cushions, and ventricular myocardium of the fetal heart. In fact, embryonic
hearts from diabetic dams had a shortened OFT length at E10.5, along with less cell
proliferation in both the OFT and ventricle, which was normalized with sapropterin
treatment. Accordingly, gene expression analysis of E12.5 hearts demonstrated lower
mRNA levels of key cardiac transcription factors, such as Gata4, Tbx5, Nkx2.5, Gata5,
which were restored to normal with sapropterin treatment. Sapropterin treatment also
restored the expression of dihydrofolate reductase (Dhfr), responsible for the conversion
of BH2 to BH4. These cellular and molecular alterations, induced by pregestational
diabetes, could be attributed to elevated levels of ROS, observed in E12.5 hearts of
diabetic dams via DHE-probe. Sapropterin treatment reduced ROS to the same levels as
L-NAME and superoxide dismutase pre-treatment to embryonic hearts from diabetic
dams, indicating eNOS-derived superoxide production. Furthermore, analysis of eNOS
dimerization via western blotting showed a loss of the functional eNOS dimer in E12.5
hearts from diabetic dams, and re-coupling of the enzyme with sapropterin treatment.
Overall, this study demonstrated the efficacy of the FDA-approved drug sapropterin
(Kuvan®) at preventing pregestational diabetes-induced CHDs by restoring gene
expression profiles, improving eNOS coupling, reducing ROS, and increasing cell
proliferation.
The development of coronary vessels that perfuse the cardiac muscle occurs
concurrently with heart development.1 This process is reliant on coordinated epicardial
EMT and eNOS-derived NO, and missteps can result in CAMs.2 In fact, eNOS-/- mice
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display hypoplastic coronary arteries and postnatal myocardial infarction.3 To this end, in
Chapter 3, we examined the effects of sapropterin on coronary artery development in
embryonic hearts of mice with pregestational maternal diabetes. This study was
conducted using the same model of pregestational diabetes and sapropterin administration
as Chapter 2. Treatment with sapropterin to mice with pregestational diabetes resulted in
a lower incidence of CAMs in their offspring from 50.0% to 20.6%. Histological analysis
revealed coronary arteries with marked decreases in luminal diameters, abundance and
volumes in fetal hearts from diabetic dams. In addition, capillary density within the
myocardium was lower in these hearts. Sapropterin treatment prevented diabetes-induced
fetal hypoplastic coronary arteries and restored capillary density. One source of coronary
artery progenitors is the epicardium. Epithelial cells delaminate and migrate into the
myocardium, where they differentiate into vascular smooth muscle cells, fibroblasts and
endothelial cells, the components of coronary arteries.2 As such, the epicardium of E12.5
hearts from diabetic dams was examined, and fewer actively proliferating cells were
noted. In addition, these hearts had a lower number of Wt1+ cells and higher expression
of E-cadherin, indicating an impairment in epicardial EMT, which was returned to
normal with sapropterin treatment. To further explore the behavior of epicardial-derived
(EPDC) coronary artery progenitors, E12.5 embryonic hearts were explanted onto a
collagen matrix and cultured ex vivo. Consequently, tetrahydrobiopterin, infused into the
culture media, prevented the lower EPDC outgrowth and number under high glucose
conditions. In a similar manner as Chapter 2, the mRNA levels of key molecular
regulators of coronary artery development involved in EMT, differentiation, and growth,
were examined. The expression of Hif-1, Snail1, Aldh1a2, -catenin and bFGF, was
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Mechanistically, these compromised molecular pathways and cellular processes can be
attributed to increased oxidative stress in the ventricular myocardium of E12.5 hearts
from diabetic dams. The increase in lipid peroxidation was attenuated with sapropterin
treatment. Moreover, Akt and eNOS phosphorylation was lower in embryonic hearts
from diabetic dams, and was returned to basal levels with sapropterin treatment. Taken
together, this data demonstrated the therapeutic potential of the FDA-approved drug
sapropterin at preventing pregestational diabetes-induced CAMs. This study also
provides insight into factors contributing to altered coronary artery development, such as
impaired Akt/eNOS activity and oxidative stress.
Thus far, in Chapter 2 and Chapter 3 of this thesis, oxidative stress and impaired
eNOS-derived NO signaling was been investigated as a major driver of diabetic
embryopathy. In addition to elevated oxidative stress, pregestational diabetes may alter
maternal/fetal microRNA profiles, leading to the pathogenesis of CHDs.4,5 Recent
clinical data indicates that miR-122 is elevated in patients with impaired glucose
tolerance, insulin resistance and obesity, and is a biomarker for cardiovascular disease.6-9
In Chapter 4, I studied the role of miR-122 in the pathogenesis of pregestational
diabetes-induced CHDs. To achieve this goal, we implemented ex vivo and in vivo
experimental approaches to determine the effect of miR-122 on heart development, and
antimiR-122 pharmacotherapy on mitigating diabetes-induced CHDs in mice. Along with
confirming higher levels of miR-122 in E12.5 hearts from diabetic dams, an upregulation
of primary-miR-122 was also noted. As miR-122 functions to inhibit the expression of
mRNA transcripts, the levels of key cardiogenic targets of miR-122 were examined by
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qPCR. Genes critical for cell cycle progression, angiogenesis, and heart development,
such as Cyclin D1, Snail1, Gata4 and Hand2, were downregulated in normal E10.5 hearts
transfected with miR-122. Antagonism using antimiR-122 to hearts cultured in high
glucose media restored normal expression of these genes. Furthermore, transfection of
miR-122 to heart explants inhibited cell proliferation, increased apoptosis and inhibited
epicardial EMT, to the same level as explants exposed to high glucose levels. The high
glucose-induced deregulation of these cellular processes was prevented by antimiR-122
transfection. Since these experiments suggest that elevated levels of miR-122 disturb key
process of cardiac development, in vivo administration of antimiR-122 was tested for its
effects on pregestational diabetes-induced CHDs. To this end, diabetes was induced in
female C57BL/6 female mice using the same method as in Chapter 2 and 3; however,
prior to breeding, diabetic mice were administered 10 mg/kg LNA antimiR-122 or
scramble control, subcutaneously. Another dose was injected at E7.5, and heart
morphology was examined at E18.5 following fetal echocardiography. The blood glucose
levels of diabetic dams increased progressively throughout gestation, and neither LNA
treatment had any effect on glycemic levels. An equal number of males and female
offspring from scramble LNA-treated diabetic dams had CHDs, and antimiR-122
treatment was more effective in reducing the incidence of CHDs in male offspring. No
significant changes in offspring litter size was noted between groups. Further, antimiR122 treatment prevented cardiac dysfunction, measured through M-Mode analysis of LV
ejection fraction and fractional shortening, in offspring of diabetic dams. A spectrum of
CHDs was observed in offspring of scramble LNA-treated diabetic mice, which were
consistent with the malformations observed in Chapter 2. In fact, the total ratio of
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abnormal fetal hearts was stable, upwards of 50%, between this thesis and previous
studies using the same model of pregestational diabetes.10 Notably, the incidence of
CHDs in the offspring of diabetic dams was reduced from 55.6% to 23.0% by antimiR122 administration. Overall, this study is the first to reveal the role of miR-122 in the
pathogenesis of pregestational diabetes-induced CHDs, and demonstrates the efficacy of
in vivo antimiR-122 treatment at reducing the incidence of these cardiac malformations.
In summary, the results of this thesis highlight the potential protective effects of
sapropterin and antimiR-122 treatment against pregestational diabetes-induced CHDs.
We show that daily sapropterin therapy to diabetic dams inhibits oxidative stress and
eNOS dysfunction in the embryonic heart, which regulates cardiogenic gene expression.
This normalized impairment in cell proliferation and epicardial EMT, leading to normal
heart and coronary artery development. Additionally, we showed that the incidence of
CHDs in offspring of diabetic dams could be reduced via a miRNA-mediated
mechanism. By relieving the repression of targets of miR-122, antimiR-122 treatment
restored cellular processes of cell proliferation, apoptosis and epicardial EMT to normal
levels, reducing the incidence of CHDs. A summary of findings from these studies is
illustrated in Figure 5.1.
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Figure 5.1. The role of eNOS uncoupling/oxidative stress and miR-122 in the
pathogenesis of pregestational diabetes-induced congenital heart defects.
Pregestational diabetes leads to a concurrent increase in oxidative stress and miR-122 in
the embryonic heart. This brings about eNOS uncoupling, leading to a reduction in many
critical factors. Cell proliferation, apoptosis, and epicardial EMT are perturbed, and lead
to CHDs. Treatment with sapropterin or antimiR-122 reduces the incidence of these
malformations by regulating heart development, albeit through different mechanisms.
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5.2 Study Limitations
5.2.1

Justification of a Mouse Model of Pregestational Diabetes
Diabetes is a global health issue with a rapidly increasing prevalence, and is

estimated to affect 693 million people by 2040.11 Currently, 40% of women with diabetes
are of reproductive age.12 T1D is characterized by autoimmune destruction of pancreatic
-cells, resulting in a lack of insulin production; whereas, T2D is the result of insulin
resistance and usually has a later onset, but is much more prevalent.13 Biomedical
research utilizes various experimental approaches to study diabetes. In animal models,
diabetes can be induced via many techniques, including diet, drugs, surgery, or genetic
alterations. A common, established method for the generation of a T1D model in rodents
is STZ administration.14, 15 This chemical agent is a glucose analogue, which is taken up
by pancreatic -cells via the glucose transporter 2 (GLUT2). STZ within the cell causes
DNA damage, oxidative stress, and ultimately results in cell death.16 This depletion of
pancreatic -cells and thereby insulin supply recapitulates T1D in humans. A benefit of
using this model of diabetes is the relatively quick induction period, taking approximately
7 days for the onset of hyperglycemia. In addition, this method is fairly cost-effective,
and requires a simple high dose or multiple low doses of intraperitoneal injections.
However, a drawback to this approach remains the potential off-target effects of STZ,
such as carcinogenesis.17 Nevertheless, as seen in Chapters 2 and 3, insulin
administration to STZ-induced diabetic dams did not result in CHDs or CAMs,
suggesting that STZ does not impose any teratogenic effects on the heart. Another
limitation of this model is that clinically, most women with pregestational diabetes are
insulin resistant, meaning they have T2D.12 The pathogenesis of T2D has environmental
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and lifestyle components, altering a patient’s metabolism.13 Although a T2D model may
be more clinically relevant, effectively reproducing it without confounding variables,
such as a high-fat diet or genetic modifications, remains difficult. In fact, previous
experiments done in our lab indicate that mice on a prolonged period of high-fat diet
rarely reach hyperglycemic levels needed to induce CHDs in their offspring. While T1D
and T2D have systemic physiological differences, in this study, elevated levels of blood
glucose was regarded as the primary factor behind diabetic embryopathy.18 Importantly,
in the clinic, both types of diabetes in women confer an equal risk of having a child with
a CHD.19 Therefore, by using a STZ-induced model of pregestational diabetes in this
thesis, a consistently high rate of CHDs and CAMs were noted, which enabled testing the
efficacy of two pharmacotherapies.

5.2.2

Genetically Altered Mice
Mice represent a practical and appropriate model organism to study physiological

concepts, understand human diseases, and develop potential therapies. Embryonic heart
development and the genetic and molecular mechanisms leading to congenital heart
disease in humans, have been extensively studied using mouse models.20 Cardiac
anatomy and developmental pathways are very similar between humans and mice.21
Sequencing of the mouse genome revealed approximately 99% homology of genes to the
human genome.22 In addition, manipulation of the mouse genome is relatively simple,
even more so now with the advances in CRISPR technology, allowing for endless
possibilities in studying development and disease. One of these genetic engineering
technologies utilized in Chapter 2 of this thesis was the Cre/loxP system, which enabled
lineage tracing of SHF cardiac progenitors.23 Specifically, we used the anterior SHF-
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specific Mef2c-Cre transgenic mouse and the global double fluorescent Cre reporter line
Rosa26mTmG to trace and characterize the development of SHF-derived cardiac structures,
broadening our knowledge of heart development under pregestational diabetes.24 Along
with the many benefits of using this technology, some possible limitations of the
Cre/loxP system exist. The insertion of the Cre recombinase gene or the lox P sites into
the mouse genome could alter expression of surrounding genes.25 In addition,
endonuclease activity of Cre recombinase can have toxic effects.26 Although driven by a
tissue-specific promoter, the expression of Cre can occur in unwanted tissues. For
instance, in lineage tracing experiments, all descendants of the original cell expressing
Cre will be labeled with the reporter. Moreover, the Mef2c-Cre transgene is considered a
“leaky” Cre, as mesodermal cells in other organs can also be labeled. In fact, in these
mice, full body expression of Cre recombinase has been noted when this transgene is
inherited via females. To mitigate this, the Mef2c-Cre transgene remained on a single
allele and was inherited as a single copy in male mice.27 In spite of the drawbacks, the
ability to lineage trace the SHF using the Cre/loxP system in this thesis demonstrated a
specific insult of diabetic pregnancy to SHF progenitors, directly contributing to the
septal and OFT defects in fetal mice.

5.2.3

Use of ex vivo Organ Culture Systems
In Chapters 3 and 4 of this thesis, embryonic hearts were explanted and grown ex

vivo to delineate the effects of high glucose, tetrahydrobiopterin (BH4), miR-122 or
antimiR-122 on many parameters intimately linked to heart development. Specifically, in
Chapter 3, E12.5 heart ventricles from control dams were isolated in sterile conditions
and explanted onto a collagen matrix to study epicardial EMT and migration of
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epicardial-derived cells (EPDCs). This enabled us to determine the migratory capacity of
coronary artery progenitors under conditions of high glucose and when exposed to BH4,
providing support to our immunohistological data in vivo. Similarly, in Chapter 4, this
EMT assay was performed; however, in addition to simulating a diabetic pregnancy ex
vivo with high glucose, miR-122 and antimiR-122 were transfected into these explants. In
addition, E10.5 hearts from non-diabetic dams were explanted onto plastic and exposed
to the above conditions for gene expression, cell proliferation and cell death analysis.
Limitations exist with using these types of organ culture systems. For instance, in the
embryo, blood vessels supply cardiac progenitors with continuous nourishment and
remove cellular waste products. This is not matched in experimental conditions as
growing heart explants on top of a collagen matrix or plastic well does not effectively
replicate the in vivo environment of the cells, and could result in an altered response. In
addition, the biomechanical forces within the live embryo, including the shear stress on
cells by blood flow, cannot be simulated in this ex vivo setting. Finally, in Chapter 4,
miR-122 or antimiR-122 were delivered to embryonic heart explants using the JetPrime
transfection reagent and buffer system. Although considered generally less toxic and
more efficient method of delivery compared to electroporation, sonoporation or viral
transduction, the incubation time and ratio of nucleic acid to transfection reagent must be
carefully optimized. Despite these drawbacks, employing this organ culture system was
critical to advance our understanding on the impact of high glucose, BH4, and miR-122
on embryonic cardiovascular development, and support our in vivo findings.
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5.3 Suggestions for Future Studies
This thesis investigated the pathogenesis of congenital abnormalities of the heart
induced by pregestational maternal diabetes. We tested two clinically relevant
pharmacotherapies and elucidated developmental pathways leading to a spectrum of
cardiac and coronary artery defects. However, further research is warranted regarding the
effects of sapropterin and antimiR-122 on diabetic embryopathy.
All three chapters of this thesis investigate a model of T1D in mice. Indeed, both
pregestational T1D and T2D diabetes in patients induce CHDs in newborns.19 However,
T2D is more prevalent in the population, encompassing 90-95% of cases, and can be
brought about by environmental factors, such as obesity, which can also impact fetal
heart development.13 Future animal studies should try to model T2D and its metabolic
complications, while testing therapeutics like sapropterin and antimiR-122 on fetal
cardiovascular malformations. The FDA-approved drug sapropterin (Kuvan ) has an
acceptable safety rating and with very minor adverse effects, and represents a viable
option for pregnancies affected with T2D.28
This thesis examined the impact of two distinct treatments on diabetes-induced
CHDs. Sapropterin and antimiR-122 decreased the incidence of CHDs from 59.4% to
26.5%, and from 55.6% to 23.0%, respectively. As such, neither therapy had complete
penetrance at preventing cardiac malformations. Although sapropterin prevented all
major CHDs, such as AVSD, VSD, and DORV, minor defects like ASD, valve
thickening and ventricle thinning were still present. Since sapropterin and antimiR-122
function via distinct mechanisms on mitigating perturbations in heart development, as
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demonstrated in this thesis, a combination of both agents may further reduce the
incidence of CHDs and should be examined in future studies. Correspondingly, previous
studies in the same model of diabetes have demonstrated the beneficial effects of Nacetylcysteine (NAC) and maternal exercise on reducing the incidence of these defects by
maintaining the oxidative balance within the embryonic heart.10, 29 Future studies should
test attenuating elevations in oxidative stress and miR-122 by sapropterin, NAC or
maternal exercise, and antimiR-122 together, and investigate possible synergistic effects
at preventing CHDs induced by pregestational diabetes.
In Chapter 2, I performed lineage tracing experiments to map SHF progenitors
using the anterior SHF-specific Mef2c-Cre transgenic mouse, as many of the CHDs
present at birth were in structures originating from the SHF. All SHF-derived cells and
structures were GFP+ and therefore easily identifiable, and our findings indicated a
specific insult of diabetic pregnancy on these progenitors, which could account for the
septal and OFT defects. However, the impact of sapropterin treatment on this group of
cells in particular was not examined, and should be tested in future studies. Conversely,
in Chapter 3, we observed pregestational diabetes-induced CAMs and demonstrated a
deficiency in epicardial EMT as a causal factor, reversed by sapropterin treatment.
Indeed, coronary artery progenitors delaminate from the epicardium via EMT and
migrate into the myocardium where they differentiate into vascular smooth muscle cells
and fibroblasts, forming vessels.2 However, lineage tracing experiments confirm that the
sinus venosus and endocardium also contribute to the formation of these arteries.30 In
fact, the majority of the coronary arteries that perfuse the septum are endocardialderived.30 Future studies should employ lineage tracing using the Apj-CreER and the
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Nfatc1-Cre transgenic mice to map sinus venous and endocardial contributions to
coronary arteries in the embryonic heart from diabetic dams, respectively. 30 This analysis
should be conducted with both sapropterin and antimiR-122 treatment. In Chapter 4,
antimiR-122 is effective at restoring epicardial derived cell (EPDC) outgrowth and
number ex vivo, however the efficacy of antimiR-122 treatment at reducing the incidence
of CAMs should also be defined in vivo.
Cardiac and coronary artery malformations were the focus of this thesis.
However, in Chapter 2, one extra-cardiac defect, exencephaly, was reported. It has been
well documented that along with CHDs, neural tube defects in the offspring can result
from gestational hyperglycemia.31-33 In fact, a study using a similar model of STZinduced diabetes noted a 3-fold increase in offspring neural tube defects in comparison to
our study.32 The pathogenesis of these defects may differ from CHDs; however,
sapropterin or antimiR-122 therapy should be tested on the formation of cranial structures
during diabetic pregnancy. Similarly, in Chapter 3, the development of the coronary
vasculature was analyzed; however, pregestational diabetes may have consequences on
vessel development in other parts of the body. Mouse models of maternal diabetes have
demonstrated hyperglycemia-induced vasculopathy in the yolk sac, with specific insult to
vascular endothelial cells by oxidative stress.34 Although the role of eNOS has not been
explored in these studies, sapropterin therapy may have potential in mitigating these
vascular abnormalities.
Additionally, in Chapter 4, I demonstrated that in vivo treatment with antimiR122 reduced the incidence of CHDs in pregestational diabetes. This study utilized a
pharmacological approach to correct a genetic irregularity. It would be of particular
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interest to also determine if conditional knockout of miR-122 in the developing heart can
reduce the incidence of CHDs induced by pregestational diabetes to the same extent.
Using the Cre/loxP system, a floxed miR-122 could be excised by Cre recombinase in the
diabetic embryonic heart driven by the cardiac-specific Nkx2.5 promoter. A complete
knockout of miR-122 would not be ideal as it is necessary for liver homeostasis and
could result in hepatocellular carcinoma.35 Finally, as discussed before, a T2D model
may have greater relevance, especially as an extension of Chapter 4. In patients with
obesity, insulin resistance, and diabetic retinopathy, elevated circulating levels of miR122 have been reported.6-9, 36 Therefore, plasma levels of miR-122 should be analyzed in
both a T2D and STZ-induced model of diabetes. In addition, plasma samples from
diabetic patients should be analyzed to confirm reported findings. As miR-122 plays an
important role in cholesterol and fatty acid metabolism in the liver, and is a potential
prognostic marker for adult cardiovascular disease, elucidating its deregulation in
diabetes is imperative.37-40

5.4 Conclusion
This thesis provides evidence for the critical roles of oxidative stress, eNOS and
miR-122 in heart and coronary artery development in a mouse model of pregestational
diabetes. Here, I demonstrate for the first time that pregestational diabetes impairs eNOS
coupling and elevates levels of oxidative stress and miR-122, leading to functional and
morphological cardiovascular anomalies in the offspring of diabetic dams. These
malformations range in severity, and include ASDs, VSDs, OFT defects, ventricular
myocardium defects, and hypoplastic coronary arteries. Additionally, I have shown that
deficits in cardiogenic gene expression, enzyme activity, cell proliferation, and epicardial
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EMT, induced by pregestational diabetes, contribute to the development of these defects.
Importantly, this thesis exhibits the efficacy of two clinically relevant pharmacotherapies
at regulating heart development disturbed by diabetic pregnancy. Treatment with
sapropterin (BH4), a cofactor of eNOS, or antimiR-122 reestablishes normal
cardiovascular development and reduces the incidence of pregestational diabetes-induced
CHDs in mice. These results suggest that sapropterin and antimiR-122 may have
therapeutic potential in preventing CHDs in children of women with pregestational
diabetes.
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